[{"article": "As things stand now, men have to provide samples \u201cin these specific rooms in hospitals under so much stress and embarrassment,\u201d the study\u2019s principal investigator, Hadi Shafiee, PhD, told CBS News.\nThough the system is in the prototyping stage, it could eventually shake up the world of fertility testing by allowing men to evaluate their sperm in their own homes and helping health centers with fewer resources offer easy, cheap testing.\nThe app\u2019s user experience is hard to forget: users can see vivid moving images of their sperm right on the screen.\n\u201cThe accuracy of this approach was very similar to that of computer-assisted laboratory analysis, even when it was performed by untrained users with no clinical background,\u201d they wrote in the study.\nThe app is similar to a fitness tracker, in a sense, in that it stores any history of previous semen samples as well.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Readers are told each test is 98% accurate, but aren\u2019t told where that number comes from or what it means.\nEqually as important, the story doesn\u2019t explain that sperm count is only one facet of fertility, at least as defined by the World Health Organization; motility, morphology, pH, and other factors are similarly important, though less frequent issues, and require more advanced testing to establish.", "answer": 0}, {"article": "Low sperm count, or oligospermia, is a main cause of male infertility.\nThese tests can be expensive (costing hundreds of dollars and not typically covered by insurance), inconvenient and are often embarrassing.\u201d\n\nMORE: \u2018Sonicated\u2019 Sperm: Could Ultrasound Be the Next Male Contraceptive?\nFor women who are having trouble getting pregnant, the test may very well be one they \u2014 and not their squeamish partners \u2014 snap up along with over-the-counter ovulation kits.\nAs SpermCheck\u2019s website puts it, a \u201ctrip to a fertility clinic for a semen analysis is not for everyone.\nThe test reveals whether sperm count appears normal, at 20 million or more sperm per ml; lower than that indicates a trip to the doctor is pretty much unavoidable.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story \u2013 with copy that sounds like it came from an ad agency \u2013 claims the test \u201c\u2026assesses sperm count with 98% accuracy in 10 minutes and does away with the unpleasantness of conjuring up a sperm sample in a doctor\u2019s office\nIn fact, compare that line with this copy from the company\u2019s news release:\n\u201cIn just 10 minutes \u2026It\u2019s more than 98% accurate \u2013 as reliable as a lab test \u2013 yet much more convenient and at much less cost than a visit to the doctor. It also alleviates the embarrassment and inconvenience of providing a semen sample to a doctor or nurse in a lab setting.\u201d\n\u00a0\nWhile there is a general relationship between sperm count and fertility, the equation is not quite that simple.\u00a0 The test may accurately provide a sperm count but that single piece of information is not sufficient to make assumptions about the ability to induce pregnancy.\u00a0 See \u201cHarms\u201d criterion below.", "answer": 0}, {"article": "But \"that trial is never getting done, nor should it be done,\" Golden said.\nThe findings come as the American Academy of Pediatrics debates updating its recommendations regarding circumcision among newborns.\nAnd there's more to consider, Perera said.\nThe American Academy of Pediatrics has more on circumcision.\nThe academy now takes a neutral stance.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "", "answer": 0}, {"article": "Magnetic resonance imaging measured cortical thickness and resting-state functional connectivity (rsFC) before training, after training and three months post-training.\n\"People who showed the greatest change in cortical thickness and connectivity, showed the greatest performance increases in our cognitive tasks.\nBuilding upon previous research, the study challenges the widely held belief that recovery from a TBI is limited to two years after an injury.\nThe findings, published in Brain and Behavior, further suggest that changes in cortical thickness and neural network connectivity may prove an effective way to quantitatively measure treatment efficacy, an ability that has not existed until now.\nIndividuals in the strategy-based reasoning training showed a greater change in cortical thickness and connectivity compared to individuals who received the knowledge-based training.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release said that brain training \u201ccan stimulate structural changes in the brain and neural connections even years after a traumatic brain injury.\u201d But how do these structural and neural changes translate to meaningful patient outcomes? The release said the training is correlated to \u201can individual\u2019s ability to switch between tasks quickly and consistently to achieve a specific goal.\u201d Which tasks? Which goal? To make the study findings meaningful to people with TBI or their caregivers, the release should have included some specific examples of how patients benefited from the therapy.\nThe lack of numbers to put the findings in context is another weakness of the release. There are no numbers to show the differences in neural connectivity or cortical thickness between the two treatment arms. Ideally we would be told\u00a0the absolute difference in outcomes between the two groups, the clinical significance of any difference, and the statistical significance.\nThe only quantitative figures\u00a0come from the image included in the news news release. The news release might have done a better job explaining this figure.", "answer": 0}, {"article": "But 'fish oil supplements just don't cut it.'\nFran Visco, president of the National Breast Cancer Coalition, said the task force's guidelines for women in their 40s \u2014 that they should discuss whether to get mammograms with their doctors and make individual decisions \u2014 come closest to following the evidence accumulated over the past three decades.\n[In major shift, these guidelines scaled back breast cancer screening for women in their 40s]\n\nThe debate over when to start regular screening involves only women of \"average risk\" who don't have specific risk factors for breast cancer such as the BRCA1 and BRCA2 genetic mutations or a family history of the disease.\nAs a result of the congressional action, women in their 40s will continue to be able to get annual mammograms at no cost.\n\u201cThe U.S. Congress thinks it's perfectly acceptable, even preferred, for a scientific document from 14 years ago to guide coverage policy on screening for breast cancer in women,\u201d says Kenneth Lin, a Georgetown University family medicine doctor who teaches preventive and evidence-based medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not offer any detailed information on the potential benefits associated with mammogram screening. Instead, the story uses vague language, describing the USPSTF\u2019s recommendations as saying that \u201cscreening mammography had the greatest benefit for women ages 50 to 74\u201d and that \u201cthe likelihood of benefit is less\u201d for women in their 40s. Exactly how much different are the potential benefits for these groups? That\u2019s an important point, and the story doesn\u2019t tell us.\nThe story does note that the USPSTF recommendations are aimed only at women with an average risk of breast cancer, and it attempts to explain what that means, noting that it refers to women \u201cwho\u00a0don\u2019t have specific\u00a0risk factors for breast cancer such as the BRCA1 and BRCA2 genetic mutations or a family history of the disease.\u201d That\u2019s useful information for readers, but the story could have noted that there are other factors that place women at elevated risk. A history of prior breast surgery, especially if the pathology demonstrated atypical hyperplasia [an abnormal overgrowth of cells] significantly increases the risk of a subsequent breast cancer. In addition, a woman\u2019s menstrual history, age at first pregnancy, and other factors also influence risk. There are several risk assessment models that are widely available, but are underutilized, to help women and their physicians assess risk. It would have been helpful to at least acknowledge this, as there remains a lot of confusion over just what constitutes \u201caverage risk.\u201d", "answer": 0}, {"article": "Autologous CD34?\nAll of the 167 patients participating in the ACT34-CMI study saw significant improvement in both angina frequency and exercise at 12 months and a trend toward decreasing major cardiac events.\nThere was also a reduction in angina in the placebo group at six months, but the effect was less prominent at 12 and 24 months, reported the researchers.\nThe researchers concluded that for \"no option\" patients with class III/IV angina refractory that was unresponsive to conventional medical therapy and who were not candidates for revascularization, injection of CD34+ cells resulted in persistent improvement in angina at two years post-treatment.\n\"The results of our study are even more provocative given that the outcomes represent the effect of a single treatment,\" wrote the researchers.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not quantify benefits at all. The headline tells readers that the treatment \u201creduced angina frequency.\u201d The body of the release notes that there was \u201ca significant reduction in angina frequency\u201d and that \u201csignificant improvement in both angina frequency and exercise at 12 months and a trend toward decreasing major cardiac events.\u201d However, there are no numbers here. How much improvement was there? How much less frequent were episodes of angina in patients who received the treatment relative to patients who received a placebo? The release doesn\u2019t tell us. The release also says there was some effect at 6 months for the placebo group that dropped off over time, but how much and what was the benefit compared to the group that received treatment?", "answer": 0}, {"article": "\"So a breath test would be most useful in that kind of challenging situation,\" Fonarow said.\nToday a diagnosis in that environment is based on a patient's history and exam, but symptoms for heart failure can easily overlap with a lot of other diagnoses.\n\"But I would say it would be perhaps more helpful for primary care physicians in an outpatient setting, because that is where it's most challenging to identify heart failure.\nDr. Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles, said that if further research were able to establish its effectiveness, a breath-driven tool for identifying heart failure would be a helpful diagnostic innovation -- but more so in a doctor's office or clinic than in the hospital.\nThe study authors pointed out that the most common reason American patients are admitted to a hospital is when there is a suspicion of heart failure -- a tough-to-treat condition in which the heart's pumping action grows gradually weaker over time.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story merely speculates about potential advantages without describing what they would be. The potential advantage would be more accurate diagnosis, but that was not studied here (no comparison). It is too early to say where such a test might be used, in an ER or in a primary care clinic, or how it would influence treatment. Would it help speed up treatment of some patients who would benefit from rapid intervention or would it avoid hospitalizing people who don\u2019t need aggressive care? The story implies benefits without specifying what they might be.", "answer": 0}, {"article": "\u201cThe increased levels of testosterone explain the greater reported sexual satisfaction,\u201d he said.\nBut after treatment, the group exposed to the bright light was scoring sexual satisfaction scores of around 6.3.\n\u201cBefore treatment, both groups averaged a sexual satisfaction score of around 2 out of 10.\nFagiolini\u2019s team recruited 38 men diagnosed with either hypoactive sexual desire disorder or sexual arousal disorder \u2013 both characterized by a lack of interest in sex.\nAndrea Fagiolini, a professor who led the study and presented it at the European College of Neuropsychopharmacology conference in Vienna on Monday, said the treatment may prove useful during the Northern hemisphere\u2019s darker winter months.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quotes the lead researcher saying that the light treatment group had an average sexual satisfaction score of \u201caround 6.3\u201d on a 10-point scale after treatment compared with an average score \u201cof around 2.7\u201d for the group that used a placebo device.\nThe story does not give ranges, which might let readers know whether all of the patients or just some of them experienced improvements from light exposure.\u00a0 It also does not report that average testosterone levels increased in men who had been treated to 3.6 nanograms per milliliter from 2.1 nanograms per milliliter with no significant change in the control group, according to the news release.", "answer": 1}, {"article": "Digital rectal exams can tell a specialist that the prostate is getting bigger, but that happens with normal aging as well as with cancer.\n\u201cThat\u2019s pretty good, actually,\u201d said Dr. David Crawford of the University of Colorado School of Medicine, who helped lead the study.\n\u201cIf the PCA3 is abnormal, above about 35, you have got an 80 percent chance of having cancer,\u201d Crawford said.\nThe test had a sensitivity of 49 percent, meaning it correctly identified 49 percent of cancers.\n\u201cIt reflects on the aggressiveness of the cancer,\u201d Crawford said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story reported on the specificity of this test as compared with test most commonly in use in the US.", "answer": 1}, {"article": "Soy supplements also have side effects such as nausea, bloating, and constipation, according to the National Institutes of Health.\nWong cautioned that the new study was small and that the women involved only had few hot flashes.\nThe new study didn\u2019t find significant hormone changes in women who took soy supplements, and Wong said the compounds are probably safe for women.\nAt six months, their Kupperman scores \u2014 a measure of symptom severity that ranges from 0 to 63 \u2014 had dropped by more than 40 percent from an initial value of about 25 in the soy groups.\nIn one of his own studies, Wong found no effect on soy germ isoflavones among women who took the supplements for two years.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There was a discussion about the reductions of symptoms among patients in the study in both relative and absolute terms. \u00a0Would have liked a better idea if the levels in the study among Chinese women are what American women also experience.\nIn most prior studies of hot flashes, the frequency has been much higher in study subjects \u2013 more like 5 \u2013 10 per day, not per week.\u00a0 So, as commenter in story notes, these Chinese women were not very symptomatic compared to their American counterparts.", "answer": 1}, {"article": "Inflammation is implicated in a wide range of illnesses, from heart disease to cancer and joint pain.\nThe researchers didn\u2019t examine the effect of curcumin on any diseases, and it was a fairly brief study, so it\u2019s not clear what the long-term implications may be they caution in their report.\n\u201cCurcumin is the active ingredient of the famous spice turmeric and has a long history of culinary and medicinal use in the Asian countries,\u201d said the study\u2019s senior author Amirhossein Sahebkar.\n\u201cWhilst turmeric is known to have several medicinal properties, and its regular use in diet is strongly suggested, it cannot be regarded as an equivalent substitution of curcumin,\u201d he said.\n\u201cTwo key effects of curcumin that account for most of the therapeutic effects of this compound are its strong antioxidant and anti-inflammatory properties,\u201d said Sahebkar researcher at the Mashhad University of Medical Sciences in Iran, in an email.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains that the study reported \u201cimproved blood levels\u201d of three biomarkers of inflammation, but does not say how much lower the biomarkers were \u2014 or what that might mean in terms of reducing the risk for heart disease. Assessing heart disease risk can be extremely complex, but even addressing the issue in broad terms would have been useful. In addition, the story allows one of the researchers to claim that the study results \u201cindicate the usefulness of daily use of curcumin supplement for the prevention and treatment of several diseases.\u201d Why use that quote if you need to add, in the very next sentence, that \u201cthe researchers didn\u2019t examine the effect of curcumin on any diseases\u201d?", "answer": 0}, {"article": "Guadecitabine is an experimental drug that has not been approved for use by the U.S. Food and Drug Administration.\nDuring the study, 15 patients had at least one imaging scan to retest the extent and location of their cancers -- with 12 patients experiencing stable disease -- for more than the four-month period, on average, and one patient experiencing a partial response to the treatment (measured as at least a 30 percent reduction in the size of the tumors.)\nThe study also showed signs that guadecitabine reduced methylation among the cancer cells.\nLee says the research team will measure the amount of methylation in patients' cells when they begin their treatment and the presence of genes associated with irinotecan resistance, among other possible biomarkers.\n\"We did see that giving a higher dose of the drug seemed to produce a better methylation response among patients,\" says Valerie Lee, M.D., a fellow at the Johns Hopkins Kimmel Cancer Center.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a good job here in two ways. First, the release makes clear that the goal of this study was not to assess benefits, but to assess potential harms. That places the findings \u2014 and the study design \u2014 in context. Second, the release notes that 15 of the 22 patients had at least one imaging scan to track the extent and location of their cancers. Twelve of those 15 patients had \u201cstable\u201d disease, while one saw a 30 percent decrease in the size of the tumors.", "answer": 1}, {"article": "Chronic insomnia is defined by the Diagnostic and Statistical Manual of Mental Disorders as sleeping poorly at least three nights a week for a month or longer, despite adequate opportunity for a full night's sleep.\nTaylor discovered that the study participants who received in-person cognitive behavioral treatment for their insomnia reported significantly greater improvements in sleep quality -- as determined by the sleep diaries and activity monitors -- than those who received the Internet therapy.\nIn a previous study of civilians with insomnia, Taylor and his research team discovered that cognitive behavioral therapy led to significant improvements in sleep efficiency, with the research subjects' use of sleep medication declining from 87.5 percent before therapy to 54 percent afterward, although the subjects weren't required to stop taking their medication.\nA third control group of participants was contacted by the researchers every other week during the six weeks, but did not receive cognitive behavioral therapy.\nBoth groups had greater improvements in sleep quality than those who did not receive cognitive behavioral therapy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There were numbers to back up the claimed benefits. The only references to benefits are very vague: \u201cthe study participants who received in-person cognitive behavioral treatment for their insomnia reported significantly greater improvements in sleep quality \u2014 as determined by the sleep diaries and activity monitors \u2014 than those who received the Internet therapy. Both groups had greater improvements in sleep quality than those who did not receive cognitive behavioral therapy. \u201d\nThe release could have given some stats from the sleep diaries kept by the participants or data collected from the the activity monitors (he \u201cActiwatch\u201d) they were asked to wear.\nThe release provides somewhat better context for understanding benefits when describing an unrelated study in civilians in which \u201ccognitive behavioral therapy led to significant improvements in sleep efficiency, with the research subjects\u2019 use of sleep medication declining from 87.5 percent before therapy to 54 percent afterward\u2026\u201d", "answer": 0}, {"article": "\"There's no magic in a liter-and-a-half,\" he said.\nYoung women plagued by UTIs who drank an additional 6 cups of water each day were nearly half -- 48 percent -- as likely as a control group to have another infection, the study showed.\nHalf of the women in the study were asked to consume 1.5 liters of water, or about 6 cups, each day in addition to their usual daily fluid intake.\nAnd while the study involved younger women, he said older women who experience recurrent UTIs may benefit from increasing their daily fluid intake as well.\nHooton noted that it's not clear exactly how much fluid intake must increase to deliver a benefit.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story addressed the scope of the benefits in this way:\nYoung women plagued by UTIs who drank an additional 6 cups of water each day were nearly half \u2014 48 percent \u2014 as likely as a control group to have another infection, the study showed.\nThe water group also reduced their use of antibiotics by roughly half \u2014 or 47 percent.\nThis is a good start. However, we need the absolute numbers. As the study abstract shows, the increased water group had 111 UTIs while the control group had 217.\nIt\u2019s also noteworthy that the women enrolled in the study had a low fluid intake of water to begin with \u2014 about 1 liter per day (half of the amount considered necessary to replenish fluids excreted daily). We don\u2019t know whether women who already have a healthy fluid intake would have a similar benefit.", "answer": 0}, {"article": ".\nUsing an incision originally designed for another purpose, surgeons can gain direct access to the nerves involved in some types of chronic temporal headache, according to the report by ASPS Member Surgeon Dr. Ziv M. Peled of Peled Plastic Surgery, San Francisco.\nThe simplified approach using the Gillies incision combines the advantages of other approaches to chronic temporal headache surgery while minimizing the disadvantages, Dr. Peled believes.\nBefore and after surgery, headache symptoms were assessed using a standard score, the Migraine Headache Index (MHI).\nOf the 19 patients, 16 had at least a 50 percent reduction in headache symptoms.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release mentions that headache symptoms were assessed using the Migraine Headache Index (MHI), which is calculated by multiplying together the frequency, intensity, and duration of migraine headache, according to another paper published by the American Society of Plastic Surgeons.\nOut of the 19 patients mentioned in this news release, 16 had at least a 50 percent reduction in headache symptoms.\u00a0 It also reveals the absolute numbers, pointing out that the average MHI score decreased from approximately 132 points before surgery to 52 points afterward.\nSince the release communicates a quantitative estimate by giving both absolute and relative benefit data, we give it a Satisfactory rating here.", "answer": 1}, {"article": "THC interacts with receptors in the brain\u2019s endocannabinoid system, which is involved in many physiological functions, including pain, mood, memory and appetite.\nMoving this research forward, however, will be problematic: \u201cTesting in humans is going to be difficult.\n\u201cTogether, these results reveal a profound, long-lasting improvement of cognitive performance resulting from a low dose of THC treatment in mature and old animals,\u201d the scientists write.\n\u201cThis paper is addressing a possible role for that compound in memory and cognition, which is relevant to disorders such as Alzheimer\u2019s and other dementias.\u201d\n\nHe said that while it is important to remember the study was carried out on mouse models, the differences in the effect of the drug on younger animals versus older animals tells us a lot about our understanding of the differences between old and young brains.\nIn humans it could be years before an effect is noticed.\u201d\n\n\u201cFinally, there is the issue surrounding safety.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Given that the research was on mice, there\u2019s no way to determine whether the intervention\u00a0would have any benefit at all to people, let alone to determine the scope of\u00a0the likely benefit. The story was at least upfront about this. But, anytime a story can\u2019t realistically answer this question as it would apply to humans, it\u2019s a sign that the research may be too preliminary to warrant coverage in a national magazine. For this reason, we\u2019re rating it Not Satisfactory.", "answer": 0}, {"article": "In rural or underserved areas, doctors sometimes must rely on a patient's symptoms or use their own judgement in looking at test sample color results to determine whether a patient has an infection.\nThe researchers tested the device, which is about the size of a hand, with 771 patient samples at Hospital of University of Pennsylvania and found that it provided false positives only about one percent of the time (was 97. to 99.9 percent accurate).\nThe WSU researchers found that their portable smartphone reader worked nearly as well as standard lab testing in detecting 12 common viral and bacterial infectious diseases, such as mumps, measles, herpes, and Lyme Disease.\nIf they send results off to a lab in a distant city, the doctors sometimes must wait for days -- by which time the infection may have become widespread.\nThe work could lead to faster and lower-cost lab results for fast-moving viral and bacterial epidemics, especially in rural or lower-resource regions where laboratory equipment and medical personnel are sometimes not readily available.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release reports details of a direct comparison between test results produced by this device and standard lab equipment. However, relative accuracy of lab tests is not, by itself, a health benefit. The release says that using conventional lab testing services takes too long \u201cby which time the infection may have become widespread.\u201d The obvious implication is that this hand-held device would lead to more rapid and more effective outbreak detection in the field. Perhaps\u2026but that\u2019s not what was tested. The release should have been clearer that actual human health benefits won\u2019t be known until after testing in the field.", "answer": 0}, {"article": "But \"we could never get it to sustain beyond maybe a day,\" he says.\nAnd ketamine's safety record is so good that it's often the painkiller of choice for children who arrive in the emergency room with a broken bone.\nBut the studies of ketamine have produced results so dramatic that some doctors, including Feifel, are bypassing the usual protocols.\nIt found that current antidepressants really aren't much better than a placebo.\nOne is that its ability to keep depression at bay can fade pretty quickly.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Perhaps the main reason this story doesn\u2019t quantify the benefits of ketamine for people with depression is that the small studies done so far have only shown that it is possible there are benefits, without fully testing how consistent or durable the effects are. The story does point out that the FDA has not approved ketamine for the treatment of depression and it mentions that the drug \u201cdoesn\u2019t always work\u201d, but the most prominent and memorable summary of the evidence is that \u201ca single intravenous dose of ketamine produced \u2018robust and rapid antidepressant effects\u2019 within a couple of hours.\u201d That sort of vague endorsement of benefits doesn\u2019t give readers or listeners an accurate sense of how meager the trial evidence of benefits really is.", "answer": 0}, {"article": "Men who had the highest levels of lycopene in their blood were 55% less likely to have a stroke, compared with men who had the lowest levels of the antioxidant in their blood.\nThe findings appear in the Oct. 9, 2012, issue of Neurology.\nDuring that time, 67 men had a stroke.\nTomatoes are not the only food that is rich in this antioxidant.\nThe new study included slightly more than 1,000 men from Finland aged 46 to 65.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides\u00a0relative\u00a0risk numbers, not\u00a0absolute comparisons.\u00a0 Please read our primer on why that\u2019s an important issue.", "answer": 0}, {"article": "Good overall health was defined as having no major chronic diseases, such as heart disease or diabetes, as well as having no significant decline in their thinking or physical abilities.\nFor women who like a nice glass of wine at the end of the day, there\u2019s more good news: Even middle-aged women can have about a drink a day of any kind of alcoholic beverage as part of what they do to try to stay healthy as they age, according to new research.\n\u201cThese data suggest that regular, moderate consumption of alcohol at midlife may be related to a modest increase in overall health status among women who survive to older ages,\u201d the researchers wrote.\nNow, the researchers stressed that wasn\u2019t the case for women who consumed more than two drinks a day or four drinks or more at a time.\nIn a paper published online Tuesday by the journal PLoS Medicine, the researchers found that those who consumed 15 grams or less of alcohol a day, which is the equivalent of one drink of any alcoholic beverage, when they were about 58 years old on average were more likely to have good overall health when they were about 70 years old.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story cites the same relative risk comparisons reported by WebMD, which we think are misleading to the average reader for the reasons discussed in that review. The story should have found a way to communicate that the \u201calmost 50 percent\u201d difference\u00a0between teetotalers and daily\u00a0drinkers probably\u00a0doesn\u2019t translate into a very big difference in risk\u00a0for the individual.\u00a0 See how the \u201cBehind the Headlines\u201d site in the UK analyzed the evidence and included the absolute differences. ", "answer": 0}, {"article": "Parkinson\u2019s disease is a progressive neurological disease that causes symptoms including muscle tremors, shaking, and stiffness.\nThis was an observational study and therefore can\u2019t establish cause and effect.\nIf confirmed, flavonoids may be a natural and healthy way to reduce your risk of developing Parkinson's disease .\"\nNor is it clear why the results differed for men and women.\nThe study, to be presented in April at the annual meeting of the American Academy of Neurology in Honolulu, looked at the relationship between flavonoid intake and Parkinson\u2019s disease in 49,281 men who participated in the Health Professional Follow-up Study and 80,336 women who participated in the Nurses\u2019 Health Study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Inadequate.\u00a0 The story consistently used only relative risk reduction estimates \u2013 35% lower risk or 22% lower risk.\nBut 35% or 22% of what?\u00a0 How many people in either arm of the study developed Parkinson\u2019s?\u00a0 Why not spell it out in absolute terms?\u00a0 Again, we urge WebMD to read another of our primers, \u201cAbsolute vs. Relative Risk.\u201d", "answer": 0}, {"article": "Breathing problems -- already a high risk because labor helps clear the baby's lungs of fluid -- happened four times as often in babies born at 37 weeks than those born at 39 weeks.\n\"I think it points to a role for the baby in the initiation of labor and the baby's readiness to make the transition.\"\n\"I think there is something inherent in labor -- probably a signal from baby to mother that the baby is ready to make the transition -- that we choose to circumvent when we schedule an elective, repeat C-section,\" Thorp said.\nAll of the women had previously had C-sections.\nThe findings from the study sponsored by the National Institute of Child Health and Human Development's Maternal Fetal Medicine Units Network also underscore the importance of a woman seeking medical care as early into her pregnancy as possible, so that doctors can accurately gauge the gestational age with an ultrasound, Mercer said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifiies the risks of C-section. The story could have provided context for these numbers by comparing them to natural birth.", "answer": 1}, {"article": "During widely used colonoscopy, for instance, bleeding or perforation of the colon may happen in rare cases.\nAs a result, he said, it is hard to know whether removing polyps in younger people would in turn lower their risk of getting cancer.\nTo find a late-stage polyp, which may or may not turn into cancer, the researchers calculated they would have to test 23 of the people who were in their 50s.\nLeFevre, a member of the U.S. Preventive Services Task Force, a federally appointed expert panel, said the chances that a polyp turns into cancer is currently a matter of debate.\nAs part of their employer-provided health benefits, each participant in the study underwent screening colonoscopy at Konkuk University, which also sponsored the research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the number of people who would need to be screened in order to find one late-stage polyp (and is clear to point out that they may or may not develop into cancer).", "answer": 1}, {"article": "The findings appear in the latest Archives of Surgery.\nBy year three, the data were only available for 288 patients, about 13 percent of those who got the surgery.\nThe researchers argue that the findings, drawn from data on four years of claims made in seven states, support coverage of bariatric surgery by insurers because of the savings and improvements in patients' health.\nAlso, at two years after surgery, data were available for less than half the patients.\nBut an analysis of insurance claims for more than 2,200 people with Type 2 diabetes who underwent stomach-reducing surgery found that the vast majority of them were able to drop drugs they had been taking to treat the condition beforehand.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\"/>\n\n\n\n \nOur primary reviewers (a journalist and a physician) were split on this one.\u00a0 \nThe journalist said that the story reports specifics of how many participants in this study stopped taking diabetes medications following stomach-reduction surgery, but it does not provide any context. All of the study participants were extremely obese and had diabetes. How many obese people have diabetes? Readers are not told. How many people with diabetes are so obese that they may be candidates for stomach-reduction surgery? Readers are not told. How does the reduction in health care spending following surgery compare to the spending trends of other people who are obese and have diabetes? Readers are not told that the study did not explore that question. The lack of context makes it difficult to appreciate the true value of the reported benefits.\nThe physician agreed that context was not provided but felt the story did a satisfactory job of summarizing the main benefits as presented in the study. \nThe publisher tilts the scales toward a satisfactory score.\u00a0 The call for context by the first reviewer is appropriate.\u00a0 But the story met the baseline criterion for a passing grade \u2013 especially within the confines of a brief blog entry.\u00a0 We also note that this blog \u2013 using best practice on the web \u2013 linked to the published study so readers could dig deeper if they wished. \n ", "answer": 1}, {"article": "Drinks such as POM have become increasingly popular with consumers in recent years, thanks in part to public health campaigns against soda that have been prompted by the obesity epidemic.\nThat's the paradox of products such as POM, Silverglade says: The health claims on these products strain the imagination, yet studies have repeatedly shown that health claims sell food.\nHealth.com: You are what you drink\n\nBut the fact is, even when people don't buy the health claims they often still buy the beverage.\nBut that doesn't mean the claims are invented -- most are based in research.\nMost health beverage drinkers aren't as enthusiastic as the realtor from Alaska who posted the above testimonial.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story explained why the purported health benefits of POM and other drinks are difficult\u00a0to quantify due to a lack of appropriate research. This gap between claims and proof is highlighted in the story headline and the lead sentence, which points out the absurdity of the claim that POM is \u201c40% as\u00a0effective as Viagra\u201d \u2014 a statistic which has no real meaning or purpose except to make the product sound more appealing.\nStill, the expectation is that somewhere in a story there will be some discussion of the absolute risk reductions seen in the primary studies used to substantiate a claim about benefits. This is a problem touched on earlier under the Evidence Evaluation criterion; we\u2019ll dock the points here.", "answer": 0}, {"article": "Pneumonia is a leading cause of death for elderly patients, with over 90 percent of pneumonia-related deaths among those 65 and older.\nThe data were analyzed by intention-to-treat analysis of all participants and by per-protocol analysis of participants who finished the study without missing any protocol treatments.\nDisclosures: The basis for this analysis, The Multicenter Osteopathic Pneumonia Study in the Elderly (MOPSE) clinical trial, was funded by a consortium of foundations including the Foundation for Osteopathic Health Services.\nThe study analyzed 375 patients ages 50 or older who were randomly assigned to three groups, either receiving OMT, a light touch or conventional care only.\nDifferences between treatment groups were evaluated for subgroups of participants based on their age, Pneumonia Severity Index and type of pneumonia.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release briefly but adequately covers the major quantitative findings. For example, the 1.1 reduction in hospital stay mentioned in the release is an absolute reduction. The release would have been greatly strengthened by including more of the results in the narrative that are confined to the graphic. Describing the actual length of stay in each group, which is provided in the graphic, as opposed to just the amount of the reduction would provide some context for how meaningful the benefit it is. (i.e. a 1-day reduction on a 30-day stay being less impressive than a 1-day reduction on a 4-day stay).\u00a0It also could have given more attention to a comparison of the full manipulative therapy and \u201clight touch\u201d therapy groups. For the mortality data, it wasn\u2019t clear from the text if they are referring to an absolute or relative risk reduction.", "answer": 1}, {"article": "The most common form of breast cancer uses oestrogen to grow.\nOur study also demonstrates that statins could be a valuable addition to breast cancer treatment, and that this warrants investigation in clinical trials.\u201d\n\nThe research has not yet been tested in humans.\n\u201cWe know that many women can be consumed with fear of their breast cancer coming back, which can have a huge impact on their ability to move forward after treatment.\n\u201cThis study breaks new ground in uncovering how some breast cancers continue to survive without oestrogen and suggests that women could benefit from adding statins to standard anti-hormone treatments.\n\u201cThis early study raises an interesting question of whether cholesterol-reducing treatment, such as statins, could help lower the chances of breast cancer returning for some women who have developed a resistance to hormone therapy,\u201d said Jane Murphy, clinical nurse specialist.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "At this point, there are no demonstrable benefits to quantify, even though the story states that the research \u201cdemonstrates that statins could be a valuable addition to breast cancer treatment\u201d warranting more investigation.\nWhat the scientists found was production of a cholesterol molecule in cancer cells\u2013and that there was potential to slow the cancer cells\u2019 growth by interfering with this molecule. Whether this translates into clinical benefits for women is not known, and won\u2019t be anytime soon. The story should have said this.", "answer": 0}, {"article": "Achillion\u2019s ongoing mid-stage study tests its NS5A inhibitor, ACH-3102, with Sovaldi in previously untreated genotype 1 hepatitis C patients over six and eight weeks of therapy.\nMonday\u2019s data shows Achillion\u2019s NS5A inhibitor, ACH-3102, looks best-in-class, which could make up for its nuke, ACH-3422, being perhaps less effective than Sovaldi, analysts said.\nThe main goal is to achieve a cure, or sustained virological response, 12 weeks after the completion of therapy.\nThe question then becomes whether ACH-3422 plus ACH-3102 - a weaker nuke and a stronger NS5A inhibitor - could be a good enough doublet as Harvoni, William Blair\u2019s Katherine Xu said.\nShe expects the treatment to cost about $35,000 per patient per year, assuming a 55 percent discount.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of the drug, even as it is presenting the findings as proof of a \u201ccure.\u201d The story says the drug \u201ceradicated signs of the virus,\u201d but there is nothing about who the patients were, how sick they were, or how many there were. It may be easier to eradicate the virus in individuals whose disease is not very advanced. Would patients with longstanding disease respond as favorably? We can\u2019t answer any of these questions because the details simply aren\u2019t provided.", "answer": 0}, {"article": "And if I can be saved, so can other people.\u201d\n\nThe study results were unveiled Thursday in advance of a major cancer conference next month.\nAnderson Cancer Center researchers Thursday reported the results of a study that showed a simple blood test, tracked over time and followed by an ultrasound if needed, accurately picks up the disease in early, more curable stages.\nAmong the study participants was Liz Stegall, who enrolled at the request of the family of Linda Nelson Taylor, a friend who died of ovarian cancer that wasn't diagnosed until it was advanced.\nThree of the eight turned out to have benign tumors.\nOver the study's nine years, 85 women had ultrasounds and eight had surgery.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides the number of cancers identified and false positives.", "answer": 1}, {"article": "Zied is also the author, with Ruth Winter, of a book titled \"So What Can I Eat?\"\nElisa Zied, a registered dietitian and a spokesperson for the American Dietetic Association, talked about how to properly interpret information on food labels.\nFor more information on this subject, see these two articles on WebMD: Weight Loss: How To Read Food Labels and Cracking the Code.\nFears says kids do follow their parents' leads, \"even though they may never admit it.\nFor more information about the businesses featured in the series, click on:\n\nThe Consumer Product Safety Commission wishes to remind you that using camp stoves, portable camping heaters, or lanterns or charcoal grills inside your home produces dangerous levels of carbon monoxide, as does using a portable generator inside your home.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "That adequate folic acid intake\u00a0reduced risk (a 28% reduction in neural tube defects; 40% reduced risk of cleft lip or palate) was presented as relative risk only.\u00a0 Especially as these are both rare birth defects, the change in numbers that potentially results from insuring adequate folic acid intake is small. The context of absolute risk reduction was important, but missing. ", "answer": 0}, {"article": "\u201cMy first reaction to this study, because it came as a bit of a surprise, was, \u2018Oh, are we doing our job explaining that point to patients?\u2019\u201d Dr. Gralow said.\nThough the researchers had limited information about the patients, Dr. Tuttle suggested that younger women might be choosing the procedure because their cancers tended to be very aggressive, and they had more years ahead of them in which a second cancer might develop.\n\u201cFewer women are having just one breast removed.\u201d\n\nYounger women, white women and women with a previous cancer diagnosis were more likely to opt for a contralateral prophylactic mastectomy, the study found, as were women who had lobular histology, meaning the cancer started in the lobules or milk-making glands of the breast.\nThough all women with breast cancer are at risk of developing a second cancer in the uninvolved breast, the risk is slightly greater with lobular histology, Dr. Tuttle said, and white women may be more likely to carry genetic mutations associated with an increased risk of developing cancer in the contralateral breast.\nThe numbers were much higher among women who had the breast with cancer removed, rather than a lumpectomy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The focus of the story was the increase in bilateral mastectomies in women diagnosed with breast cancer in one breast.\u00a0 The story notes that the survival difference between lumpectomy and mastectomy is about the same; however, the story does not mention that radiation is given with lumpectomy in order to reduce the risk of recurrence. Lumpectomy is not comparable to mastectomy without radiation. The story might have benefited from listing these data comparing lumpectomy and radiation with mastectomy. The story appropriately notes that having a mastectomy does not reduce a recurrence risk to zero as some cancer cells may remain. ", "answer": 0}, {"article": "When Finnish researchers randomly assigned 230 babies at high risk of type 1 diabetes to receive either a regular infant formula, or one that was extensively hydrolyzed -- which means the proteins in the formula are already partially broken down and more readily available for digestion -- they found that the extensively hydrolyzed formula cut the rate of developing diabetes-linked antibodies in the blood by about half.\nWEDNESDAY, Nov. 10, 2010 (HealthDay News) -- Offering your baby a special formula when weaning off breastfeeding may offer some protection against the development of the antibodies associated with type 1 diabetes, if you have a family history of the disease, new research suggests.\n\"I think this is an important study because we need to understand what causes type 1 diabetes,\" said Harlan, who added the caveat: \"In this study, while there is an apparent signal, there are also some causes for withholding complete faith in the conclusion that the formula caused diabetes.\"\n\"I think the authors designed this study to address their hypothesis that proteins present in non-hydrolyzed formula might incite an immune response, and by breaking them down, you might eliminate the immune response.\nPeople who have two or more type 1 antibodies have between a 50 and 100 percent risk of developing type 1 diabetes, according to background information in the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019ve already penalized the story in \u201cevidence\u201d\u00a0above for not giving the absolute risk reduction, so we won\u2019t do it again here. The story reports on a study which showed about 50% fewer diabetes antibodies in at-risk children who were fed special hydrogized infant formula. But 50% of what?\u00a0 This may or may not translate into fewer cases of childhood diabetes. If there are other side effects or harms associated with using hydrolyzed versus standard formula, they are not described.", "answer": 1}, {"article": "Suvorexant is part of a class of drugs called Dual Orexin Receptor Antagonists or DORAs, which work by blocking chemical messengers called orexins.\n\u201cThese treatments work by forcing the brain to go to sleep,\u201d said study leader Jason Uslaner of Merck in an interview on the website of Science Translational Medicine, which published the study.\nFor this study, the team wanted to find out what would happen if someone is awakened on this drug and has a very high level of it in their system.\n\u201cWhen you hit those, you don\u2019t just hit the sleep system,\u201d John Renger, executive director and head of neruoscience basic research at Merck and one of the study\u2019s authors, said in a telephone interview.\nExperiments in animals suggest Merck\u2019s sleep drug Suvorexant, now before the U.S. Food and Drug Administration, may avoid these side effects, the company said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This study was in animals and the researchers note that tests will have to be done in people to see if there are similar results. The researchers also note that this animal experiment did not look at the \u201changover\u201d effects that many patients complain about. The story gives readers the impression that there is much more known about benefits than was actually tested in this experiment \u2013 especially with the lead saying the drug \u201cmay cause fewer side effects\u201d\u2026letting a researcher say \u201cThese treatments work by forcing the brain to go to sleep\u201d (when the jury is still out on whether/how well they work\u2026etc.", "answer": 0}, {"article": "So we need to follow up on anything that looks promising.\"\n\"Because Nathalie had previously shown that parvalbumin passes into the body of the person eating fish, it made sense to study its interaction with human proteins.\nWhat the Chalmers researchers have now discovered, is that parvalbumin can form amyloid structures that bind together with the alpha-synuclein protein.\n\"Parvalbumin collects up the 'Parkinson's protein' and actually prevents it from aggregating, simply by aggregating itself first,\" explains Pernilla Wittung-Stafshede, Professor and Head of the Chemical Biology division at Chalmers, and lead author on the study.\nWith the parvalbumin protein so highly abundant in certain fish species, increasing the amount of fish in our diet might be a simple way to fight off Parkinson's disease.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t include any numbers to help put the benefits claimed in context. Early in the news release a lead author is quoted as saying:\nParvalbumin collects up the \u2018Parkinson\u2019s protein\u2019 and actually prevents it from aggregating, simply by aggregating itself first.\nLower down in the news release it says:\nIncreasing the amount of fish in our diet might be a simple way to fight off Parkinson\u2019s disease\nThe italics are ours to emphasize that unjustified leaps of causality, and unjustified language, are used to imply benefits that can\u2019t be supported by this study.\nThis study simply hypothesizes that PV, by binding with alpha-synuclein, prevents it from forming amyloid chains with other proteins.\u00a0We\u2019ve written many times about the uncertainty surrounding amyloids (of all types/subtypes) as a sign of, or contributor to, neurodegenerative diseases like Parkinson\u2019s or Alzheimer\u2019s.", "answer": 0}, {"article": "Gout occurs when uric acid builds up in the body and forms crystals in the joints or in soft tissue.\nSavient expects Krystexxa to be available by prescription later this year.\nTwo six-month clinical trials of 212 total patients showed that the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.\nThe drug is associated with some serious side effects.\nThe crystals cause swelling, redness, pain, and stiffness in the joints.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Unsatisfactory.\u00a0 All the story said was \"that the drug lowered uric acid levels and reduced deposits of uric acid crystals in joints and soft tissue.\"\nHow many people saw a benefit? How much did the drug lower these levels?\u00a0 Was that significant in peoples\u2019 lives?\u00a0 This, again, is where the story could have benefited from an independent perspective. ", "answer": 0}, {"article": "Avastin is a so-called monoclonal antibody that works by blocking vascular endothelial growth factor A, which stimulates the growth of the tumor's blood supply.\nThe funder was involved in study design, coordination of data collection, data analysis, data interpretation, and writing of the report, the journal noted.\nThe Food and Drug Administration on Tuesday will ask a panel of outside experts to review the evidence on the Roche drug, the Associated Press said.\nThe efficacy of the drug has been proven previously, he noted, but this study provides an in-depth analysis of Avastin's safety profile under \"real life\" conditions, he added.\nThe researchers reported few clinically significant adverse events, meaning that most were no greater than what one would expect in the general population.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story failed to report that the study reported on examined whether the use of this drug in this clinical situation was safe but did not look at the question of whether it was of benefit to the patients. \u00a0The story mentioned that a previous study has indicated that this drug has benefit but did not provide information about the type of benefit that was observed.", "answer": 0}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story did a better job than a competing ABC News story in explaining what the test found. It broke down the different ranges of scores and the corresponding risk of premature death. A good next step would have been to explain how many people fell into each category. It\u2019s unclear from most of the coverage of this study just how many people \u2014 of those who died \u2014 had a particular score with this new test.", "answer": 1}, {"article": "This was not statistically different.\nThe study suggests most patients can have just aspirin without increasing the risk for venous thromboembolism, but doctors need to consider factors such as a patient's history of clots, obesity and ability to mobilize after surgery when determining the best measure for clot prevention, Hallstrom adds.\nBased on the experience of 41,537 Michigan patients undergoing knee replacement, the study may further the debate about the routine use of aspirin for clot prevention.\nThe U-M study involved patients undergoing knee replacement surgery at any of the 29 Michigan hospitals in the surgical quality group.\nThe new U-M study suggests patients may be adequately protected if they take aspirin alone from day one.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release lists the percentages of patients who had a blood clot within three months of their knee replacement and emphasized that there was no statistical difference between those who took only aspirin and those who took anticoagulants.\u00a0 However, the release is remiss in not\u00a0pointing out that the majority of patients were also treated with pneumatic compression boots.", "answer": 1}, {"article": "Rectal cancer affects some 2,000 men and women in Sweden every year.\n\"The results of the study will give rise to improved therapeutic strategies, fewer complications with a sustained low incidence of local recurrence, and better survival rates for rectal cancer patients,\" says Professor Martling.\nThe results of the study show that patients with delayed surgery develop fewer complications with equally good oncological outcomes.\nThe study now presented in The Lancet Oncology is based on the claim that the adverse effects of rectal cancer treatment can be reduced by administering more but lower doses of radiation for a longer time, or by increasing the interval between radiotherapy and surgery.\n\"Back then we showed that preoperative radiotherapy reduces the risk of local recurrence by over 50 per cent for patients with rectal cancer,\" says principal investigator Anna Martling, senior consultant surgeon and professor at Karolinska Institutet's Department of Molecular Medicine and Surgery.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release itself does not quantify benefits. But according to the study, short-course radiation therapy with no delay in surgery resulted in postoperative complications 53 percent of the time, versus 41 percent of\u00a0 cases in which surgery was delayed. The release would have been much stronger had it provided the outcomes of this randomized trial of 840 patients who were divided into different treatment arms.\nWe give the release credit for trying to convey what the study\u2019s findings mean for patients through these statements:\nThe results of the study show that patients with delayed surgery develop fewer complications with equally good oncological outcomes. It also showed that there is no difference between long-course and short-course radiotherapy other than that the former considerably lengthens the time for treatment.\n\u201cThe results of the study will give rise to improved therapeutic strategies, fewer complications with a sustained low incidence of local recurrence, and better survival rates for rectal cancer patients,\u201d says Professor Martling. \u201cThe results can now be immediately put to clinical use to the considerable benefit of the patients.\u201d", "answer": 0}, {"article": "Prostate cancer remains the second leading cause of cancer death among men in the U.S., with nearly 30,000 deaths annually.\nThe study showed that 12 months after the draft guidelines were published diagnoses of new low risk cancers had fallen by 37.9%, and continued to fall more rapidly than other disease risk strata, suggesting that, in this regard, the USPSTF recommendation had its intended effect,.\nThis study helped quantify the potential benefits (reduced harms of over diagnosis and overtreatment of low risk disease and disease found in elderly men) and potential harms (missed opportunities to diagnose important cancers in men who may benefit from treatment).\n\"While some of the effects of this guideline may be beneficial in terms of reducing harms of over diagnosis and overtreatment, the reduction in intermediate and high risk cancer diagnoses raises concern for delayed diagnoses of important cancers associated with inferior cancer outcomes,\" noted Dr. Barocas.\nThe uncertain benefit of PSA based screening, combined with the complications associated with treatment, led the USPSTF to conclude in October 2011 that the harms of PSA based screening outweighed the benefits, leading it to recommend against regular screening.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The apparent\u00a0benefit of the USPSTF guidelines is the 37.9% reduction in the incidence of\u00a0low-risk cancers\u2013the over-diagnosed cancers that lead to over-treatment. While this benefit takes second billing to the potential risks of finding fewer higher-risk cancers in the release, there is at lease some discussion of this benefit. The fact that the rate of non-localized cancer did not increase in the study is reassuring\u2013though the follow-up time is actually way too short to know whether\u00a0trend\u00a0will be durable.", "answer": 1}, {"article": "\u201cMany have been told all their lives that if they ingest peanuts they will have a severe reaction and die,\" he said.\nIt means that \u201cthey are not going to have to worry about traces of peanut in a package that came from a plant where peanuts were used or minor contamination of food in a restaurant,\u201d said the study\u2019s lead author, Dr. Hugh Sampson, a professor of pediatrics at the Icahn School of Medicine and director of the Jaffe Food Allergy Institute at Mount Sinai.\nResearchers are trying to discover why food allergies have increased among children \u2014 the number of kids living with peanut or tree nut allergies tripled between 1997 and 2008, studies show \u2014 but there\u2019s no clear answer.\nFor those plagued with peanut allergies, protection may eventually come in the form of a patch worn on the skin, a new study suggests.\nIn the second phase of a drug trial, half of participants wearing the highest dose \u201cpeanut patches\u201d for a year were able to consume the equivalent of four peanuts without reacting, researchers reported Sunday at the annual meeting of the American Academy of Allergy, Asthma, and Immunology.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The level of specificity in the description of benefits in this story is laudable. The text makes it clear that the highest dose intervention desensitized half of the allergic participants by a relatively modest amount, enabling these individuals to be exposed to a gram of peanut protein without reacting. The story also goes on to explain the value of this modest change: this desensitization level may permit allergic individuals to manage \u201cchance\u201d encounters with bits of peanut that can contaminate food products.\nSince this was a placebo-controlled trial, however, we wish that the story had provided details about the placebo response rate, as that would have made it clear that the patch was more effective than the placebo. In addition, the take-home message from the headline and first sentence seems less careful than the clearly stated benefit in the story body. As a result, readers may infer a greater benefit than the study actually describes. One could easily conclude that the patch can provide complete protection from an allergic reaction, and that simply is not the case.", "answer": 1}, {"article": "Shift workers with chronic sleep deprivation also face an increased risk of accidents.\nIn two scenarios, participants spent a night being sleep-deprived in a lab and then spent 45 minutes in dim or bright light before a driving test.\nAfter sleep deprivation in the lab, five people exposed to dim light therapy got in car accidents during the driving simulations.\nThe proven way to avoid the effects of sleepiness on the road is to consistently get enough sleep, said Dr. Flaura Koplin Winston, a researcher at the University of Pennsylvania and the Children\u2019s Hospital of Philadelphia who wasn\u2019t involved in the study.\n\u201cThere is evidence that the use of bright light at the office (or even at home directly prior to beginning the work shift) may be beneficial in preventing sleep deprivation-related motor vehicle collisions,\u201d said Russell Griffin, a researcher at the University of Alabama at Birmingham who wasn\u2019t involved in the study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is specific about the number of sleep-deprived participants who crashed their simulated cars\u00a0after exposure to dim light (5) compared\u00a0to those whose simulated drive home was preceded by 45 minutes of bright light (0).", "answer": 1}, {"article": "In 2016, he was ranked the No.\nIn this trial, all randomized subjects were given the same brushing protocol and received a 60-day supply of toothpaste containing either Plaque HD\u00ae or an identical non-plaque identifying placebo toothpaste.\nThese results, published today online ahead of print in the American Journal of Medicine, with an accompanying editorial by the editor-in-chief, show that Plaque HD\u00ae, produced statistically significant reductions in dental plaque and inflammation throughout the body as measured by hs-CRP.\nFor hs-CRP, levels were measured by an independent laboratory using an enzyme linked immunosorbent assay.\nThis large scale randomized trial will test whether Plaque HD\u00ae reduces risks of heart attacks and strokes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release fails to quantify the observed reductions in tooth plaque and high-sensitivity C-reactive protein. Although the body of the release notes that the researchers are planning a much larger trial in order to see whether this toothpaste can reduce the risk of heart attack and strokes, the sub-heading (\u201cFindings support reductions in heart attacks and strokes\u201d) overstates the study conclusions.\nAlso, by not including the patients with low CRP levels, the results could be more impressive than if used in a larger population with patients who have elevated CRP and those who don\u2019t.", "answer": 0}, {"article": "Frustrated by the high relapse rate of traditional addiction treatments, scientists are working on a strategy that recruits the body's own defenses to help addicts kick drug habits.\n\nThe new approach uses injected vaccines to block some addictive substances from reaching the brain. If a vaccinated addict on the path to recovery slips and indulges in a drug, such as tobacco or cocaine, no pleasure will result.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We wanted to see\u00a0better coverage of the data here. The story leads with an anecdote about a patient who kicked a pack-a-day smoking habit after treatment with a nicotine\u00a0vaccine in a study.\u00a0And later,\u00a0the story says that smokers who received that\u00a0vaccine were \u201cabout three times as likely to be off cigarettes 44 weeks after vaccination than subjects given a placebo.\u201d\u00a0The story should have provided\u00a0the absolute rates of success reported in the study, which were only 16% for the treatment group compared with 6% for the placebo group, according to theheart.org. Elsewhere,\u00a0the story\u00a0describes an experimental anticocaine vaccine that was apparently very effective in a mouse study; it could have reported on\u00a0phase II human data that is available for the\u00a0TA-CD\u00a0anticocaine vaccine that was also mentioned in the story.\u00a0These data again suggest that only a minority of patients\u00a0may benefit from the use of anti-addiction\u00a0vaccines.", "answer": 0}, {"article": "\"There is a tremendous lack of kidneys for transplant,\" he explained.\nTUESDAY, Aug. 7, 2018 (HealthDay News) -- Dialysis patients waiting for kidney transplants might safely accept an organ from a donor infected with hepatitis C virus (HCV), a new study finds.\nThough some patients might not want to take the risk associated with an infected kidney, others might consider it a good option, given the high death rates for dialysis patients awaiting transplants, the researchers suggested.\nBut the cost effectiveness of using these kidneys versus remaining on dialysis would be significant, he noted.\nUsing hepatitis C-infected kidneys would expand the organ pool and save lives, said lead researcher Dr. Peter Reese.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported the main benefit of using infected kidneys, which is shorter wait time for a transplant. It said that the average wait time for a non-infected kidney is more than two years, compared to eight months for an HCV-infected kidney.\nThe story also said transplanting infected kidneys and then treating recipients for HCV resulted in a \u201c100 percent cure rate. Half were evaluated six months after their transplant and the others a year after.\u201d\nIt quoted the lead researcher, Peter Reese, M.D.: \u201cAnd we found that these kidney transplants were working as well as kidney transplants from uninfected patients.\u201d\nWe\u2019ll rate this as satisfactory. However, we\u2019d note that the story didn\u2019t point out that we don\u2019t know much about long-term benefits or overall survival at this point. Do these patients live as long? Are their rates of liver problems the same as those who receive uninfected kidneys? It will take much more than one year of follow-up to learn the answers to these questions.", "answer": 1}, {"article": "A second infection study, also reported in the journal, found that a chlorhexidine-alcohol combination produced 41 percent fewer surgical-site infections as the commonly used mixture of povidone and iodine, which gives a yellow-orange tinge to the skin.\nThe research team, led by Dr. Lonneke Bode of Erasmus University Medical Center in Rotterdam, estimated that 250 patients would need to be screened to prevent one infection.\nAlthough his team did not evaluate enough patients to study the problem directly, \u201cWe feel this technology is capable of preventing those types of infections as well,\u201d Verbrugh said.\nThe new study, published in the New England Journal of Medicine, used a rapid test to identify which patients, most of whom were scheduled to undergo surgery, had the bacteria in at least one nostril.\nThe treatment combination also shaved two days off a typical 14-day stay in the hospital.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The potential benefits are quantified.\u00a0We were pleased to read absolute risk reduction data following the relative risk reduction data.", "answer": 1}, {"article": "Like aspirin, salsalate is an anti-inflammatory drug derived from salicylate and is often used to treat arthritis.\nThe results showed those who took salsalate at each of the dosage levels experienced a beneficial decrease in blood sugar A1c levels of 0.5% or more.\nIn the study, published in the Annals of Internal Medicine, researchers randomly assigned 108 people with type 2 diabetes to receive 3, 3.5, or 4 grams per day of salsalate or a placebo in addition to their current diabetes therapy for 14 weeks.\nOther markers of glycemic control and heart disease risk also improved in the three salsalate groups compared with the placebo group.\n\"Because of salsalate's anti-inflammatory effects, our results suggest that inflammation plays a role in the pathogenesis of type 2 diabetes and that anti-inflammatory therapy may be useful for treating diabetes,\" write researchers Allison B. Goldfine, MD, of the Joslin Diabetes Center in Boston, and colleagues.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story makes the same misinterpretation of the key result as the other story on this topic we reviewed. It states that \"The results showed those who took salsalate at each of the dosage levels experienced a beneficial decrease in blood sugar A1c levels of 0.5% or more.\" That makes it sound like the floor \u2014 that everyone in each salsalate group had no less than a 0.5% drop. As discussed in more detail in our review of the other article, that wasn\u2019t the case.", "answer": 0}, {"article": "(Reuters) - The U.S. Food and Drug Administration (FDA) on Friday expanded the use of Novartis AG\u2019s relapsing multiple sclerosis (MS) drug Gilenya to treat children and adolescents.\n\nMS is a chronic, inflammatory, autoimmune disease of the central nervous system that disrupts communication between the brain and other parts of the body and is among the most common causes of neurological disability in young adults.\n\nGilenya is the first FDA-approved drug to treat pediatric patients suffering from relapsing MS, the U.S. health regulator said.\n\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\n\nGilenya was first approved by the FDA to treat adults with relapsing MS.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated:\nIn a clinical trial 86 percent of patients receiving Gilenya remained relapse-free after 24 months of treatment, compared to 46 percent of those who were administered another MS drug.\nHowever, it didn\u2019t explain how many relapses patients in either groups experienced, so readers can\u2019t tell how much of an impact these drugs actually had.", "answer": 0}, {"article": "We are actively seeking the best-suited licensees having resources and marketing expertise to maximize sales for each of our products in the U.S. and globally.\"\nAfter 48 hours, the average pain reduction for OsteoRx\u2122 users was nearly three times greater than for patients using the competing brand.\nAfter just 24 hours, patients using OsteoRx\u2122 experienced an average improvement in range of motion that was more than twice as large as the competition.\nIndependent statistical experts determined that, over the course of the study, patients using OsteoRx\u2122 experienced significantly higher reduction in pain and significantly greater improvement in range of motion than did patients using the competing product.\nAt 72 hours, OsteoRx\u2122 results were nearly five and a half times better.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release provides incomplete and potentially misleading information regarding benefits. The benefits are never given in specific numbers but only as X times the amount the other drug provided. Examples:\n\u201cAfter 48 hours, the average pain reduction for OsteoRx\u2122 users was nearly three times greater than for patients using the competing brand. At seven days, average pain reduction was more than three times greater than the competition. After 14 days of treatment, average pain reduction was more than twice as large as the competition.\u201d\n\u201cAfter just 24 hours, patients using OsteoRx\u2122 experienced an average improvement in range of motion that was more than twice as large as the competition. At 72 hours, OsteoRx\u2122 results were nearly five and a half times better.\u00a0After 14 days of treatment, the average improvement was still nearly twice as large as the competition.\u201d\nThat\u2019s like claiming if the other drug provided a smidgen, this drug provided 2 smidgens. Not very good evidence.", "answer": 0}, {"article": "We could not find the requested page.\n\nPlease visit our home page to explore our services.", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release reports a 98% sensitivity and 36% specificity for melanoma detection, which is a level that approaches that of an expert lesion diagnosis.\nBut the release could have noted that this still isn\u2019t very accurate: A 36% specificity means that 64% of those without melanoma will test positive (i.e. false positive). That translates to a lot of unnecessary anxiety and follow-up testing to rule out suspicious growths.", "answer": 1}, {"article": "For more information on heart disease, visit the American Heart Association.\nBut a cardiology expert said that although the study adds to evidence supporting meditation, it doesn't prove a cause-and-effect relationship between the practice and better health outcomes.\n\"In addition, since this study was conducted at a single center and the primary [change in heart attack, stroke and death] was not statistically significant without adjustment for other factors, more studies and replication of these findings are needed,\" he said.\nAn outside expert, however, said the study is too limited in size and scope to allow conclusions as to whether meditation really reduces risk of death or disease.\nAfter more than five years of follow-up, the researchers found those who meditated saw significant reductions in blood pressure and anger compared to those receiving health education.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story tells us that 20 people in the medication group had a heart attack or stroke or died, compared with 32 in the health education group. It also provides the number of subjects who participated in the study (201).\u00a0 We would have liked to have seen both the numerator and denominator provided for completeness (20/99 in the TM\u00a0 group vs. 32/102 in the HE group for example). This is still preferable to simply telling readers that there was a \u201c48% reduction\u201d in risk.", "answer": 1}, {"article": "Depression presents an enormous disease burden, with a reported 350 million people worldwide suffering from the disease, but traditional SSRI treatments carry a burden of their own - in dollars and side effects.\nThe study team found that in 112 participants with analyzable data, consumption of magnesium chloride for six weeks resulted in a clinically significant improvement in measures of depression and anxiety symptoms.\nParticipants in the active arm of the study received 248 milligrams of elemental magnesium per day over six weeks, while those in the control arm received no treatment.\nThe study participants, who were currently experiencing mild-to-moderate depression, had a mean age of 52, with 38 percent of them male.\nTheir results showed that magnesium is safe and effective and comparable to prescription SSRI treatments in effectiveness.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "According to the news release, consuming magnesium chloride \u201cresulted in a clinically significant improvement in measures of depression and anxiety symptoms.\u201d But the release made no mention of what these measures were, or how the measurements were taken.\nThe published study notes that the primary outcome measure was a mental health questionnaire given by phone bi-weekly (the Patient Health Questionnaire-9, or PHQ-9). Like any survey, this method of data collection is vulnerable to bias in the form of self-reporting. In the published study, the researchers said that the results of the PHQ-9 survey are clinically significant if there is a 5-point or more difference between treatment and baseline. The net improvement was a difference of 4.2 points, but when the researchers adjusted for other factors (including age, race, gender, smoking, alcohol use, and treatment adherence), the difference rose to 6 points, making it clinically significant.\u00a0Importantly, however, the duration of this treatment benefit beyond this brief trial is unknown.\nNone of these nuances were mentioned in the news release.", "answer": 0}, {"article": "Your cells might be aging faster than you are, and new tests purport to help you find out.\n\nA few companies are offering mail-order testing to measure the length of people\u2019s telomeres, the protective caps of DNA on the ends of chromosomes that have been likened to the plastic tips that prevent shoelaces from fraying. Telomeres gradually shorten as people age and eventually may disappear, leaving cells vulnerable to disease and death.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provides some quantification (via a discussion of a prostate cancer study) but overall clearly establishes that there is a lack of benefit.", "answer": 1}, {"article": "\"The next questions are, 'how do we increase the number of patients who respond?'\nIn addition to demonstrating increased overall survival, the researchers showed a higher objective response rate - the number of patients who respond to the treatment - with nivolumab.\nMore than 12 months later, 31% and 27% of patients treated with nivolumab and everolimus, respectively, continued to show a response.\nThis ongoing response was observed among 44% of those treated with nivolumab and 36% of those treated with everolimus.\nThese results led the trial to be halted early in July 2015 when an assessment conducted by the independent Data Monitoring Committee (DMC) concluded that the study met its primary endpoint, demonstrating superior overall survival in patients receiving nivolumab.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The primary outcome measure for the study was median survival.\u00a0 The news release notes, \u201cIn the randomized phase III clinical trial, patients whose disease progressed on antiangiogenic therapies were treated with either nivolumab or everolimus. Median overall survival was 5.4 months longer with nivolumab (25 months) compared with everolimus (19.6 months).\u201d We are also told, \u201cMore than 12 months later, 31% and 27% of patients treated with nivolumab and everolimus, respectively, continued to show a response.\u201d\nIf one is discerning, it becomes clear that this new treatment buys a patient about 5 months of survival time. That\u2019s certainly valuable time, but it\u2019s debatable whether that amounts to the kind of benefit patients associate with the term \u201cbreakthrough.\u201d", "answer": 1}, {"article": "For instance, yoga may influence brain chemicals known as neurotransmitters (boosting levels of feel-good agents like serotonin), lower inflammation, reduce oxidative stress and produce a healthier balance of lipids and growth factors \u2014 just as other forms of exercise do.\nBut while the research is promising, yoga likely won\u2019t be a panacea for mental illness.\nDespite all of this, the vast majority of studies looking at the benefits of yoga are all small studies.\n\u201cMost individuals already know that yoga produces some kind of a calming effect.\nSome of the studies included in the analysis even suggested that yoga might affect the body in ways similar to antidepressants and psychotherapy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u2019s description of benefits is unacceptably\u00a0vague. It reports that the yoga has \u201cpositive effects on mild depression and sleep problems, and it improves the symptoms of psychiatric disorders like schizophrenia and ADHD among patients using medication.\u201d\nBut which symptoms or outcomes specifically does yoga\u00a0improve? And by how much?\u00a0Which of the dozens forms of yoga out there should patients look for? These key details are not provided. And without them the story is far less useful than it could be for people trying to make decisions about their treatment.\nAnd if the journal article on which the story is based didn\u2019t make this clear \u2013 or if the scientists\u2019 methods were questionable \u2013 then the entire basis for the story itself is questionable.", "answer": 0}, {"article": "\"Generally, people wonder if it is worth it.\nThe study also looked at different characteristics associated with patients being more likely or less likely to experience clinically meaningful change from massage.\nMore than 50 percent of those who participated in the study experienced clinically meaningful improvements in their low back pain with disability, according to Munk.\nWhile the study results are promising, much more work needs to be done, Munk said: \"The fact of the matter is that chronic lower back pain is very complex and often requires a maintenance-type approach versus a short-term intervention option.\"\nIn this study, patients were referred by a physician to a massage therapist.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does not explain the benefit in useful numerical terms. It includes the statement that more than 50 percent of patients received \u201cclinically meaningful improvements.\u201d We need the release to describe a single one of those improvements and define \u201cmeaningful\u201d using numbers.\nOne could argue that \u201c50 percent\u201d is a quantified benefit, however, the use of \u201cmore than 50 percent\u201d does not appear accurate since they are claiming improvement in low back pain without telling us that the benefit fell away in time. The number reported in the study for the \u201cbodily pain domain\u201d is 49.4 percent clinical improvement at 12 weeks and 40 percent improvement at 24 weeks \u2014 a lessening of the benefits over time.", "answer": 0}, {"article": "Genetic factors that increase prostate cancer risk include inheritable variations in genes known as BRCA1 and BRCA2.\nThe findings suggest that by narrowing the focus of prostate cancer screening to those whose genes put them at most risk, doctors would catch more cancers early as well as reducing the potential for costly and damaging overdiagnosis.\nThe ICR-led study is aiming to find out whether screening men who have genetic variants that increase their prostate cancer risk could lead to earlier diagnosis.\nThe study found that the predictive value of screening these men \u2014 expressed as the number of cancers detected relative to the number of tissue samples taken \u2014 was 48 percent, far higher than the 24 percent achieved in population-wide screening.\nBut fears about overdiagnosis, which can lead to treatments such as surgery, radiation or hormone therapy that can cause serious side-effects such as impotence and incontinence, have so far dissuaded many European countries from nationwide screening.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports the results in a way that is typically rare in journalism \u2013 using the positive predictive value of the test. This is a much more helpful way to present the information to consumers than other measures commonly used in screening tests, such as sensitivity/specificity. At the same time, the heart of the PSA screening controversy remains. Even if one improves on the performance of the PSA test to detect more prostate cancers early, we still don\u2019t know if the potential benefits in terms of mortality reduction outweigh the known harms of overdiagnosis and overtreatment. The ability to one day differentiate the indolent prostate cancers from the aggressive cancers will be key. This study did not do that, despite the comments from the author.", "answer": 1}, {"article": "Several studies have found that dark chocolate, with its heart-healthy flavonols, can lower blood pressure and improve cholesterol.\nHowever, Reid believes theirs is the first study to model the long-term effects of eating dark chocolate in reducing cardiovascular risk.\nThe study is published in the journal BMJ.\nThe researchers also computed whether it would be cost-effective to spend money on a public education campaign about dark chocolate's benefits.\nReid and his team constructed a mathematical model to predict the long-term health effects of eating dark chocolate daily in high-risk people.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "On the one hand, the story dutifully reported what the researchers reported about projected benefits.\nBut on the other hand, the input of the Harvard nutritionist/epidemiologist raised important questions about over-assumption of benefits, and relying on intermediate risk factors (not actual heart disease events like heart attacks).\nSo we\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "Jan. 24, 2011 -- Using electrical pulses to stimulate nerve centers deep within the brain may reduce high blood pressure that can\u2019t be controlled with medication, a case report shows.\nPatel says that makes the impact of the case study \u201cstartling and exciting\u201d because if studies bear the findings out, deep brain stimulation may one day help people with hypertension whose blood pressure remains uncontrolled on multiple medications.\nThe case study is published in the Jan. 25 issue of Neurology.\nThat was a surprise because experts had long thought that pain had to be reduced to see a reduction in blood pressure.\n\u201cPain creates stress and that can have an effect on one\u2019s blood pressure,\u201d says Nikunj J. Patel, MD, a neurosurgeon at Frenchay Hospital in Bristol, U.K., and an author of the case study.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a better job than HealthDay of describing the effects of DBS on this patient\u2019s blood pressure, providing actual quantitative data about how his blood pressure fluctuated when the device was turned on and off.\u00a0Although we\u2019re tempted to flag the story for relying too heavily on unrepresentative patient anecdotes (something the standards for this criterion say stories\u00a0should avoid),\u00a0this is something addressed previously under the Evidence criterion.\u00a0We\u2019ll award a satisfactory here to acknowledge the story\u2019s greater overall attention to the details of this particular case.", "answer": 1}, {"article": "Researchers have found strong evidence that adenotonsillectomy \u2014 the surgery to remove the tonsils and adenoids \u2014 can help relieve childhood behavioral or attention problems, including attention-deficit hyperactivity disorder, or A.D.H.D.\nFinally, a child psychiatrist determined which children's difficulties merited the diagnosis of attention-deficit hyperactivity disorder.\nAccording to the paper, which was published yesterday in Pediatrics, it has been known that children with sleep disorders often have behavior problems.\nBut no cause-and-effect relationship has been established.\nAbout half of the patients undergo the procedure to control chronic throat or ear infections.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does provide the reader with adequate quantification of the benefits of treatment. Specifically, the number of children with ADHD is provided in the control and surgery group at baseline and at one year follow-up.", "answer": 1}, {"article": "Obese children who cut sugar from their diets saw improvements in markers of heart disease after just nine days, a study in Atherosclerosis found.\n\u201cWithout changing total carbohydrate, or fat, or protein, we were able to accomplish this enormous improvement in their cardiovascular risk factors,\u201d unrelated to weight loss, he said.\nThough this study is small and short-term, it builds on this group\u2019s previous research implicating added sugars as a contributor to metabolic disorders and heart disease.\nThe only change was their sugar intake: The researchers swapped foods high in added sugars, like pastries and sweetened yogurts, for options like bagels and pizza.\nThe children were given food and drinks totaling the same number of calories, fat, protein and carbohydrates as their typical diets.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This short narrative does an admirable job of getting specific about physiological changes that took place in these children over the course\u00a0of nine days.\nHowever, the story should have\u00a0established what this means in terms of an outcome that someone cares about. What would be the expected reduction in risk of heart attack or stroke? How big are the changes clinically, and how do they compare with other approaches? It\u2019s probably hard to say since these are children, but then the story should acknowledge that.", "answer": 0}, {"article": "Cigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally.\nFewer than half of all lung cancer patients who do well after a first course of chemotherapy get more treatment, but the Italian group said their study shows this is worth doing.\nFederico Cappuzzo from Ospedale Civile di Livorno in Italy and colleagues did a phase 3 trial in 889 patients who had already had chemotherapy and whose tumors had not come back.\n\u201cOral iloprost showed promise for preventing lung cancer in former, but not current, smokers in a phase II clinical trial,\u201d they wrote in a summary presented to a meeting of the American Thoracic Society in New Orleans.\nThis was seen even among patients who did not have the EGFR genetic mutation that Tarceva targets, they reported in Lancet Oncology.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "No data are presented for the iloprost study. As this was the lead item in the article, we have to give an Unsatisfactory rating. Even though\u00a0preliminary\u00a0data from a conference presentation has to be taken with a skeptical eyebrow, the public learns even less from a vague, flat, non-quantified summary of the benefits.\u00a0\nSome data are presented for the erlotinib study.", "answer": 0}, {"article": "They were divided in groups of 10.\n\u201cHowever, much more work needs to be done until we can say with certainty that it will tackle the disease in humans as mouse models don't always faithfully replicate the human disease.\nOur research shows for the first time that mefenamic acid, a simple [NSAID] can target an important inflammatory pathway called the NLRP3 inflammasome, which damages brain cells,\u201d David Brough, lead author of the study said, in a statement.\nBut, they also warned that these \u201cdrugs are not without side effects and should not be taken for Alzheimer\u2019s disease at this stage - studies in people are needed first.\u201d\n\nThe research was published in the journal Nature Communications on Thursday.\n\u201cThere is experimental evidence now to strongly suggest that inflammation in the brain makes Alzheimer\u2019s disease worse.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Given the over-the-top headline and first sentence, we would have expected to see at least a little in the way of quantification of the benefits in mice. The story provides no numbers, though. The story says,\u00a0\u201cResearchers observed that memory loss was fully reversed to the levels seen in mice without Alzheimer\u2019s.\u201d\nBut even if the story had provided specific study findings on benefits, this was a mouse study\u2013known as a pre-clinical trial. Any benefits measured in mice\u00a0is far too premature to make any extrapolative statements to people.", "answer": 0}, {"article": "Unfortunately, our previous study indicated that, despite their benefits, many patients on statins discontinue their treatment,\" Chodick said.\nDr. Robert Myerburg, a professor of medicine and physiology at the University of Miami Miller School of Medicine, stressed that \"this is a study looking for an association, and it doesn't prove that starting statins early in life will prevent or delay the onset of rheumatoid arthritis.\"\nA previous study on the same group indicated that persistent use of statins was associated with substantially lower all-cause mortality, which could not be explained only by the prevention of cardiovascular disease, he said.\nWEDNESDAY, Sept. 8, 2010 (HealthDay News) -- Statins, lauded for their ability to lower cholesterol and prevent heart attacks and strokes, may also reduce the risk of developing rheumatoid arthritis, Israeli researchers report.\nThe researchers looked for connections between statin use and the development of both rheumatoid arthritis and osteoarthritis, a degenerative joint disease that is unlikely to be affected by statins, the researchers noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nAlthough the story includes cautionary comments warning that this study does not prove that statins can prevent rheumatoid arthritis, throughout the story were comments about the \u201ceffect\u201d of statins and the \u201creduction of rheumatoid arthritis risk,\u201d thus creating a strong impression that statin use was responsible for the lower rate of rheumatoid arthritis, something this type of study cannot demonstrate.\nThe story also does not tell readers what the underlying risk of rheumatoid arthritis is, so it is impossible to put the \u201c40 percent lower risk\u201d into context. The story reports that the researchers looked at health data from almost 2 million people over a decade and that a total of about 2,500 new cases of rheumatoid arthritis were diagnosed. But it does not give readers what they need in order to get a good feel for how many people might be affected if further research demonstrated that statins could actually reduce the risk of rheumatoid arthritis.", "answer": 0}, {"article": "Most head and neck cancers are linked to alcohol consumption and to smoking.\nBut whether these substances actually protect against cancer in humans is a question for future studies.\nThough there weren't enough data on decaf drinkers to draw conclusions, drinking tea -- even massive quantities -- was not protective.\nInterestingly, the protective effect of coffee was not diminished in drinkers and smokers.\nThat's probably not what University of Milan researchers Carlotta Galeone, ScD, PhD, and colleagues thought they'd find when they analyzed nine studies comparing 5,139 people with head and neck cancer to 9,028 people without cancer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As already stated, it\u2019s inaccurate to talk about benefits of \"lowering risk\" with results from a study that can\u2019t establish a causal link.\u00a0 ", "answer": 0}, {"article": "\"You don't normally have this degree of increased blood supply to this lining.\nThose eight patients averaged a 58-point decrease in pain, as measured on a 100-point visual scale used to estimate pain, Bagla said.\n\"Patients overall were able to improve their physical function in the knee after the procedure, and there were no adverse events related to this treatment,\" said lead researcher Dr. Sandeep Bagla.\nOverall, the two scales represented an 80 percent improvement in function, the researchers concluded.\nDr. Suresh Vedantham, president of the Society of Interventional Radiology, called the new procedure \"very promising,\" given that it focuses on the inflamed knee lining that causes the pain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story passed muster by saying patients studied so far \u201caveraged a 58-point decrease in pain, as measured on a 100-point visual scale used to estimate pain,\u201d starting from an average baseline of 72. It said that meant pain was \u201cbrought down to manageable levels.\u201d", "answer": 1}, {"article": "J Transl Med.\nPHOENIX, Oct. 19, 2017 /PRNewswire/ -- Creative Medical Technology Holdings (OTCQB \u2013 CELZ) announced today completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem\u2122 procedure.\n\"Based on establishment of safety of the CaverStem\u2122 procedure in a formal university-based clinical trial, and independent confirmation of efficacy in an European clinical trial1, we have launched commercialization for the CaverStem\u2122 procedure,\" said Timothy Warbington, President and Chief Executive Officer of Creative Medical Technology Holdings.\nThe trial, sponsored by Creative Medical Technology Holdings, was conducted at the University of California Los Angeles Harbor Hospital/LA Biomed under Institutional Review Board (IRB) approval.\nWe anticipate that the procedure will be available to patients that meet the eligibility criteria within the next 60 days.\"\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release didn\u2019t quantify benefits in any way. We\u2019re told only that they looked at 20 patients, but none of the endpoints of the study were listed. On the procedure website, they list the primary endpoint as \u201cSafety and tolerability based on number and severity of adverse events,\u201d but the news release doesn\u2019t say how many patients, if any, experienced adverse effects.\nThe prior study cited was an uncontrolled study involving a total of 18 patients. Though initial results showed improved symptoms, the abstract mentions that the benefit declined over time and that repeat stem cell treatments may be needed.", "answer": 0}, {"article": "Symptoms include recurring headaches, loss of appetite, blurred vision, vomiting, shifts in personality and the ability to learn, seizures and the gradual loss of speech.\n\u201cFor example, we need to make sure that the therapeutic vaccine virus does not infect and kill normal neurons in humans.\u201d\n\nDr. Harry Bulstrode, brain tumor expert funded by the charity Cancer Research U.K. who is researching how Zika could be used to treat aggressive brain tumors, who was not involved in the study, told Newsweek: \"This study is another interesting piece in the jigsaw, but it is never going to demonstrate what we believe to be the really exciting properties of the virus.\nShi said: \u201cScientists may turn the 'bad' side of a devastating pathogen\u2014Zika virus\u2014for potential cancer therapy.\u201d\n\nHowever, he cautioned any potential treatment which could emerge from the study is far from being rolled out.\nThat\u2019s because glioblastoma stem cells have similar properties to neural stem cells.\nThe study showed that a live-attenuated Zika vaccine (containing a weakened version of the virus that does not cause disease in humans) could selectively infect and kill human glioblastoma stem cells, explained Shi.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We learn from this story that mice with the attenuated Zika virus lived 50 days, in comparison to mice in the control group that lived 30 days. We aren\u2019t given specific numbers on how much tumor development was delayed. We\u2019ll award a satisfactory grade since the story did at least quantify the overall survival difference between the two groups (something rarely reported on in coverage of rodent studies). However, given that this was a study in mice, we were looking for strong cautions that we simply have no evidence if this will work in humans, which is true of all animal studies on potential human treatments. That\u2019s a deficit we\u2019ll address below under the Evidence criterion.", "answer": 1}, {"article": "It's OK to ask the question,\" Hoberman said.\nIf many children in prior studies didn't really have ear infections, then it's not surprising the antibiotics didn't work for them, says Dr. Jerome Klein of Boston University, who wrote an editorial that accompanies the new studies.\nStudy authors and other experts say doctors should be sure the child really is suffering from an ear infection before writing that prescription.\nIt's based on a slew of studies over the past couple of decades indicating that most children with ear infections get better without antibiotics.\nTo do a correct diagnosis, says Dr. Alejandro Hoberman of the University of Pittsburgh, the doctor needs to be able to see the child's eardrum, which may mean cleaning out earwax first.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Neither the blog post nor the radio piece quantified the benefits. The post says, \u201cBoth studies, which appear today in the New England Journal of Medicine, find these kids get over painful ear infections faster, and have less severe symptoms, if they get prompt treatment with Augmentin, an inexpensive antibiotic often used to treat respiratory infections.\u201d This is understandable given how confusing the findings are in these articles. But, the story could have made use of one key number that was presented by the authors of the Finnish study: the number needed to treat. \u201cThe number needed to treat for 1 child to benefit from antimicrobial therapy, as calculated on the basis of the results of our study, is 3.8, as compared with 7 to 17 on the basis of the meta-analyses.\u201d", "answer": 0}, {"article": "Although the use of NSAIDs for arthritic conditions such as knee OA has potential risks, including heart attack and stroke, existing evidence indicates that naproxen has less potential for adverse cardiovascular events.\nAn analysis of 12 articles also found that results with HA are not significantly different from those with IA placebo for treatment of knee OA.\n\"Because knee OA has both a high disease burden and high treatment costs, additional prospective studies using similar outcomes, timelines, and measures of clinically important changes are needed,\" explained Dr. Jevsevar.\n\u2022 HA injections did not achieve a rank in the top five treatments for pain, function, or combined pain and function.\nThey found the following:\n\u2022 For pain reduction, cortisone injections provided the greatest short-term (4 to 6 weeks) pain relief, followed by ibuprofen, PRP injections, naproxen, and celecoxib.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release does not provide any specifics about the benefits of the treatments, referring only to their relative rankings. It should be noted that the researchers also did not address absolute clinical benefits in their journal article. The conclusions as stated may still be useful to patients who may have personal experience with at least some of the treatments. However, to satisfy this criterion the release should have provided some description of the absolute clinical benefit to patients.\nWe note that the news release highlights the conclusion of the researcher\u2019s analysis that the results of hyaluronic acid injections were not significantly different than placebo injections. The attention to a lack of benefit is important news for patients.", "answer": 0}, {"article": "Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.\n\nThe test, developed by closely held Epic Sciences Inc., San Diego, detects a mutation associated with a poor response to two new drugs, Xtandi from Medivation Inc. and Astellas Pharma Inc. of Japan, and Zytiga from Johnson & Johnson.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says \u201cin a study published last month, patients who tested positive for the anomaly\u2014a variant of the androgen receptor called AR-V7\u2014lived substantially longer if they were treated with chemotherapy than those given the two new drugs.\u201d\nHowever, the story doesn\u2019t provide specifics on what that means in number terms.", "answer": 0}, {"article": "DOI: 10.1016/j.ajog.2017.11.570.\nOnly 25 percent of women in the control group reported a similar reduction in pain intensity at both the 3-month and 6-month marks.\nAfter three months, 37 percent of participants in the acupressure group reported a 50 percent reduction in pain intensity.\nWomen in the acupressure group also used less pain medication than women in the control group and reported lower levels of pain overall.\nAcupressure-based features - with instructions on how to administer self-acupressure shortly before and during menstruation - were only made available to the intervention group.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release put the benefits experienced by the treatment and control groups in numerical context:\n\u201cAfter three months, 37 percent of participants in the acupressure group reported a 50 percent reduction in pain intensity. After six months, this proportion had increased to more than half of the women in this group (58 percent). Only 25 percent of women in the control group reported a similar reduction in pain intensity at both the 3-month and 6-month marks. Women in the acupressure group also used less pain medication than women in the control group and reported lower levels of pain overall.\u201d", "answer": 1}, {"article": "In the United States, an estimated 42,000 corneal grafts a year are performed using tissue from posthumous donors, but there are sometimes problems with rejection and experts say failure rates are significant.\nThe scientists, whose work was published Wednesday in the Science Translational Medicine journal, said their findings offered hope for the millions of people who go blind each year because of a worldwide shortage of corneas for donation.\nFagerholm said the patients in this trial had no problems with rejection and did not need long-term immune suppression drugs to help their bodies accept the corneas.\n\u201cThis study ... is the first to show that an artificially fabricated cornea can integrate with the human eye and stimulate regeneration,\u201d said May Griffith of the Ottawa Hospital Research Institute, who led the study.\nThe researchers found that, eventually, the cells and nerves from nine of the 10 patients regrew completely and packed themselves into the implant, resulting in a kind of \u201cregenerated\u201d cornea that looked and functioned like normal, healthy eye tissue.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Like the other two stories reviewed, this reporter made the smart choice of avoiding the use of percentages in explaining the benefits. It would have been easy to say that 60% of the patients had improved vision, which sounds more impressive than six of the 10. More numbers and more context would have been ideal, but, given the size of the study, the amount of explanation of the potential benefits is adequate.", "answer": 1}, {"article": "It\u2019s easy to get into the habit of popping a pill to have a good night\u2019s sleep. Insomnia, which affects a third of adults, becomes more common as we age.\n\nBut as evidence has mounted about the risks of drugging the brain to induce or maintain slumber, more doctors are steering patients away from sleep aids, including over-the-counter medications, and are offering innovative behavioral-change solutions.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes that one study of cognitive behavioral therapy showed that it reduced chronic insomnia and helped patients function more effectively during the daytime for up to two years. However, it does not specify whether the relief from chronic insomnia meant that patients had no bouts of insomnia or simply had less prolonged instances of insomnia, nor does it quantify how much improvement patients experienced in daytime functioning. In its discussion of chemical sleep aids, the article provides no specifics about effectiveness; rather, it focuses on the mechanisms by which the prescription drugs encourage sleep.\n(For an example of how to provide more specifics, see this criterion in our review of the Times\u2019 story on this same data.)", "answer": 0}, {"article": "Thirty-two of the women attempted pregnancy.\nDr. Avner Hershlag, chief of the Center for Human Reproduction at North Shore University Hospital in Manhasset, N.Y., called the new research \"innovative and exciting.\"\n\"The tissue restores ovarian organ function, and women regain menstrual cycles and sex hormone levels that will avoid menopause,\" Andersen added.\nAnd no cancer developed in the transplanted tissue, Jensen said.\nThe women's average age when the tissue was removed and frozen was nearly 30.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story arguably overstates the impact of transplantation, allowing a researcher to claim that \u201cmany\u201d women who survive cancer will be fertile because of this surgery \u2014 when the story clearly states that less than a third of the women in this tiny study had a good outcome.\nBut since the main thrust of this criterion is numbers, and the story does provide them, we\u2019ll give the benefit of the doubt here. However, we wish that the story had pushed back harder against this framing \u2014 \u201csome\u201d or \u201ca minority\u201d of women would have been a better descriptor here than \u201cmany.\u201d", "answer": 1}, {"article": "\u201cDr.\n\u201cThis variation of a standard technique used during breast reconstruction will revolutionize the post-operative recovery in patients who meet certain criteria for the procedure,\u201d notes Dr. Small.\n\u201cHere at Valley, we are proud to offer this option for our patients and are excited about its potential for vastly improving patient care for women with breast cancer.\u201d The technique involves placing tissue expanders (interim implants) under the skin on top of a woman\u2019s pectoralis muscles after her breast tissue has been removed.\nIn addition to exceptional cosmetic results, the technique is likely to improve clinical outcomes as evidenced by ongoing research that shows women who undergo this procedure experience less pain and a shorter recovery period.\n\u201cOver the past decade there have been dramatic improvements in breast reconstruction that utilize various types of surgical innovations, implants, and biologic tissue,\u201d notes Dr. Small.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are described \u2014 \u201cdiminished post-operative pain, quicker recovery time, improved mobility, and an excellent aesthetic outcome\u201d \u2014 but not quantified, neither alone nor in comparison to other options.\nHow much is pain reduced by this procedure? How much faster is the recovery time? How much better can women get around? What constitutes \u201cexcellent\u201d when it comes to the look of a reconstructed breast? We aren\u2019t told.\nEven if the release had quantified the results or made a comparison to other techniques, this is a report of one procedure in one patient. It is not possible to make general statements about the benefits of a procedure when only one procedure has been performed.", "answer": 0}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article describes the median survival time afforded the women with ovarian cancer under different scenarios \u2013 with or without beta blockers in addition to their chemotherapy. For example, women who had been taking any beta blocker at the time of their chemotherapy had a median survival of 47.8 months while women who were not being treated with beta blockers while on chemo had median survival time of 42 months.", "answer": 1}, {"article": "Women.\nData on aspirin and other NSAID usage came from the women\u2019s responses on questionnaires.\nThe researchers analyzed data on 57,164 women, most in their early 60s, who had no history of breast cancer.\n[Certain adults should take a daily baby aspirin, expert panel says]\n\nWho may be affected?\nThe researchers suggested that the difference in results between low- and regular-dose aspirin may have been attributable to most women taking low-dose aspirin more often than three times a week, even daily, for cardiovascular protection as opposed to more-sporadic use of regular-dose aspirin for pain relief.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes the same mistake here that the news release did, sharing only relative risk reduction numbers \u2014 not the actual numbers of people who reduced their risk of breast cancer by taking aspirin. In addition, the story would have been stronger if it had explained that observational studies, like this one, cannot determine whether a specific intervention (i.e., aspirin use) was responsible for reducing cancer risk.", "answer": 0}, {"article": "\"I say, 'Go for it!'\nJudy Foreman, another of Metson's patients, offers an example of both how surgery can help -- and why patients' expectations shouldn't be too high.\n\"But probably in over 90 percent of the cases, it does significantly improve a patient's quality of life.\nFor about 80 percent of patients, these nonsurgical alternatives manage the problem adequately, Metson says.\nBut they can't stop the inflammation some people are prone to, and that inflammation can cause new obstructions.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story focuses almost exclusively on the experience of one patient, a practice we generally think should be avoided. In this case, however, the patient in question was a health columnist\u00a0with the Boston Globe who brings a well-informed and appropriately skeptical perspective to the story. Whereas many stories\u00a0seek out patients who embody the best possible outcome for a new technology or procedure, this\u00a0patient describes an incremental benefit that was \"disappointing\" in size but\u00a0in the end, still worth the trouble.\u00a0Instead of getting 5 or more sinus infections per year, she now gets 3 or 4 infections that are not as bad\u00a0as\u00a0before. In addition, the story emphasizes that surgery is \"rarely a cure\" and should be viewed\u00a0as a \"last resort\" for most patients with sinus problems. \u00a0We wish\u00a0more\u00a0stories\u00a0were this measured in their assessment of medical\u00a0benefits.\n\u00a0\u00a0", "answer": 1}, {"article": "This condition occurs when the cushions, or discs, that serve as shock absorbers for the spine become inflamed and bulge or break open.\nNone of the people in this study had been helped by other nonsurgical therapies, and supporters say the new therapy could become a standard treatment for such patients.\nStill, ozone therapy could even help many patients with unrelenting back pain to avoid surgery, Lehnert tells WebMD.\nLehnert presented the findings here at the annual meeting of the Radiological Society of North America.\nBut a back pain specialist who spoke to WebMD says that further research is needed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did a good job explaining the benefits observed in this study. However, where it fell short was in comparing these outcomes to those that may be expected with alternative treatments \u2013 specifically, an epidural steroid injection alone or disc surgery.", "answer": 1}, {"article": "The U.S. Preventive Services Task Force, a federal expert panel, recommends screening all women over 65 for osteoporosis.\nThat works out to nearly three times the risk of those who\u2019d taken the drugs for roughly three months or less, after accounting for other risk factors.\n\u201cIf you\u2019re taking the drugs and you\u2019ve been on them for a while, but aren\u2019t sure if you\u2019re at high risk, you should ask your doctor about it,\u201d Park-Wyllie advised.\nAnd the actual risk of having one of the unusual fractures was low, said Laura Y. Park-Wyllie, of St. Michael\u2019s Hospital in Toronto, who worked on the new study.\nThe risk of a thighbone fracture differed depending on how long the women had been taking the medicine.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did a good job \u2013 starting with the headline \u2013 of portraying the tradeoffs between harms and benefits as found in the latest study.", "answer": 1}, {"article": "Asked if the 34% improvement in cognitive decline is meaningful to a patient, Carrillo said, \"I have a family member with AD.\nThe latest results come from a combined analysis of a 1,012-patient study and a 646-patient study, both of which involved people with mild to moderate Alzheimer's disease.\nThe results really became clear when the researchers looked only at those patients with mild, early-stage disease.\nThe benefit is small and studies have been inconsistent, says researcher Rachelle Doody, MD, head of Alzheimer\u2019s disease research at Baylor College of Medicine.\nLarger studies in many more patients are needed before the drug will be available, though, she says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "On this score, the WebMD story comes up short in comparison with the AP story.\nThe lead sentence says the treatment \u201cslowed memory loss by about one-third in people with mild Alzheimer\u2019s, offering hope that the drug can alter the course of the progressive disease.\u201d But the story doesn\u2019t really explain what was measured or if the differences are in fact clinically important. And while one expert was asked \u201cif the 34% improvement in cognitive decline is meaningful to a patient,\u201d the expert\u2019s answer that she\u2019d be happy if her mother-in-law got a \u201csustained cognitive benefit,\u201d still doesn\u2019t define what this drug did or did not do for people in these trials.", "answer": 0}, {"article": "The Lancet.\nThe clinical efficacy results reported today are from the JET8 Phase-III clinical study (3107) (the JET8 study).\nThe magnitude of the total sleep time benefit of 85 minutes improvement over placebo is significant and clinically meaningful.\nThis clinical design allowed for the study of HETLIOZ\u00ae without the confounding effects of sleep deprivation and variable light conditions.\nThe JET8 study design induced the circadian challenge experienced by travelers who cross 8 times zones, which leads to jet lag disorder.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release offered a dense table of results of the clinical trial, although without more information about the trial design, especially the make up of participants and comparison groups if any, it\u2019s hard to know exactly how significant the clinical findings are, particularly for those who are leisure travelers who don\u2019t have to negotiate world peace the moment they land at the end of a 16-hour flight. The primary outcomes from the sleep study are not clearly described and the clinical significance of those results are unclear. Therefore, it is difficult to draw conclusions about the\u00a0benefit of the drug.", "answer": 0}, {"article": "For advice, information and support, visit http://www.\nThe research, published today in The Lancet Neurology (1), shows people with Parkinson's who were given the oral drug rivastigmine were 45% less likely to fall and were considerably steadier when walking, compared to those on the placebo.\n\"We already know that rivastigmine works to treat dementia by preventing the breakdown of acetylcholine, however our study shows for the first time that it can also improve regularity of walking, speed, and balance.\n\"This trial shows that there may be drugs already available, being used for other purposes, that can be tested to help treat Parkinson's.\n70% of people with Parkinson's will fall at least once a year, with over a third experiencing falls repeatedly, resulting in fractures, broken bones and hospital admissions (2).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefits are vaguely described in the release as being a 45% reduced risk in falling and becoming \u201cconsiderably steadier when walking.\u201d\u00a0 We\u2019d like to see more quantification of the benefits, and more clarity, particularly an explanation of what \u201cconsiderably\u201d actually means. Did the researchers measure steadiness \u2014 there are different tools for the measurement of postural and motor steadiness \u2014 or did they just report the number of falls? In addition, does the 45% mean that 58 of the 130 patients taking part didn\u2019t experience falls during the 8-month study period but that the other 55% (71 volunteers) continued to experience falls? The release isn\u2019t clear about what a 45% reduced risk means and what the actual numbers of falls were in each group.", "answer": 0}, {"article": "Dr. Eric A. Klein, chairman of the Cleveland Clinic Glickman Urological and Kidney Institute, said that the study \"is confirmatory of a lot of other, smaller studies.\nAnti-hormone therapy was developed to treat the pain and other problems of advanced prostate cancer, Albertsen said, and so it was generally used for only three to five years.\nDr. Peter Albertsen, a professor and chief of urology at the University of Connecticut Health Center, said that \"the point of this paper is to help physicians understand that long-term use of this therapy carries consequences.\"\nPrevious studies have shown potential dangers related to androgen deprivation therapy in older men, Keating said.\nHormone deprivation therapy is started, Keating said, when levels of cancer-associated prostate-specific antigen (PSA) increase after surgery or radiation therapy, but there are no other indicators of danger.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0While describing that androgen deprivation therapy was initially developed as a means of treating symptoms of advanced prostate cancer, and that there are situations in which it has demonstrated clear benefit, the story did not include quantitive information about benefit. \u00a0It could have at least mentioned that when used to treat men with metastatic prostate cancer, meaning it has spread to the bone \u2013 this treatment provides symptom relief and slightly longer survival.", "answer": 0}, {"article": "\u201cSome men go to the bathroom several times a night, get right back to sleep and are not bothered,\u201d he said.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\n\u201cThere is a big difference between having the symptoms and being bothered by the symptoms,\u201d said Dr. Kevin T. McVary, professor of urology at the Feinberg School of Medicine at Northwestern University.\nNor does it lead to cancer.\nWatchful waiting, or monitoring symptoms while holding off on medical or surgical treatments, is a reasonable plan for these men, he added.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Other than the quote from a clinician which mentioned that almost all patients \"end up with less bothersome symptoms once they chose to do something,\" the story did not provide much insight about the extent of symptom relief, the proportion of men who will experience symptom relief, and the length of time the different treatments could be expected to provide symptom relief.", "answer": 0}, {"article": "A new study confirms that long-acting forms of contraception such as intrauterine devices and implants are better than birth control pills and patches at preventing pregnancies, giving doctors new ammunition to recommend these methods.\n\nThe study, to be published Thursday in the New England Journal of Medicine, involved about 7,500 women in a project promoting long-acting birth control to reduce unintended pregnancies. There are an estimated three million unplanned pregnancies a year in the U.S., often because of incorrect or...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The report clearly\u00a0quantifies the difference in failure rates of the various methods, which range from less than 1% for long-acting methods to\u00a0about 5% (after 1 year of use) and 9% (after 3 years) for the pill and patch.\u00a0There is no consideration of other benefits aside from prevention of pregnancy, which can be an important factor in choice of method for some women. For example, the oral contraceptive pill can\u00a0lessen menstrual cramps, and some IUDs\u00a0also treat excessively heavy periods.", "answer": 1}, {"article": "\"Once injected into a patient's artery, many stem cells are lost due to the combination of tissue blood flow, which can wash out stem cells, and cardiac contraction, which can squeeze out stem cells.\n\"This remarkably simple method could easily be coupled with current stem cell treatments to enhance their effectiveness.\"\n\"Tissue viability is enhanced and heart function is greater with magnetic targeting,\" Marban said.\nMarban and his wife, Linda, are founders of a company that has filed patents for the techniques.\nThe study was published online April 8 in the journal Circulation Research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We weren\u2019t told how many times the approach was tested, in how many rats.\u00a0 ", "answer": 0}, {"article": "\"It would be overreaching to say that we're curing cancer with this,\" Woodrum said.\nThe result: Among the 15 patients seen roughly three months post-procedure, tumor control was found to be 100 percent, although six patients were found to have developed new lung tumors in the interim.\nFor his part, Dr. David Carbone, a professor and director of the James Thoracic Center at the Ohio State University Wexner Medical Center, said that the findings regarding cryoablation are \"not incredibly novel,\" given that the procedure has been around for years.\nThe study authors cautioned that while the initial findings are encouraging, the treatment should not be seen as a cure for this type of metastatic (spreading) lung disease.\nHowever, some patients developed new tumors in that time period, the researchers noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Yes, the story did explain \u2013 although in a way we find flawed and incomplete:\n\u201cThe result: Among the 15 patients seen roughly three months post-procedure, tumor control was found to be 100 percent, although six patients were found to have developed new lung tumors in the interim.\nAmong five patients seen six months after the procedure, tumor control continued to be 100 percent.\u201d\nThe story goes to some length to note the study is preliminary, and involves a small number of subjects to date.\u00a0 However, we believe that it overstates the benefits by not providing any context.\u00a0 A bit of background would have been helpful. The people treated have metastatic disease, these were not primary tumors.\u00a0 So eliminating single metastatic lesions does not automatically equate to improved survival.\u00a0 There is a high likelihood of additional lesions appearing as was the case with 6 of the 15 seen three months after the procedure.", "answer": 0}, {"article": "At Cooper, cardiologist Phillip Koren said he and colleagues have used the Lariat on the left atrial appendage of about 10 patients in the last six months. The closure was unsuccessful in a few of those cases, but in those, there have been no strokes, said Koren, deputy director of the Cooper Heart Institute. None of the 10 patients suffered adverse events from the device.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story discusses research on the use of the Lariat device for closing off a portion of the heart to lessen risk of clots. It says the procedure was performed in 309 people, successfully in 90 percent of them. It does not give us context to understand whether that level of benefit is equal or less than most other alternatives. There is lengthy discussion of harms \u2013 which we will address below. Perhaps more important, the story states that there is no evidence that the procedures lessen the risk of future strokes. That reduction in risk would be the most important benefit, and the fact that the story calls attention to this lack of evidence for benefit earns it a Satisfactory rating.", "answer": 1}, {"article": "The American Cancer Society has more on lymphoma.\nPeople whose physical activity was greater than normal before diagnosis were less likely to have died from lymphoma, or from any other cause, than were those who'd been less active, the study found.\nPeople who'd boosted their physical activity level after being diagnosed with lymphoma also were less likely to have died in that three-year span than were those who hadn't increased their activity level.\nOn the other hand, people whose physical activity level had declined after their diagnosis had higher death rates from lymphoma and other causes than those who had not changed their level of physical activity.\n\"As physicians, we recommend physical activity for all cancer survivors to improve overall quality of life, but we did not know if physical activity would have an impact on survival in lymphoma patients,\" said study author Dr. Priyanka Pophali, a hematologist at Mayo Clinic.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story makes no attempt to quantify benefits, relying instead on the same general language found in the news release. For example, the story states:\n\u201cPeople whose physical activity was greater than normal before diagnosis were less likely to have died from lymphoma, or from any other cause, than were those who\u2019d been less active, the study found. People who\u2019d boosted their physical activity level after being diagnosed with lymphoma also were less likely to have died in that three-year span than were those who hadn\u2019t increased their activity level.\u201d\nHow much less likely were the folks in either group to die of any cause? How much less likely were they to die from lymphoma? Was there a difference in the level of benefit from being active before diagnosis as compared to becoming more active after diagnosis? How did they measure what constituted physical activity? The story doesn\u2019t tell us.", "answer": 0}, {"article": "In the increasingly popular \"no-scalpel vasectomy,\" a doctor uses an instrument called a dissecting forceps to poke a very small hole in the skin of the testicles to reach the vas deferens.\nEven the IUD can't stay in place for more than 10 years.\nOne for the Guys Men, too, have an option for a faster, less painful procedure than vasectomy to tie the vas deferens -- the tubes that carry sperm from the testicles to the penis.\nThe biggest drawback, Whitaker says, is the need for X-rays three months after the procedure to confirm the fallopian tubes are blocked.\nWhat's New The Pill.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does quantify the effectiveness of Essure compared to tubal ligation.\u00a0 But it cites the manufacturer as the source of the information.\u00a0 Why not turn to the studies? ", "answer": 1}, {"article": "When the researchers used the longer Tao brush, they were able to detect endometrial cancer in all but 7% of the women who had the disease, and close to half of the ovarian cancers. Combined with the fact that these tests were performed with a mere swipe of the uterine wall, these measures of \u201csensitivity\u201d \u2014 the ability to detect cancers that are actually there \u2014 represent a major improvement over the screening tests currently available.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story explains how adding a genetic test to a routine (though uncomfortable) gynecological procedure for women \u2014 i.e. Pap smears \u2014 could help doctors catch endometrial and ovarian cancers at an early stage, for which there is not yet a standard test. The article also does a nice job showing how layer-caking genetic tests on other tissues (inner uterus and blood) can nearly double the detection rate of ovarian cancer, from 33% (Pap-smear genetic test) to 63% (a full PapSeek test), and improve endometrial cancer detection from 81% to 93%.", "answer": 1}, {"article": "Esther Landhuis is a freelance science journalist in the San Francisco Bay Area.\nThe results point to a real-time biomarker for impulsive behavior, says Dennis Turner, a Duke University neurosurgeon who was not involved in the study but wrote an October review about ongoing research on a range of potential brain stimulation biomarkers.\nAnd based on the new findings, a clinical trial testing this off-the-shelf system for some forms of obesity could start as early as next summer, says Casey Halpern, the study's leader and an assistant professor of neurosurgery at Stanford.\nIn the current study, Halpern and coworkers tested the RNS device in the binging mice.\nIn a report published Monday in the Proceedings of the National Academy of Sciences, Stanford neuroscientists say they've achieved this sort of mind-reading in binge-eating mice.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article offers a summary statement or two about how much better mice receiving responsive neurostimulation system (RNS) therapy did than control mice. But, it needed to make it more clear that regardless of what the researchers measured, mice studies should not be extrapolated to human benefits. It\u2019s a risky endeavor.\u00a0\u00a0In this story, any caveats about the research were often followed up by statements that watered them down. For example:\n\u201cWhether this strategy could block harmful impulses in people remains unclear. For now the path seems promising.\u201d", "answer": 0}, {"article": "UCSF Benioff Children's Hospital Oakland (formerly Children's Hospital & Research Center Oakland) is a premier, not-for-profit medical center for children in Northern California, and is the only hospital in the East Bay 100% devoted to pediatrics.\nIn the absence of sufficient zinc, our ability to repair everyday wear and tear on our DNA is compromised.\nZinc is an essential part of nearly 3,000 different proteins, and it impacts how these proteins regulate every cell in our body.\nIn addition to King, the study's other authors are Sarah J Zyba, Swapna V Shenvi, David W Killilea, Tai C Holland, Elijah Kim, Adrian Moy, Barbara Sutherland, Virginia Gildengorin, and Mark K Shigenaga, conducting the research at CHORI's Nutrition and Metabolism Center.\nZinc is ubiquitous in our body and facilitates many functions that are essential for preserving life.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is absolutely no discussion of any benefit data in the news release. Only vague, sweeping language is used to describe the effect of increased zinc intake. For example, the release states that the addition of 4 milligrams of extra zinc a day \u201ccan have a profound, positive impact on cellular health that helps fight infections and diseases\u201d and \u201creduce oxidative stress and damage to DNA.\u201d\nIn addition, the news release does not describe how the benefit was measured. It only mentions that scientists \u201cused the parameter of DNA damage to examine the influence of zinc on healthy living.\u201d How did scientists exactly count DNA strand breaks?\nWe would have liked to have seen some numbers here, which is why we give the news release a Not Satisfactory rating.", "answer": 0}, {"article": "For more on childhood obesity, visit the U.S. Centers for Disease Control and Prevention.\nAt the study's start, about one-third of the Head Start kids were obese or overweight, compared to 27 percent of those on Medicaid and less than 20 percent of kids not on Medicaid.\nIn their first year in Head Start, obese and overweight kids lost weight faster than two comparison groups of children who weren't in the program, researchers found.\nAlmost one-quarter of preschool-aged children in the United States are overweight or obese, and obesity rates within Head Start populations are higher than national estimates, the study authors noted.\n\"It [also] may be that when kids go to Head Start, it reduces stress in the household and frees up time and resources at home to dedicate to healthier eating patterns,\" she noted.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says that \u201cobese and overweight kids [in Head Start] lost weight faster than two comparison groups of children who weren\u2019t in the program.\u201d\u00a0It also says that \u201cinitially obese and overweight Head Start children were substantially less obese and overweight than the children in the comparison groups.\u201d But how\u00a0much weight did these children lose? How much did rates of obesity go down? The story doesn\u2019t quantify what it means by \u201csubstantial.\u201d", "answer": 0}, {"article": "That view is shared by Deborah Giaschi, a professor of ophthalmology and visual sciences at the University of British Columbia in Vancouver who has conducted MRI studies of the brains of people with dyslexia. \"There's really no scientific basis\" for ChromaGen lenses, she says. In her opinion, the claim that the lenses slow down visual processing doesn't make sense. Even if the lenses had that effect, she doesn't see how that would help anyone read.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story allows the manufacturer to state that the lenses can help about 50% of people with dyslexia but that \u201cthe true rate is probably much higher.\u201d\nBut then it added repeated notes of skepticism from others:", "answer": 1}, {"article": "The excruciating pain in her right knee made simple tasks like grocery shopping impossible.\nBecause it was just approved by the FDA in April, the treatment is not widely available yet, but pain centers across the country are beginning to offer it.\nMarketed as \"Coolief\", the procedure uses radio frequency to target and mute the nerves responsible for sending pain signals from the arthritic knee to the brain.\nWhile it reduces pain, it can't stop the progression of osteoarthritis.\nThe treatment, recently approved by the Food and Drug Administration, is called \u201ccooled radio frequency ablation\u201d and is a less drastic option for people with moderate to severe osteoarthritis pain who are not ready to have knee replacement surgery, or who have health conditions that don\u2019t make them a good candidate for surgery.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the story makes clear that the process relieves pain, it offers little in the way of quantification. According to the one study mentioned, by how much did it help? How was that measured? That is particularly important here, as this procedure appears to reduce\u2014but not necessarily eliminate\u2014pain. The story does use verbs such as \u201ceases\u201d and \u201creduces,\u201d but then it focuses on one patient who, after the procedure, seems to be pain-free. The text later does a good job of indicating that the pain reduction is relatively short-lived, lasting 6 months to a year.", "answer": 0}, {"article": "For more information, visit http://www.nei.nih.gov.\nHowever, patients with 20/50 or worse vision loss may benefit from Eylea, which over the course of the two-year study outperformed Lucentis and Avastin.\u201d\n\nThe number of injections participants needed was about the same for all three treatment groups.\nAt two years, Eylea participants were able to read about 3.5 additional lines on an eye chart; Lucentis participants were able to read about three additional lines, and Avastin participants improved about 2.5 lines, compared with visual acuity before treatment.\nBy two years, 41 percent of participants in the Eylea group received laser treatment to treat their macular edema, compared with 64 percent of participants in the Avastin group and 52 percent in the Lucentis group.\nA two-year clinical trial that compared three drugs for diabetic macular edema (DME) found that gains in vision were greater for participants receiving the drug Eylea (aflibercept) than for those receiving Avastin (bevacizumab), but only among participants starting treatment with 20/50 or worse vision.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states the general benefits over time for each group assigned to one of three drugs and gives some specifics about the improvements seen.\nAmong participants with 20/50 or worse vision at the trial\u2019s start, visual acuity on average improved substantially in all three groups. At two years, Eylea participants were able to read about 3.5 additional lines on an eye chart; Lucentis participants were able to read about three additional lines, and Avastin participants improved about 2.5 lines.\nThe release also does a pretty good job of quantifying how many people in each group needed laser surgery.\nBy two years, 41 percent of participants in the Eylea group received laser treatment to treat their macular edema, compared with 64 percent of participants in the Avastin group and 52 percent in the Lucentis group.", "answer": 1}, {"article": "Now she's sharing their secrets with back pain sufferers across the U.S.\n\nAbout two decades ago, Esther Gokhale started to struggle with her own back after she had her first child.\nLost Posture: Why Some Indigenous Cultures May Not Have Back Pain\n\nEditor's note, June 10: We have added an acknowledgement of several sources that Esther Gokhale used while developing her theories on back pain.\nShe puts Gokhale's method in the same category as Pilates and yoga for back pain.\nNobody has done a study on traditional cultures to see why some have lower rates of back pain, he says.\nAnd people who are thinner probably have less curvature\" \u2014 and thus a spine shaped more like J than than an S.\n\nAmericans are also much less active than people in traditional cultures, Mummaneni says.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t quantify the benefits of the Gokhale Method in any way. Nor does it quantify the potential benefits of mimicking traditional cultures with low rates of back pain or of having the so-called \u201cJ-shaped spine\u201d that the Gokhale Method promotes. Now, perhaps that\u2019s understandable, since the story does eventually acknowledge that the Gokhale method has never been studied in a clinical trial, and that it\u2019s not clear whether J-shaped spines are really more common in indigenous societies. But we thought it was unacceptable for the story to wait some 750 words \u2014 all focused on benefits \u2014 before introducing these notes of caution. Moreover, while the story does note that stronger abdominal muscles may help limit back pain, there\u2019s no attempt to quantify the potential benefits of abdominal exercise either. And those approaches (Pilates, physical therapy, etc.) have been well-studied. Instead, the story rests largely on anecdote. For example, it notes that Esther Gokhale (who developed the method) \u201cworked to get her spine into the J shape\u2026.[and] her back pain went away.\u201d", "answer": 0}, {"article": "Then the researchers, led by Dr. Frank Hu of the Harvard T.H.\nFirst Take: The new research, published in Circulation on Monday and funded by the National Institutes of Health, mined three large, ongoing epidemiological studies (74,890 women in the Nurses\u2019 Health Study, 93,054 women in the Nurses\u2019 Health Study 2, and 40,557 men in the Health Professionals Follow-up Study), following them for at least 20 years.\nBut surely the population in this study is so huge and socioeconomically similar (all health professionals) that correlation is more likely to reflect causation?\nIt might mean instead that a third factor \u2014 another behavior, socioeconomic status, even personality or genetics \u2014 might go hand in hand with Behavior A and be the true cause of Outcome B.\nThis same Nurses Health Study, for instance, infamously found a correlation between post-menopausal hormone therapy and lower risk of cardiovascular disease and death, here and here.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "STAT\u2019s story, like the coverage in CNN, gets the details, strengths and weaknesses of the data right, but STAT\u2019s piece\u00a0more precisely quantifies the findings and goes to exceptional lengths to clearly describe what an observational study can and cannot do, and did and did not do in this current piece of analysis.", "answer": 1}, {"article": "The procedure didn't help everyone, though.\nThe technique is \"a minimally invasive treatment option,\" said the study's lead author Dr. Kenneth Mandato, a vascular and interventional radiologist at Albany Medical Center in Albany, N.Y.\nEarly findings suggest that a single outpatient treatment can reduce migraine pain levels by about 35 percent for up to a month after the procedure, according to this small, ongoing study.\nThe researchers acknowledged that this procedure is a temporary solution that would need to be repeated.\nSeven of the patients (about 6 percent) failed to get any benefit from the treatment, the investigators found.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was on point with the reduction of pain levels. It mentioned that a single outpatient treatment seemed to reduce migraine pain levels by \u201cabout 35 percent for up to a month after the procedure,\u201d which was close to the 36 percent reduction rate researchers saw on day 30. The article also explained very well the range of \u201cpain scores\u201d that patients experienced during the study, such as pain levels recorded from a day to a week to a month after the procedure. We\u2019d note that in headache research, investigators usually also record the frequency of headaches as well, since this is an important quality of life measure for patients. It\u2019s not clear why that outcome wasn\u2019t measured in this study.", "answer": 1}, {"article": "Mihai G. Netea, PhD, professor in the Department of Internal Medicine at Radboud University Medical Center in the Netherlands, says of this study, \"The clinical effects and the proposed mechanism demonstrated are exciting and add to the emerging consensus that the BCG vaccine can have a lasting and valuable impact on the immune system.\nAn extension and expansion of that trial with long term follow-up, the current results are based on data from 282 human study participants - 52 with type 1 diabetes who participated in the BCG clinical trials and 230 who contributed blood samples for mechanistic studies.\nBut by the end of that short, 20-week trial, there was no reduction in HbA1c, the established measure of blood sugar levels over time.\nThat reduction was maintained over the next four years, with treated participants having an average HbA1c of 6.65, close to the 6.5 considered the threshold for diabetes diagnosis, and with no reports of severe hypoglycemia.\nThe MGH team's findings set the stage for further testing of BCG administration, including the FDA-approved phase 2 study currently underway, testing multiple BCG doses in a large group of participants with longstanding type 1 diabetes.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release mentions only relative, not absolute numbers\u00a0when describing the results in just 52 type 1 patients:\nIt\u2019s stated that an average HbA1c level of 6.65 was achieved (normal is below 6.0, with many doctors shooting for below 6.5 in people with type 1 diabetes) and the reduction was maintained over the last 5 years of the 8-year-long trial.", "answer": 0}, {"article": "April 28, 2010 -- Federal researchers say a new treatment can reverse vision loss in many patients with diabetic macular edema, a leading cause of blindness in people with diabetes.\n\nIn a news conference yesterday, researchers announced findings from a government study comparing treatments for swelling of the retina caused by leaking blood vessels in the eye.\n\nNearly 50% of patients given eye injections of the drug Lucentis along with laser treatments showed improvement in vision after a year of treatment, compared to just over a fourth of patients treated with laser alone.\n\nFor several decades, laser has been the standard treatment for diabetic macular edema, or DME, in which fluid builds up near the center of the retina.\n\n\u201cFor the first time in 25 years we have definitive proof that a new treatment can lead to better results for the eye health of people with diabetes,\u201d said Neil M. Bressler, MD, who oversaw the study as chairman of the Diabetic Retinopathy Clinical Research Network.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate quantification of benefits seen in the study. ", "answer": 1}, {"article": "Surgical removal of cancerous tissue also can spur the spread of cancer in the body.\n\u201cThis method is effective for both diagnosing and treating metastasis cancer and can be used in combination with traditional chemotherapy and radiation therapy,\u201d he added.\nWe have also found it very effective in late stage cancers to stop the spread of the disease and to prolong lifespan,\u201d he added.\nThis cancer trap can be used for early diagnosis and treatment of metastasized cancer.\n\u201cSo the cancer trap is really complementary to current cancer treatments and especially beneficial at the early stages when it is difficult to see if the cancer is spreading as there are few cancer cells.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are not put into any numerical context. In fact, benefits are discussed only in the most general of terms, referring to \u201cearly diagnosis\u201d and the idea of \u201crecruit[ing] the cancer cells into a small area where we can treat them with less overall side effects to the whole body.\u201d However, the release also raises questions about how viable these potential benefits may be in human cancer patients. We\u2019ll address this further under \u201cQuality of Evidence.\u201d", "answer": 0}, {"article": "CML is a slowly progressing type of blood cancer that develops in the bone marrow.\n\"Our findings suggest inhibition of Ezh2 should be considered as a way to eradicate CML when used in combination with current targeted therapies.\n\"In only 10-20 percent of patients, however, are the leukemia cells fully cleared from the body.\nThe findings, reported online today by the journal Cancer Discovery, raise the prospect that Ezh2 blockers, in combination with Gleevec and similar drugs, could eradicate the disease in some patients in relatively rapid fashion or could be an effective therapy for those who become resistant to Gleevec-like agents, the authors state.\n\"The vast majority of patients with CML do remarkably well on imatinib [Gleevec] and similar drugs: The disease is well controlled and side effects are tolerable,\" says Stuart Orkin, MD, the study's senior author and a pediatric hematologist/oncologist at Dana-Farber/Boston Children's Cancer and Blood Disorders Center.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release\u00a0makes clear that its discovery of a potential weak point in a frustrating form of leukemia has the potential to push CML patients into remission. But it doesn\u2019t quantify those results in any way. Even more importantly, the release drags its feet when disclosing that the research was performed in animal subjects. It remains to be seen if the treatment would have similar benefits for people. And that result could be many years down the road.", "answer": 0}, {"article": ".\nBut the researchers wanted to know if the drug, when combined with statin treatment, could also reduce the risk of heart disease in people with type 2 diabetes.\nHowever, a randomized study is needed to confirm these findings, according to the authors.\nWHO: Jerome Fleg, MD and Yves Rosenberg, MD, M.P.H., Division of Cardiovascular Sciences, NHLBI, NIH, are available to comment on the findings and implications of this research.\nThe findings suggest that fenofibrate therapy may be beneficial in the way the researchers hoped: by reducing cardiovascular events in patients with type 2 diabetes who take statins but still have especially high triglycerides levels and low HDL cholesterol levels.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "To actually see what the benefits were, one would have to read the full study in JAMA Cardiology. While we always recommend that reporters read the actual study that is the subject of their story, we live in an age where releases like this quickly find their way into the news cycle without the journal ever being consulted. So one of the most basic elements of any good release is a quantification of the benefits found in the study it\u2019s based on. Instead, the release offers vague language like this: \u201cThe findings suggest that fenofibrate therapy may be beneficial in the way the researchers hoped: by reducing cardiovascular events in patients with type 2 diabetes who take statins but still have especially high triglycerides levels and low HDL cholesterol levels.\u201d Even the abstract, a much abbreviated summary of the study, provides data that could have easily been used in the news release.", "answer": 0}, {"article": "Dr. Heather Hayes, Director of Food Innovation with Devenish, said:\n\n\"Offering birds a natural and sustainable source of omega-3 PUFA is good for the bird and good for the consumer.\nThe results from the clinical study saw an increase in omega-3-PUFA levels in blood and a positive shift in what is described as the 'omega-3 Index'-a test that measures the amount of the omega-3 fatty acids, Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) in red blood cell membranes, which reflects the levels in your heart and other tissues.\nThe study showed that consuming omega-3 enriched chicken and eggs resulted in a halving of the number of subjects with such a high-risk omega-3 Index.\nThe chicken meat and eggs used in the study came from birds offered OmegaPro, a sustainable and algae-based source of omega-3 PUFA, developed by Devenish.\nThe 161 subjects involved in the study consumed at least three portions of chicken and eggs per week, that were naturally enriched with omega-3 Polyunsaturated Fatty Acids (PUFA), the same nutrients found in oily fish.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release gives only vague references to the benefits gained by study participants who consumed chickens, or their eggs, raised using the supplemented feed. We\u2019re never told how much omega-3 was consumed, just that participants ate the special meat or eggs at least three times a week. How much omega-3 did each serving contain? The release doesn\u2019t say.\nThe lede of the release states use of the feed \u201cis likely to reduce risk of heart attack, stroke, dementia and depression,\u201d but offers no numbers to back up that claim or quantify that supposed risk reduction.\u00a0\nLater, it states, \u201cThe results from the clinical study saw an increase in omega-3-PUFA levels in blood and a positive shift in what is described as the \u2018omega-3 Index\u2019-a test that measures the amount of the omega-3 fatty acids, Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) in red blood cell membranes, which reflects\u00a0the levels in your heart and\u00a0other tissues.\u201d Regardless, readers have no way of knowing the amount of \u201cincrease\u201d or \u201cpositive shift,\u201d so the statement is meaningless for gaining actual information about changes that can be traced back to the new food.", "answer": 0}, {"article": "Adding small amounts of powdered ginger to food may help take the edge off seasonal allergy symptoms, according to an animal study published online in the Journal of Nutritional Biochemistry. Daily intake of dried ginger significantly reduced sneezing and other signs of allergy in rodents with induced allergic rhinitis, or hay fever.\n\nA major component in ginger, 6-gingerol, suppresses the activation of T lymphocytes, or T cells, a type of white blood cell that plays an important role in sensitizing people to specific allergens,...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did a good job of sharing the limited results of the rodent study. Mice sneezed less (2.1 rather than 15.2 times) in the group that swallowed ginger, and had lower levels of immunoglobulin E, after exposure to an allergen. It was good to see that story used absolute numbers to quantify the benefits rather than stating the results as a percentage decrease.", "answer": 1}, {"article": "Professor Babaeva said: \"Our findings suggest that the decreased rheumatoid arthritis disease activity with the combination of anticytokines translates into decreased cardiovascular risk.\nPatients taking the combination of anticytokines had a lower rheumatoid arthritis disease activity score, as measured by the DAS28,2 and more dramatic decreases in IL-1, IL-6 and TNF\u03b1 than the group on standard therapy alone.\nFlorence, Italy - 9 July 2016: Immunotherapy reduces cardiovascular risk in patients with rheumatoid arthritis, according to research presented today at Frontiers in CardioVascular Biology (FCVB) 2016 by Professor Aida Babaeva, head of the Department of Internal Medicine, Volgograd State Medical University, Volgograd, Russia.1 The combination of two extra-low dose anticytokine drugs reduced rheumatoid arthritis disease activity and cardiovascular events.\nThe incidence of cardiovascular events (unstable angina, severe hypertensive crisis, and deterioration of chronic heart failure) was more than double in the group on conventional disease-modifying drugs alone (37%) compared to those also taking the combination of anticytokines (13%).\nThe effect was more apparent and developed earlier when patients were treated with a combination of anti-TNF\u03b1 and anti-IFN?, both at extra-low doses.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release offers some quantification of benefits when it describes the \u201cincidence of cardiovascular events (unstable angina, severe hypertensive crisis, and deterioration of chronic heart failure)\u201d as being 37% in conventional disease-modifying drugs group\u00a0compared to those who also took anticytokines (at 13%).\nNormally, that quantification would earn the release a satisfactory rating but the definition provided here for \u201ccardiovascular risk\u201d does not include heart attacks and strokes. It\u2019s misleading to leave them out.", "answer": 0}, {"article": "It\u2019s very apparent that he\u2019s dying.\u2019\u201d\n\nLandon began to refuse chemotherapy and turn into a \u201clittle psychopath,\u201d says Riddle.\nWhen Riddle made the decision to give her son cannabis, the information on its safety and efficacy was (and still is) limited to anecdotal accounts, a handful of case reports and lab studies published in obscure medical journals.\nBut there\u2019s also an emerging body of research that suggests marijuana might be effective as a treatment for cancer on its own, or in conjunction with standard therapies.\nRiddle says that once he hits the five-year mark this fall, he\u2019ll set a precedent for pediatric leukemia patients in the U.S., and maybe even worldwide.\nIn Utah, all cannabis is illegal, so when their story went public, she and Landon had to move permanently to Colorado, so he could continue to have access to the drug.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story gives the impression that the mother made the right choice for her son: stopping conventional chemotherapy and other treatment, and instead giving him cannabis oil. But more than once, the story warns that there is no evidence that cannabis oil fights cancer in people. It reports the mother\u2019s beliefs that the cannabis oil benefited her son, but it does not tell readers that her beliefs are supported by any independent scientific evidence; in other words, there are no specific claims that the cannabis oil provided proven benefits. So we will give the story a passing grade on this criterion.\nHowever, the story could have more clearly noted that the improvements in the boy\u2019s quality of life could be explained by the end of toxic chemotherapy and other treatments, and that it\u2019s just a coincidence that the cannabis oil treatment started at the same time.", "answer": 1}, {"article": "\u201cWe are not hopeful here.\u201d\nThere was no significant difference in the rate of deaths from all causes between the placebo group and those on canakinumab.\n\u201cI don\u2019t think you can necessarily just make comparisons to existing benchmarks, such as the PCSK9s.\u201d\n\nEven so, Tim Anderson, a Bernstein analyst, said the \u201cmarginal\u201d data are not compelling enough to dispel what for Novartis will remain a pricing conundrum, should canakinumab\u2019s approval be expanded for heart patients.\nThat\u2019s after an analysis of Cantos data found total cancer mortality among patients getting canakinumab was significantly lower than in those receiving the placebo.\nHe downplayed critics who said the benefit was small, saying that one large subgroup in the so-called Cantos trial had shown a 27 percent reduction in cardiovascular risk.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The thoughtful reader will understand that the benefits are modest, as indicated by the well-written headline and carefully worded opening sentence. However, missing from the story was a discussion of the study findings in absolute terms.\nThe story says the study that \u201cheart-attack survivors on one of three doses of canakinumab were 15 percent less likely to suffer another major cardiac event than those on a placebo.\u201d\nWhat does this mean in absolute numbers? The way researchers measured it was in events per 100 person-years, and the \u201cevents\u201d were non-fatal heart attack, non-fatal stroke, or death from a cardiovascular reason. In the placebo group, there were 4.50 cardiac events per 100 person-years. In the group receiving 150 mg doses of\u00a0canakinumab, there were 3.86 events per 100 person years. Of the various doses given (50, 150 and 300 milligrams), the 150 mg dose was the only statistically significant result, and it was only because of non-fatal heart attacks.", "answer": 0}, {"article": "And I've seen patients who have gotten up in the middle of the night and they trip and fall on the tubing,\" he explained.\nThe researchers found that catheter infection rates in the new program dropped 14 percent overall in general wards (non-ICU).\nBut there was no drop in infections or catheter use in intensive care units (ICUs), the study findings showed.\nAfter 18 months of using the program, infection rates among hospital patients in general wards dropped by one-third, while catheter use had dropped about 1 percent.\nNow, researchers report that a new program shows it might be possible to reduce both catheter use and its associated infections.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story attempted to quantify the benefits but missed the mark.\nWhat was missing: The chief way to quantify the benefits of such an intervention is to explain, in absolute numbers, how much the infection rate dropped. This can be expressed in terms of \u201c1,000 catheter-days.\u201d\u00a0In this case, the\u00a0rate was reduced from 2.28 to 1.54 infections per 1,000 catheter-days in the non-ICU patients. This is a 32% reduction. Use of the catheters themselves was also reduced by the program (which was one of the goals), from 20.1% to 18.8% (1.3% total reduction).", "answer": 0}, {"article": "And, yes, they do get into the brain,\" Fleming explains.\nThe researchers hypothesize that the prebiotics may alter levels of tryptophan, serotonin's amino acid precursor, but it's too early to say.\nNot necessarily; those pigs didn't show greater anxiety than control pigs during a stress test or poorer performance when given a learning and memory test.\nAlthough more work is needed to tackle remaining questions, the study adds to the growing body of research suggesting a strong and potentially modifiable link between the gut and the brain: a link that makers of infant formula should strongly consider.\nIn a recent study from the Piglet Nutrition and Cognition Lab at U of I, scientists worked with piglets to show prebiotics included in infant formula can enhance memory and exploratory behavior.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The description of benefits lacks any mention that trials in piglets may have little bearing on how human infants would respond to the prebiotic formula.\nAll we learn is that two-day old piglets given a cow\u2019s milk-based infant formula supplemented with polydextrose (PDX) and galactooligosaccharide (GOS) were tested at 25 days old with learning, memory, and stress tests.\u00a0 There is no evidence to suggest that the same result would be found in human infants.", "answer": 0}, {"article": "Dozens of biotechnology and pharmaceutical companies including Alnylam, Merck, Pfizer, Novartis and Roche are looking for ways to manipulate RNA to block genes that make disease-causing proteins involved in cancer, blindness or AIDS.\nDavis could not say whether the therapy helped shrink tumors in the patients, but one patient did get a second cycle of treatment, suggesting it might be.\n\u201cWhen it recognizes that it\u2019s gone inside the cell, it says OK, now it\u2019s time to disassemble and give off the RNA.\u201d\n\nIn a phase 1 clinical trial in patients with various types of tumors, the team gave doses of the targeted nanoparticles four times over 21 days in a 30-minute intravenous infusion.\nThe finding, reported in the journal Nature on Sunday, offers early proof that a new treatment approach called RNA interference or RNAi might work in people.\nBut getting the treatment to the right target in the body has presented a challenge.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Three sentences from the end, the story says the lead investigator \"could not say whether the therapy helped shrink tumors.\" For that, we\u2019ll give the story a hesitant satisfactory grade on this criterion. \nYet, at the top, the story said this was \"early proof that a new treatment approach\u2026might work in people.\"\u00a0 Indeed, there isn\u2019t much you can say at all after tests on three tumor samples.\nOne thing you can say is that there isn\u2019t any evidence yet of an impact on outcomes that people really care about \u2013 impact on longevity or quality of life, for example.\u00a0 For comparison, a story on The Scientist.com placed this high in the story in the third paragraph:\u00a0", "answer": 1}, {"article": "Open and laparoscopic surgeries were still more common than robotic surgeries for kidney repairs and removals.\nThe open-surgery group also stayed in the hospital about one day longer than the robotic group.\n\u201cYears ago, this was thought to be the be-all-end-all operation, particularly with prostate surgery.\nThe trade-off was the cost, with robotic prostate removal costing about $10,000 on average, roughly $700 more than laparoscopic surgery and $1,100 more than open surgery.\nDavid Penson, a surgeon at Vanderbilt University Medical Center who was not part of the study, said more consideration should have been given to the state of patients afterwards.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did an adequate job quantifying the operative mortality, blood transfusion and length-of-stay rates among the three groups studied. (Unfortunately, it did so inconsistently \u2013 sometimes giving data for all 3 types of surgery, sometimes providing results for only 2 surgical approaches.)\nWe\u2019ll give it a satisfactory score here.\nBut are these the outcomes that really matter?\u00a0 That\u2019s something we address in the \u201cEvidence\u201d criterion below.", "answer": 1}, {"article": "The ATS publishes three journals, the American Journal of Respiratory and Critical Care Medicine, the American Journal of Respiratory Cell and Molecular Biology and the Annals of the American Thoracic Society.\nInfants in this study will continue to be followed to track their lung function and respiratory outcomes.\n\u201cFinding a way to help infants exposed to smoking and nicotine in utero recognizes the unique dangers posed by a highly advertised, addictive product and the lifetime effects on offspring who did not choose to be exposed.\u201d\n\nIn a previous study, the authors had shown that 72 hours after birth, babies of mothers who smoked had better lung function if their mothers were randomized to vitamin C (500 mg/day) during their pregnancies compared to those born to mothers who smoked and were randomized to placebo.\nSumming up the findings of the current study, Dr. McEvoy said that a relatively low dosage of vitamin C may present \u201ca safe and inexpensive intervention that has the potential to help lung health of millions of infants worldwide.\u201d\n\nHowever, she added, helping mothers quit smoking should remain the primary goal for health professionals and public health officials.\nIn \u201cOral Vitamin C (500 mg/day) to Pregnant Smokers Improves Infant Airway Function at 3 Months: A Randomized Trial,\u201d Cindy T. McEvoy, MD, MCR, and her co-authors report that at three months of age, the infants whose mothers took 500 mg of vitamin C in addition to their prenatal vitamin had significantly better forced expiratory flows (FEFs).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "From the release:\n\u201cInfants whose mothers took 500 milligrams of Vitamin C (in addition to their prenatal vitamin) had significantly better forced expiratory flows (FEFs).\u201d\nWe\u2019re told FEFs measure how fast air can be exhaled from the lungs and are an important measure of lung function (because they can detect airway obstruction).\nHowever, no data are provided in the release to show readers just how significant the improved flows are. This information is in the study and should have been described in the release, too.\u00a0The study states that changes of half this size are predictive of clinical respiratory disease later in childhood.", "answer": 0}, {"article": ".\nMONDAY, Nov. 7, 2011 (HealthDay News) -- An investigational drug called pridopidine seems an effective and safe treatment for people with the progressive movement disorder Huntington's disease, researchers report.\nMore than 70 percent of the patients taking the higher dose of the drug showed a significant benefit, according to the researchers.\nStill, pridopidine does not get at the underlying cause of Huntington's disease, Di Rocco said.\n\"However, this is the first large study to show evidence of a positive result in treating the motor symptoms of this devastating disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story did not detail the potential benefits of pridopidine. Specifically, how did the patients improve their motor function? The only number provided was that 70% of patients improved. We need to know how this function was measured and to what degree they improved (it is not clear whether the story was talking about statistical significance or clinical significance).", "answer": 0}, {"article": "Michael T. Lotze, a professor of surgery and bioengineering at the University of Pittsburgh, said that \"the work is heroic.\nThe new report, however, is believed to be the first time that genetically engineered immune system cells -- specifically, T lymphocytes -- have produced the same effect.\nWhile the good results in two patients are encouraging, \"in terms of response rates, the overwhelming data is that T cells, even in high numbers, are inadequate to mediate sufficient anti-tumor effects,\" Lotze said.\nTwo men, both with the rapidly growing skin cancer melanoma, were given immune system cells taken from their own blood and engineered to attack their tumors.\nIn the study, Rosenberg and his colleagues took lymphocytes from the blood and inserted into them genes for a receptor capable of \"recognizing\" a protein on melanoma cells called MART-1.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It is appropriate that the story mentioned that although the two men who appear to have responded to the treatment were still alive, it was still too early to conclude that they could be categorized as \u2018cured\u2019. The article cautioned that even after 5 years, when the cancer might be considered cured, it could still reoccur. The article also pointed out that this success was seen in only 2 of the 17 individuals receiving this treatment; the other 15 had died.\nHowever, the article did not mention the success rate of currently available therapies for melanoma, nor the historic mortality rate. Without knowing the mortality rate with standard therapy for widely metastatic melanomas such as these, it is not possible to quantify the potential benefit of this therapy. ", "answer": 0}, {"article": "\u201cWe are looking for corporate partners as we head into Phase II trials,\u201d Kalos said.\nThe results provide \u201ca tumor-attack roadmap for the treatment of other cancers,\u201d including those of the lung and ovaries as well as myeloma and melanoma, researchers said.\nA third had a strong anti-tumor response, and his cancer remains in check.\nThe research group plans to treat four more patients with CLL before moving into a larger Phase II trial.\nThe engineered T-cells were detected in patients\u2019 blood for several months afterward, and a portion of them turned into \u201cmemory T-cells,\u201d which could provide ongoing protection against cancer recurrence, researchers surmised.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "As in the WebMD story, this story stated that, \u201cTwo participants in the Phase I trial have been in remission for up to a year. A third had a strong anti-tumor response, and his cancer remains in check.\u201d The WebMD story provided more details, though.", "answer": 1}, {"article": "Hospitals take over with more sophisticated cooling equipment.\nThe American Heart Association recommended cooling for most cardiac arrest survivors after two small studies in Australia and Europe, published in 2002, showed a clear benefit.\nBut MetroHealth and Cleveland EMS officials say they aren't convinced the therapy is proven enough to rewrite the book on cardiac arrest treatment.\nRosenbaum, a heart rhythm specialist, also challenged whether cooling is a priority, considering that heartbeat is restored in only a small number of people who suffer cardiac arrest outside hospitals.\nMost of these patients die from brain damage but doctors have found that lowering body temperature by about 8 degrees for 12 to 24 hours protects the brain and can save lives.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the experts quoted in the story indicated that survival would be improved with the use of this treatment, there was no indication of how many more individuals might survive or might have less brain damage as a result of cooling.", "answer": 0}, {"article": "While mammography works on breast density, radiofrequency looks at contrasts between normal and diseased breast tissues.\n\u201cAlthough there is still research to be done, the system has great potential to bring a new way for breast cancer diagnosis.\u201d\n\nCarolyn Rogers, clinical nurse specialist at Breast Cancer Care in the U.K., says in an emailed statement: \u201cEvidence is needed to demonstrate the accuracy and uses of this device.\nIt could be used in doctors\u2019 offices.\nCosts are reduced and the electronics fit into a case the size of a lunchbox.\nThe scanner is based on radiofrequency technology, which is able to quickly show malignant and benign tumors when linked to a computer.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "They\u2019re not quantified. Again, if it\u2019s because the tool hasn\u2019t been tested, we need to know that.", "answer": 0}, {"article": "In the balloon-catheter method, also known as Mammosite, a doctor inflates a balloon in the tumor cavity, and a catheter delivers the radioactive pellet.\nAlthough there are no large-scale national results, doctors say studies have shown brachytherapy to be as effective as traditional radiation therapy.\nThe shorter treatment duration encouraged McCartney to have brachytherapy.\nAlthough long-term data are unavailable, results have been positive.\nShe returned twice a day for treatment.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The article includes no data on the benefits of the treatment.\u00a0", "answer": 0}, {"article": "\u201cThe weight that it takes them one year to lose is typically back in two months,\u201d often because a body with longstanding obesity defends itself against weight loss by drastically reducing its metabolic rate, an effect not seen after bariatric surgery, which permanently changes the contours of the digestive tract.\nMatched with comparable patients who did not have surgery, those who did fared much better physically, emotionally and socially.\nAnd the reason is not a lack of willpower.\nIn reviewing studies that followed patients for five to 25 years after weight-loss surgery, Dr. Twells and colleagues found major long-lasting benefits to the patients\u2019 health and quality of life.\n\u201cMost say they wish they\u2019d done it 10 years sooner.\u201d She explained that the overwhelming majority of patients who undergo bariatric surgery have spent many years trying \u2014 and failing \u2014 to lose weight and keep it off.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Benefits are discussed at length, but only in vague terms. For example: \u201cMatched with comparable patients who did not have surgery, those who did fared much better physically, emotionally and socially.\u201d What does \u201cmuch better\u201d mean?", "answer": 0}, {"article": "Their average dose of mealtime insulin decreased by seven units (30%) and their need for all-day insulin dropped by eight units (32%).\nAt the annual meeting of the Endocrine Society in Boston, Dandona reported the results of a study in which 14 adults, whose type 1 diabetes was well controlled with insulin given via an insulin pump, received once-daily Victoza for either one week or 24 weeks.\nPatients who continued treatment for 24 weeks had further decreases in insulin doses, and lost an average of 10 pounds.\nThose who continued treatment for a full year continued these improvements and felt much better overall, says study leader Paresh Dandona, MD, of the State University of New York, Buffalo.\nAfter one week, average fasting and weekly blood sugar levels each dropped by about 15%.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story attached numbers to some of the benefits reported on. We learn that patients taking the drug had less need for mealtime and all-day insulin (reductions of 7 and 8 units, respectively); that their\u00a0HbA1C\u00a0dropped from 6.5%\u00a0to 6.1%; and that they lost an average of 10 lbs. However, no numbers are provided to back up the claim in the second paragraph that patients \u201cfelt much better overall\u201d after treatment.\nThis one is close, but since the story emphasizes the drug\u2019s effects on how patients feel (in the third paragraph, the lead researcher on the study says patients experienced a \u201cdelightful improvement\u201d \u00a0in\u00a0well-being), we felt that some data should have been provided to substantiate this.", "answer": 0}, {"article": "\u201cOurs is probably a bottom estimate,\u201d Dr. Cahill said.\nWhile use of the products in such operations has since fallen, one expert said the new report should convince doctors to stop using them in anterior cervical fusions, as the procedure is known.\nThe products\u2019 use in cervical fusion procedures is a small component of their total sales, which reached an estimated $760.3 million in 2008, with Medtronic\u2019s share the larger one, according to Millennium Research Group, a consulting firm in Toronto.\nIn a statement, she said the trial would help address how the procedure, if approved by federal regulators, \u201cshould be appropriately managed to minimize complications.\u201d\n\nSome experts have speculated that the adverse effects were dose-related.\nHe added that the study also confirmed how quickly physicians had adopted the proteins both for approved and unapproved uses.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\n\n\nThe story briefly mentions that the bioengineered proteins can promote bone growth; however it does not go into any detail about why the proteins are used in certain spinal fusion procedures nor does it provide any information about treatment outcomes. The average reader is left pondering why there was a dramatic increase in the use of the product.\u00a0 ", "answer": 0}, {"article": "Watch a video about research at WPI related to this study.\n\"To our knowledge, this is the first report of dried-leaf Artemisia annua controlling ACT-resistant malaria in humans,\" the authors of the Phytomedicine paper note, adding that more comprehensive clinical trials on patients with drug-resistant malaria are warranted.\n\"Successful treatment of all 18 ACT-resistant cases suggests that DLA should be rapidly incorporated into the antimalarial regimen for Africa,\" they added, \"and possibly wherever else ACT resistance has emerged.\"\nThe 18 patients, ranging in age from 14 months to 60 years, did not respond to the standard ACT treatment, and all lapsed into severe malaria, defined by symptoms that can include loss of consciousness, respiratory distress, convulsions, and pulmonary edema.\nThe report documents the experiences of 18 patients in the North Kivu province of the Democratic Republic of Congo who showed symptoms of malaria and were originally treated with the recommended medication: artemisinin-based combination therapy (ACT), which blends artemisinin, a chemical extract from Artemisia annua, with one or more other drugs that attack the malaria parasite in different ways.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story poses a hopeful scenario, but does not back up the claim of \u201ccure\u201d with the kind of numbers or measurements that we usually expect to cement the credibility of the evidence.\nHere\u2019s what the story says about 18 patients.\n\u201cAfter five days of treatment with tablets made from only the dried and powered leaves of Artemisia (which has been prepared and analyzed using methods developed by Weathers and postdoctoral fellow Melissa Towler), all 18 patients fully recovered. Laboratory tests showed they had no parasites remaining in their blood. (Weathers noted more than 100 other drug-resistant patients also have been successfully treated with DLA tablets.)\nThese 18 patients were dying,\u201d Weathers said. \u201cSo to see 100 percent recover, even the child who had lapsed into a coma, was just amazing. It\u2019s a small study, but the results are powerful.\u201d\nSo the information provided suggests a strong likelihood of success. However, the release contradicts itself in a single paragraph. While it says more comprehensive clinical trials are warranted, in the very next sentence it states that the drug should be \u201crapidly incorporated\u201d in areas with drug-resistant malaria.\nWe also aren\u2019t told which test or tests were used to determine the absence of the malarial parasites and how sensitive they are. As testing technology advances, researchers are aware that it\u2019s possible for malaria parasites to be present but undetected using current standard tests. A word of caution about the potential to miss these \u201chidden parasites\u201d would have been helpful. In addition, another research institution states on its website that when artemisia annua has been used to treat malaria \u201crecurrence is more likely than with conventional antimalarial treatment.\u201d  ", "answer": 0}, {"article": "\u201cIt may provide more of a one-stop shop.\u201d\nThe developer, Ironwood Pharmaceuticals, said the drug, linaclotide, met all the goals in the first late-stage trial testing it as a treatment for the type of irritable bowel syndrome accompanied by constipation.\nLaxatives can relieve the constipation but often do not help with the pain, said Dr. Chey, who is a consultant to Ironwood.\n\u201cThe exciting thing about the data on linaclotide is that it improves both of those symptoms,\u201d he said.\nAbout one-third of the cases involve constipation, another third diarrhea and the rest both constipation and diarrhea, according to Dr. William D. Chey, an expert at the University of Michigan.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This story did a pretty good job with the statistics. Importantly, it provided the absolute percentage of patients who experienced benefits in each group according to the various assessments used in the study. The story tell us:\u00a0\"Fifty percent of those on the drug had a significant reduction in pain, compared to 37 percent for those on the placebo.\" Had the story used\u00a0relative measures instead, it might have told\u00a0us something along the lines of \"\u202635% more patients treated with linaclotide experienced significant reductions in pain.\" We think the first description\u00a0is a much\u00a0more accurate\u00a0and complete way to characterize the results. ", "answer": 1}, {"article": "Hoberman is chief of the general academic pediatrics division at Children's Hospital of Pittsburgh of UPMC.\nWEDNESDAY, Dec. 21, 2016 (HealthDay News) -- A shorter period of antibiotic treatment for ear infections in young children does more harm than good, a new study finds.\nWhat's more, the children in the five-day group didn't have a lower risk of antibiotic resistance or of side effects such as diarrhea or diaper rash.\n\"Though we should be rightly concerned about the emergence of resistance overall for this condition, the benefits of the 10-day regimen greatly outweigh the risks,\" he added.\n\"The results of this study clearly show that for treating ear infections in children between 9 and 23 months of age, a five-day course of antibiotic offers no benefit in terms of adverse events or antibiotic resistance,\" Hoberman said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The discussion of benefits is misleading. The story\u00a0tells us that \u201cthe\u00a0risk of treatment failure was 34 percent in the five-day group and 16 percent in the 10-day group,\u201d but what does that mean? \u201cTreatment failure?\u201d\nAccording to the study\u00a0abstract: \u201cthe mean symptom scores at the day-12-to-14 assessment were 1.89 versus 1.20 (P=0.001).\u201d\nWe are talking about a 14-point pain scale, where 0 is low and 14 is high. So do we know if an average 0.69 difference in pain scales makes any difference? Any report on the alleged \u201cbenefits\u201d of the long versus short treatment should discuss this minor\u00a0difference.", "answer": 0}, {"article": "The requested URL /usnews/health/articles/070225/5laser.htm was not found on this server.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story mentions that \"90% of patients who have laser eye surgery achieve 20/40 vision, and 10% of patients need corrective enhancement surgery\". This data is provided by the American Academy of Ophthalmology. We are not given context for these statistics, which is important.\u00a0 Is this 90% of the 1.14 million laser surgeries performed this year? We are not told how many procedures go wrong or result in permanent benign or more serious side effects.\u00a0 \nThere are available data in the literature, and this story would have been improved to include more rigorous details on quantification of benefit.", "answer": 0}, {"article": "Generalized anxiety disorder (GAD) is one of the most common anxiety disorders in older adults and is associated with poor quality of life, increased health care utilization and impaired memory.\nHowever, older adults who live in rural areas can face a number of barriers, including living in an area where psychotherapy is not available, so alternate methods of providing treatment could increase utilization, according to the study background.\nTo place an electronic embedded link to this study in your story Links will be live at the embargo time: http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2015.1154 and http://archpsyc.jamanetwork.com/article.aspx?doi=10.1001/jamapsychiatry.2015.1306\n\nTelephone-based cognitive behavioral therapy was better at reducing worry, generalized anxiety disorder symptoms and depressive symptoms in older adults who live in rural areas, where access to mental health treatment may be limited, according to an article published online by JAMA Psychiatry.\n\u201cTelephone-delivered psychotherapy is one way to overcome some barriers to mental health treatment that rural older adults face,\u201d the study concludes.\nMany older adults prefer psychotherapy to medication for the treatment of anxiety.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release fails to give readers any indication of the degree of differences between the two approaches tested, and falls back on simply saying that X \u201cwas superior to\u201d Y and \u201cresulted in a greater reduction of symptoms.\u201d\u00a0 Without any numerical values being offered, readers can\u2019t gauge for themselves the value of one approach over the other. It\u2019s difficult to gauge the clinical effectiveness versus the statistical differences. \u00a0It\u00a0would have been helpful to compare the degree of reduction of symptoms with\u00a0office-based therapy, and drug treatment. \u00a0Journal news releases can help educate journalists and all readers by quantifying potential benefits \u2013 and by reinforcing the expectation in readers that such information should be provided", "answer": 0}, {"article": "Doctors spin a few tablespoons of a patient's own blood, separating out the platelets.\nThe hope is that if PRP can get an elite athlete like Bornstein up and running, it can help the baby boom generation and their creaky joints get back in the game.\nThe hope is that the same technology that allowed Bornstein to get back on the field so quickly can now be used to treat injuries in weekend warriors as well.\nHe is one of the few patients to get it so far \u2014 clinical trials are now testing PRP's safety and effectiveness.\nA leading sports medicine expert, he believes we can speed up the body's ability to heal itself with a remarkably simple technique.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story uses only an elite athlete\u2019s impressive recovery time as an example, yet it frames the story as one that may be ready to move beyond the world of elite athletes to the world of knee pain that accounts for 15 million American visits to doctors each year. The young man\u2019s experience may not be representative of anyone else who has this procedure, something that won\u2019t be known until clinical trials are completed.\u00a0 This should have been a point of emphasis. ", "answer": 0}, {"article": "Greek researchers offered fresh evidence of the health benefits of the Mediterranean diet, reporting in a large study that it helps improve several risk factors linked to diabetes, obesity and heart disease.\n\nThe Mediterranean diet is high in monounsaturated fats such as olive oil and also relies heavily on whole-grain cereals, fruits and vegetables, fish and low consumption of animal fats. It has been shown in numerous studies and clinical trials to reduce mortality from such causes as cardiovascular disease and cancer.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported the 31% decrease in the risk of developing \u2018metabolic syndrome\u2019.\u00a0 But it is impossible for readers to know the magnitude of a 31% risk reduction \u2013 this should have been reported as an absolute change in risk. \u00a0Also \u00a0\u2013 the story should have provided some insight about how reducing the risk of this \u2018precondition\u2019 would affect individuals.\nThe story could have done a more complete job of reporting about the positive changes in individual risk factors, such as impact on HDL cholesterol, blood pressure, circulating glucose and insulin to enable readers to more fully gasp what was potentially impacted by adoption of this dietary regime.\nLastly \u2013 the story could have explained that metabolic syndrome itself is not a disease.", "answer": 0}, {"article": "Bipolar Disorder (which used to be called 'manic depression') is characterised by episodes of mood swings, between being very up or very down with periods in between the two extremes.\nThese are early results, but if replicated may mean that treatment of some mental health problems could benefit from the inclusion of dietary advice.\nNow a group of Australian, German and American scientists have shown those who have a high quality diet, a less inflammatory diet, and/or a low BMI (Body Mass Index) may respond better to an add-on nutraceutical treatment provided as part of a clinical trial.\nParticipants received the study medication in addition to any stable treatments they were already receiving.\nResearchers also rated whether a participant was improving and, if so, how much, over the next 20 weeks.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The lead author is quoted as saying:\n\u201cWe found that people who had a better-quality diet, a diet with anti-inflammatory properties, or a lower BMI (body mass index), showed better response to add-on nutraceutical treatment than those who reported a low-quality diet, or a diet including foods that promote inflammation, or who are overweight\u201d\nThe release identifies a \u201cgood\u201d diet as having \u201clots of fruits and vegetables\u201d versus a \u201cpoorer quality diet had more saturated fat, refined carbohydrates, and alcohol.\u201d\nThe foods considered anti-, or pro-inflammatory, are not identified. Nor are the \u201cadd-on neutraceuticals.\u201d The BMI criteria for being overweight is not mentioned.\u00a0Providing this information would have made it easier for readers to place the study\u2019s benefits in context.", "answer": 0}, {"article": "Prostate cancer is very common, showing up in 240,000 U.S. men every year.\n\u201cOur findings with Western diet and prostate cancer-specific mortality, however, were surprising, in part because there are very little data regarding how diet after diagnosis may impact disease prognosis.\u201d\n\nThe findings could be important for many men.\nIt\u2019s yet another piece of evidence showing that the so-called Western diet can worsen the risks for cancer, as well as all sorts of other diseases from heart disease to Alzheimer\u2019s.\n\u201cOur results suggest that the same dietary recommendations that are made to the general population primarily for the prevention of cardiovascular disease may also decrease the risk of dying from prostate cancer among men initially diagnosed with nonmetastatic disease (cancer that has not spread),\u201d said Dr. Jorge Chavarro of Brigham and Women\u2019s Hospital and Harvard Medical School, who led the study.\nThey were more than 2.5 times as likely to die of their prostate cancer than patients eating the healthiest diet and they were more than one and a half times as likely to have died of anything over the 10 years, Chavarro\u2019s team reports in the journal Cancer Prevention Research.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports relative risks and not absolute risks, which is one of our concerns with the coverage. It mentions, for example, that the researchers studied 926 men who had prostate cancer that had not spread and that those who ate the Western diet were 2.5 times more likely to die of their cancer than men on a prudent diet. But our question in this situation is: 2.5 times more likely than what? Reporting the absolute rates of death would give readers a better grasp on the scope of the problem and potential benefits.", "answer": 0}, {"article": "Atrial fibrillation is the most common heart disorder, affecting 2.2 million Americans and 10 million people worldwide.\nPatients in the pilot study had advanced atrial fibrillation and tended to have other medical problems, such as high blood pressure, diabetes or coronary artery disease,\n\nPacker, who also led the pilot study, dubbed Cabana, acknowledged that the main limitation of this study was its small size, but said it lays the foundation for a larger one.\nA small pilot study funded by St. Jude Medical Inc STJ.N compared the two therapies in a sicker population of patients and also found that the procedure worked better than drugs.\nPatients in the Medtronic-sponsored trial who underwent the cryoablation procedure \u2014 which involves using a catheter to freeze away the heart tissue where the problem originates \u2014 was just as safe as drugs used to treat the condition and far more effective, meeting the study\u2019s primary goal of eliminating atrial fibrillation one year after the procedure.\nDuring the follow-up period, 97 percent of patients who got the procedure and 92 percent of the drug therapy patients did not suffer heart attack, stroke or death.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story did provide insight about the difference in heart attack, stroke and death in the groups taking medication alone or those who had received treatment with this device. \u00a0However, since the story did note that there is currently a device on the market, it would have been helpful to readers to provide information about treatment with the other device affects the rate at which these things occur. \u00a0A comparison of effectiveness would provide insight as to the relative merit for this new device.", "answer": 1}, {"article": "Dr. Christopher B. Granger, the study\u2019s lead author and a professor of medicine at Duke University, said, \u201cI think this is a profound trial result that will have a major impact on the practice and management of patients with atrial fibrillation.\nThe companies\u2019 stock soared after they released a brief statement about the stroke and bleeding benefits in June.\nAlthough the study was financed by the drug makers, which raises the issue of bias, it met the gold standard for medical research as a randomized, double-blinded trial in which doctors and patients did not know who took which pill until the end.\nThe study included 18,201 people in 1,034 clinical sites in 39 countries and was consistent worldwide, the sponsors said.\nIt combines both greater efficacy in terms of prevention of stroke with a substantial reduction to bleeding risk, and that package is one that will be particularly compelling.\u201d\n\nWall Street has high expectations, too.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story provided only relative risk reduction figures \u2013 \u201cprevented 21 percent more strokes\u202631 percent fewer incidents of major bleeding\u2026reduced total deaths by 11 percent\u201d \u2013 but neglected to present the absolute decrease in adverse events.\n21% of what? 31% of what? 11% of what?", "answer": 0}, {"article": "This benefit is thought to come from the omega-3 fatty acids in fish, although studies of fish oil supplements have produced disappointing results in people who already have Alzheimer's.\nIn a new study, imaging scans showed that regular fish-eaters were less likely to have brain cells die off in the area of the brain responsible for short-term memory -- recalling a phone number that was just heard, for example.\nRaji presented the findings here at the annual meeting of the Radiological Society of North America.\n\"More fish, more brain, less Alzheimer's,\" he tells WebMD.\nNov. 30, 2011 (Chicago) -- Older people who eat baked or broiled fish at least once a week may be boosting their brain health.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Even more than the competing story by HealthDay, this story focused only on the surrogate marker of what brain scans showed.\nDid that make any difference in anyone\u2019s actual cognitive abilities? The story never said.\nAt least HealthDay mentioned \u2013 although inadequate in its brevity \u2013 that those who ate baked or broiled fish showed better \u201cworking memory\u201d enabling them to more effectively execute routine tasks.\n ", "answer": 0}, {"article": "Regular aspirin use can also cause side effects, like stomach bleeding and ulcers.\nOne of the most prominent followed more than 6,000 older women for nearly a decade and found that those who regularly took 100 milligrams of aspirin did no better on cognitive tests, over time, than those who were given a placebo.\nOne recent analysis of previous studies found that people who took a low dose of aspirin every day for several years reduced their risk of developing Alzheimer\u2019s by 13 percent.\nAnother study in 2003 in The European Journal of Clinical Pharmacology found a similarly beneficial effect for aspirin and other nonsteroidal anti-inflammatory drugs.\nThe claim that aspirin can prevent the disease stems from the notion that Alzheimer\u2019s is caused by inflammation that disrupts proteins in the brain.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated that \u201cpeople who took a low dose of aspirin every day for several years reduced their risk of developing Alzheimer\u2019s by 13 percent.\u201d\u00a0 However the study itself reported that use of low-dose aspirin did not result in a significant reduction in Alzheimer\u2019s disease.\u00a0 Thus the story did not accurately report on these results and compounded this with its concluding statement.", "answer": 0}, {"article": "The study is by Peter Rothwell, MD, PhD, FRCP, of John Radcliffe Hospital in Oxford, England, and colleagues, and has been published online by the journal the Lancet.\nThe fall in the risk of death broke down according to individual types of cancer: Reductions in pancreatic, stomach, and brain cancers were difficult to quantify because of smaller numbers of deaths, the authors say.\nThis 20-year follow-up established that the risk of cancer death remained 20% lower among those who had been allocated aspirin than those in the control group for all solid cancers, including lung, prostate, brain, bladder, and kidney cancers, and by 35% for gastrointestinal cancers.\nThe protective effect of taking low doses of aspirin varied according to the type of cancer and how long aspirin had been taken, the authors found.\nAfter five years, death rates were shown to fall by 34% for all cancers and by 54% for gastrointestinal cancers.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In contrast to some of the other stories about this study, this one reported that actul numbers of cancer deaths during the origial trials and over the follow-up period (up to 20 years) used by these researchers. \u201cThe study looked at eight trials examining the effects of a daily dose of aspirin on preventing heart attacks involving 25,570 patients, 674 of whom died from cancer.\u201d\u00a0That was almost enough to give it a satisfactory score in our minds, but then there were all those relative differences to contend with.\u00a0\u201cThey showed a 21% reduction in the number of deaths caused by cancer among those who had taken aspirin, compared with people who had not.\u201d Does this mean that 141 (21% of 674) more people lived than died of cancer? And, if so, what are we to make of all the other relative differences? Then, later in the story, it says \u201cParticipants were also followed up after 20 years, by which point 1,634 of the original participants had died as a direct result of cancer.\u201d This is followed by more relative differences described in percentages. Still, there was a stronger attempt made here to quantify the benefits than in the other stories, so we are giving it a satisfactory rating, if only barely. The story flunks a key point here by saying the researchers found a 10 percent reduction in prostate cancer deaths when actually the differences in did not reach statisticaly significance. That error reflects a theme throughout this story of portraying the potential benefits as being more certain than the evidence justifies.", "answer": 0}, {"article": "They were dosed before bed time and had their overnight glucose levels continuously monitored.\nThose who received the oral insulin had a mean night-time glucose reduction of nearly 6.5 percent compared with a placebo.\nThe result is likely to surprise many skeptics who did not believe insulin could be delivered orally because they doubted it could survive the onslaught of digestive juices so it could have the intended effect.\nThe 28-day study involved patients whose type 2 diabetes was not adequately controlled by metformin.\nThe positive results must be replicated in a larger Phase III trial before the drug, known as ORMD-0801, can be submitted for approval.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports a decrease in \u201cmean night-time glucose of nearly 6.5 percent\u201d compared with a placebo. However, there is no indication of what that means for control of type II diabetes\u2013absolute numbers are needed to be useful. The difference appears to be small and similar to what already-available oral medications can do. It\u2019s also not clear if these patients continued to take metformin or not.", "answer": 0}, {"article": "The superbug that doctors have been dreading just reached the U.S.\n\nScientists find new antibiotic in the human nose\n\nMore than 350 organizations write Trump to endorse current vaccines' safety\nResearchers would still need to conduct pre-clinical trials to test its medicinal benefits.\nBut she said the average person shouldn\u2019t try to use the weed to make their own medicine.\nIts leaves and bark are used to treat wounds, ulcers, burns and skin infections, Quave said.\nThe plant extracts didn't harm the skin tissues or the normal, healthy bacteria found on skin.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story discussed benefits only in general terms.\u00a0Given that the research was on mice, there\u2019s no way to determine whether the intervention\u00a0would have any benefit at all to people, let alone to determine the scope of\u00a0the likely benefit. The story should have emphasized this more.", "answer": 0}, {"article": "Dementia affects about 50 million people worldwide, with 10 million new cases occurring every year.\nThe Tohoku University team wanted to find out if whole-brain rather than focused LIPUS is effective in treating mouse models of dementia, and if it was, what was happening at the molecular levels to achieve this.\nThe mice with a condition simulating Alzheimer's disease in humans received 11 LIPUS treatments over a period of three months.\nThis limits the types of drugs and cell therapies that could be made available to treat dementia.\nThe first clinical trials to evaluate the effectiveness and safety of the LIPUS treatment are already underway.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We are not given enough detail about the findings nor given any evidence that this treatment will be of benefit to humans. We only get a cursory mention of benefits here for the mice in the experiments: \u201cwhole-brain LIPUS therapy markedly improves cognitive dysfunctions without serious side effects.\u201d But the study is full of detailed numbers. For instance, LIPUS apparently improved the brain\u2019s blood flow in mice modeled to have vascular dementia by a significant single-digit percentage, roughly doubled the memory performance of those mice in one experiment, and possibly halved the grade or severity of brain lesions.\nA more important issue with this release is the vagueness of its headline \u2014 i.e. \u201cTreating dementia with the healing waves of sound.\u201d This could be read as teasing a beneficial treatment for humans, yet using what is a very early animal-model-based study. The headline should have qualified the mouse-based nature of the research, even if it wouldn\u2019t have been as interesting to journalists looking for a research study to cover.", "answer": 0}, {"article": "\"This is moving in the right direction,\" he told CBS News.\nThe study noted that some of the patients who had to quit working as a result of their memory decline, were able to return to work after adopting MEND and participants who were struggling at their jobs reported an improvement in job performance.\nFor example, an MRI of one patient showed hippocampal volume at the 17th percentile for his age range prior to MEND.\nOne participant from the 2014 study, who had been diagnosed with late-stage Alzheimer's, did not show improvements with the protocol.\nBredesen said that his team has a couple of larger trials planned to confirm or refute the results in the current study and to address key questions about how long results can be maintained and how late in the course of cognitive decline reversal is possible.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In its attempt to quantify the benefits, the story wrongly says 10 patients who were experiencing age-related memory decline showed brain scan improvements after following the MEND program for 5 to 24 months. It gives an \u201cexample\u201d of one patient whose MRI showed hippocampal volume increase from the 17th to the 75th percentile for his age during 10 months in the program. In fact, just one patient showed improvement in a brain scan, according to the study. Six of the patients demonstrated improvements in memory tests, and three showed only self-reported improvements in cognitive function.", "answer": 0}, {"article": "Thirty years ago, electrodes were surgically implanted deep within the brain.\nThis therapy is being tested at several centers around the world and more study is needed, but this new variation on an ancient concept is promising -- using electricity to try to zap the perception of pain.\nThis new approach places them right on the scalp.\nA small electrical current seems to work by affecting pain centers deep within the brain, somehow muffling the perception of pain.\nHe says his pain drops significantly after therapy and then slowly returns over time.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The segment makes no attempt to quantify the benefits of the treatment. \nBut the report makes clear that the trials are early and the benefits not proven. This would make a specific citation of benefits unnecessary\u2013even potentially misleading\u2013just as the single positive patient anecdote may be misleading.\u00a0 ", "answer": 2}, {"article": ".\n\u201cThis is how things are in bed, covered under duvets or a blanket.\u201d\n\nFor one night of the study, 17 volunteers slept with an open window or internal door.\n\u201cThe exposure we are under while asleep is continuous .\nA limitation of the study is that the motion sensor often slipped off the sleepers at night.\nCanha, who wasn\u2019t involved with this study, researches indoor air quality and sleep during different ventilation patterns.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t quantify what \u201cimproved\u201d sleep quality means, only generalities.\nFor example, the story claims improvement in fewer awakenings:\n\u201cThe number of awakenings and sleep efficiency improved as carbon dioxide levels decreased.\u201d\nBut we are not given any way to understand the magnitude\u2013how much did these things improve?", "answer": 0}, {"article": "\"Much like you would expect if the doctor told you 'you have cancer' or 'you have diabetes,' then there are different ways you could pursue treatment,\" he said.\nThat hurdle is attributed to the fact that in order to start naltrexone, a person has to have detoxed or not used opioids for several days, whereas a user can transition from opioids to buprenorphine seamlessly.\n(CNN) The first large head-to-head comparison of two opioid addiction medications found that, although they were equally effective in getting people off of high levels of opioids, users had a significantly more difficult time starting a regimen of naltrexone, compared with buprenorphine.\nHowever, both groups also reported similar challenges staying with the regimens: Just 40% of patients still used the drugs after 24 weeks.\nSix percent of those enlisted to use buprenorphine were unable to start their treatment, whereas 28% of those assigned to naltrexone dropped out before starting the therapy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story describes duration of staying on the treatments and rates of relapse, reporting that the rates are roughly equal. The story is also clear that that those randomized to Vivitrol did not do nearly as well as those randomized to Suboxone\u2013because over a quarter did not tolerate or receive the first dose of Vivitrol. If a person is hardy enough to tolerate detoxing in preparation for Vivitrol, then their likelihood of abstaining from opioids may be similar to those getting Suboxone (a little less than half of all people in the trial were still taking the drugs after six months).", "answer": 1}, {"article": "To make sure it works, though, the Centers for Disease Control and Prevention says doctors need to do a number of things:\n\u2022 Prescribe Truvada only for men at high risk of getting infected \u2013 that is, only for men who have sex with men, those who have multiple sex partners, and those who live in areas where there's a lot of HIV circulating.\nThe study makes that last point very clear.\nIt's the first time anybody's shown that taking a pill can prevent HIV \u2013 and it was the first new weapon against HIV unveiled in many years.\nThat doesn't tell the whole story.\n\u2022 Above all, tell patients they must take the drug every day \u2013 not just when they've had risky sex.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story stated the benefits clearly \u2013 albeit only in relative risk reduction terms.\u00a0 We would have preferred absolute numbers.\u00a0 But it did such a good job in telling the updated story about proper use of the drug in question that we give it a satisfactory score.", "answer": 1}, {"article": "A compound in raspberries is being touted as the next new fat burner. But people looking to lose a few pounds may not want to go running to the produce aisle just yet. Scientists say there are no major human studies to support the idea that a berry holds the secret to weight loss.\n\nRaspberry ketones, the organic compounds that give raspberries their aroma, raised hopes as a weight-loss aid after a 2005 study by Japanese researchers found the ketones boosted fat-burning processes in rat cells in a laboratory as long as those...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story emphasizes the\u00a0fact that\u00a0the only published studies on raspberry ketones were conducted in rodents. Since the story makes it clear that these studies are inadequate to establish a benefit, we won\u2019t dock points for not quantifying the results of those studies.", "answer": 1}, {"article": "Ellis also is a McNair Scholar at Baylor.\nBased on the estimate that the new mutation is present in 2 to 3 percent of cases, the researchers calculated that approximately 4,000 to 6,000 patients with metastatic breast cancer carry a HER2 mutation and are therefore potential candidates for neratinib treatment.\nThe researchers estimate that as many as 200,000 patients are likely to be living with metastatic breast cancer today in the United States.\nThe results of the clinical trial were encouraging in that about 30 percent of the 16 patients treated with neratinib had a meaningful clinical response showing significant disease stabilization or regression.\nIn addition to bringing to the table a novel treatment for metastatic breast cancer carrying a HER2 mutation, the researchers have tested the value of the circulating tumor DNA as a disease-monitoring marker.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release mentioned that about five patients in the trial had a \u201cmeaningful clinical response showing significant disease stabilization or regression,\u201d but did not provide any details as to what that means in patients with metastatic disease.\nThe release irresponsibly speculates, based on extrapolated (not actual) data about how many people with metastatic breast cancer with the \u201cnew mutation\u201d could benefit from the drug.\n\u201cThe number of patients who could potentially benefit from this new treatment approach is estimated to be in the thousands. The researchers estimate that as many as 200,000 patients are likely to be living with metastatic breast cancer today in the United States. Based on the estimate that the new mutation is present in 2 to 3 percent of cases, the researchers calculated that approximately 4,000 to 6,000 patients with metastatic breast cancer carry a HER2 mutation and are therefore potential candidates for neratinib treatment.\u201d\nRemember, these estimates in the thousands are based on a study of just 16 people.", "answer": 0}, {"article": "Laparoscopic surgery, in which a surgeon performs the operation through small incisions, usually with the help of a surgical robot, has been touted as carrying a lower risk of incontinence and impotence than the standard \u201copen\u201d form of the surgery.\nLack of information on outcomes isn\u2019t only a problem for robot-assisted surgery, but \u201cbedevils\u201d the scientific literature on prostate removal overall, the researchers note in the journal European Urology.\nIn the current study, Murphy and his team looked at 68 studies of robot-assisted laparoscopic surgery to better understand its downsides.\nAnd while some studies showed low complication rates, the researchers add, those rates went up when doctors used a standardized approach to reporting complications.\nAlso, the researchers add, robot-assisted surgery is no easier to perform and has no better outcomes in patients with conditions that can worsen surgical outcomes, such as being obese, having a large prostate, or having had previous surgery in the area.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0It is not clear from this story what, if any, the benefits are of having a robotic prostatectomy instead of a standard surgical prostatectomy. \u00a0 There was no discussion about the decreased hospital stay or reduced recovery time that has been reported with this approach. \u00a0Although these are short term benefits, they may be of interest to certain patients. In this sense, the story was the flip side of what we often see \u2013 exaggerated benefts and no mention of harms.\u00a0 This story mentions harms (although data comes from biased literature review) and no benefits. ", "answer": 0}, {"article": "Inflammation strips the myelin coating from nerve cell extensions, called axons, and connections at the ends of nerves, called synapses, are lost, together disrupting signaling and eventually causing permanent disability depending on where this occurs.\nIn the spinal cord - an area that's critical for walking -- they found a decrease in the expression of cholesterol synthesis genes.\nThey compared gene expression changes between regions that correspond to different disabilities.\nThey treated MS mice with a drug that increased expression in cholesterol synthesis genes - and this resulted in improved walking ability.\nWorking with a mouse model of MS, the research team assessed astrocytes in various regions of the brain and spinal cord known to be involved in walking, vision or cognition.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t delve into benefits. This sentence came closest to addressing a benefit:\n\u201cFor multiple sclerosis, specifically, increasing cholesterol synthesis gene expression in astrocytes of the spinal cord can be a pathway to repair nerves that affect walking.\u201d\nThe research was done in mice, not humans. The astrocytes were from mice. The \u201cgene expression\u201d can be described with quantities, but the release does not give the reader any details. How much did gene expression change? How much improvement did the mice show? Was there a control group of mice?", "answer": 0}, {"article": "\"This is really the gold standard.\nAccording to data submitted to the FDA, the test detects each virus 78% to 100% of the time, depending on the type, and has few false positives.\nA new cold and flu test can precisely diagnose a dozen winter ailments and reduce unneeded use of antibiotics, says the company that sells it.\nThe new test, called the xTAG respiratory panel, approved earlier this year by the U.S. Food and Drug Administration, is the most comprehensive FDA-approved virus-panel to date.\nAccording to manufacturer Luminex Corp. , Austin, Texas, the viruses in the panel are expected to account for about 85% of the viral illnesses in the U.S. this year.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story presents several benefits of the\u00a0xTag test.\u00a0 It\u00a0is 1) more sensitive and more comprehensive than currently available tests and diagnostic procedures, 2) it can address the problem of under-diagnosis of the flu in vulnerable populations, such as children and the elderly, 3) it can inform treatment decisions by potentially reducing the inappropriate use of antibiotics while indicating when they might be beneficial.\u00a0\u00a0 An important caveat is\u00a0that it is not known whether diagnosing these viruses improves outcomes, i.e.\u00a0decreased use of antibiotics, fewer hospitalizations, fewer deaths. ", "answer": 1}, {"article": "A colonoscopy isn\u2019t something you get just for giggles. Beyond the obvious unpleasantness, there\u2019s the small but real risk of complications that in rare cases can lead to hospitalization or even death.\n\nThat\u2019s why the American Cancer Society and other groups recommend that people screened for colorectal cancer using a colonoscopy wait a decade in between tests if no polyps or other signs of potential cancer are found. Polyps are slow-growing, and the benefits of being screened more frequently than that don\u2019t seem to outweigh the risks \u2026", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Adequate.\u00a0 The story said that almost 24% of Medicare enrollees in the study were re-examined within seven years \u201cwith no clear indication for the early repeated examination.\u201d", "answer": 1}, {"article": "HPV, a sexually transmitted disease, can be transmitted through vaginal, anal, and oral sex and has been linked to genital warts as well as cervical, vaginal, vulvar, oral, penile, and anal cancers.\n\u201cThe most salient message is that the [Gardasil] vaccine can prevent HPV infection on the external genital region, which means that we can now prevent most cases of genital warts if the boy is vaccinated at a sufficiently early age,\u201d says study researcher Joel Palefsky, MD, a professor of medicine at the University of California, San Francisco.\nThese vaccines are now on the CDC\u2019s routine childhood vaccine schedule for girls starting at age 9.\nThe vaccine is used in girls and boys and young adults ages 9 to 26 for prevention of genital warts caused by HPV types 6 and 11.\nThe vaccine is recommended for optional use in boys and men.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This short story packed a lot of nuance into a small space, giving readers the ability to see into the muddy waters around the risk and benefit discussion for vaccinating young men.\u00a0 But the story did not give actual numbers for the benefit, and may have left an overly optimistic impression of the study results.", "answer": 0}, {"article": "People with hypertension have traditionally been advised to stay away from alcohol because excessive drinking can increase blood pressure.\nAnd, one of the study authors, Eric Rimm of the Harvard School of Public Health, has been sponsored by the Distilled Spirits Council of the United States to speak at academic conferences.\nThe forthcoming study on men doesn't include an MRI component needed for a more complete comparison.\nCAUTIONS: The study included only male healthcare providers, so it might not be generalizable to a broader population.\nBOTTOM LINE: Having one or two drinks a day may be beneficial for men with high blood pressure, but studies like these shouldn't be used to justify excessive drinking.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of moderate drinking. The story only provided qualitative descriptions of the benefits.\u00a0 Readers deserve the data in order to make their own judgments of the strength of the evidence. ", "answer": 0}, {"article": "The U.S. Centers for Disease Control and Prevention has more on flu.\nLamps with this type of UV light currently cost less than $1,000, Brenner said, but that price would likely fall if the lamps were mass-produced.\nAs the researchers explained, broad-spectrum UVC light kills viruses and bacteria, and it is currently used to decontaminate surgical equipment.\nResearchers say a certain spectrum of ultraviolet light -- called far-UVC -- easily kills airborne flu viruses while posing no risk to people.\nBut he believes \"the use of overhead, low-level far-UVC light in public locations would be a safe and efficient method for limiting the transmission and spread of airborne-mediated microbial diseases, such as influenza and tuberculosis.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told that exposure to far-UVC light \u2014 a very narrow and limited portion of the full ultraviolet-C spectrum \u2014 killed H1N1 virus (a common strain of the flu virus). Just how much light exposure is needed, and for how long, is not mentioned in the story.\nIt\u2019s mentioned these results suggest public spaces could be sterilized using far-UVC lamps, but it\u2019s not mentioned the results were obtained using a small chamber that was less than 12 by 12 inches; so it\u2019s unclear whether the results can be reliably generalized to a larger space like a doctor\u2019s waiting room.\nFinally, the lead author is quoted as saying \u201cfar-UVC is likely to be effective against all airborne microbes, even newly emerging strains. However, without supporting data, that\u2019s a speculative statement.", "answer": 0}, {"article": "Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:\n\n\"If we're going to drive further improvements in survival from cancer, it's essential that we find ways of prolonging life in people whose cancers have evolved and become resistant to treatment.\nSome 67 per cent of the 347 women in the palbociclib plus fulvestrant group showed clinical benefit - either a reduction in tumour size or control of disease for at least six months - compared with 40 per cent of the 174 women in the placebo plus fulvestrant group.\nIn the trial, researchers from 144 research centres in 17 countries followed 521 women allocated to receive either palbociclib and fulvestrant, or a dummy pill and fulvestrant.\nWomen in the palbociclib plus fulvestrant group took a median of 9.5 months to progress, as measured by CT and MRI scans, compared with 4.6 months in the placebo group.\nSome 19 per cent in the palbociclib plus fulvestrant group had a decrease in tumour size compared with 9 per cent in the placebo plus fulvestrant group.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release clearly lays out the advantages of the drug combination over the alternative of fulvestrant with placebo. The primary endpoint of time to progression is reported accurately. The benefits are summed up with these statements:\n\u201cSome 67 per cent of the 347 women in the palbociclib plus fulvestrant group showed clinical benefit \u2013 either a reduction in tumour size or control of disease for at least six months \u2013 compared with 40 per cent of the 174 women in the placebo plus fulvestrant group.\u201d\n\u201cSome 19 per cent in the palbociclib plus fulvestrant group had a decrease in tumour size compared with 9 per cent in the placebo plus fulvestrant group.\u201d", "answer": 1}, {"article": "A type of sleeping pill that several major pharmaceutical companies are racing to develop received good news yesterday when Swiss biotech company Actelion Ltd. reported positive clinical data.\n\nSleep experts say the drug class needs further study but could potentially offer some benefits beyond Ambien, the top-selling drug in the $3.8 billion global market for sleeping pills. While Ambien and similar drugs, called nonbenzodiazepine drugs, are effective and easily tolerated by most people, some insomniacs don't respond to the...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u00a0reported the benefit\u00a0(increased time spent sleeping compared with a placebo) as \u2018significant\u2019, though the only statistically significant result contained in the company presentation about this product was something termed \"increased sleep efficiency\".\u00a0 Although the data on total sleep time was greater for those taking the 200 and 400 milligram dose of this drug than placebo, it is not clear from the way the information was presented that it represented a statistically significant increase.", "answer": 1}, {"article": "Things to consider before freezing your eggs\n\n\u25a0 Beware of a false sense of security.\nDiscarding an unused embryo, which has the potential to develop into a baby, has weightier implications for many than discarding unused eggs.\nFreezing eggs now is no guarantee of a baby later.\n\u25a0 There may be significant religious and ethical advantages to freezing eggs as opposed to embryos.\nCheck out more than one clinic and make sure you know what it defines as a \u201csuccess\u2019\u2019 \u2014 a viable transferring of an egg leading to a baby, or just a safely thawed egg.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story says there are \"few reliable statistics\"\u00a0in one place and \"there are no reliable numbers for how many women have chosen to have their eggs frozen so far\" in another and \"there are no guarantees\" in a third place.\u00a0 So when you don\u2019t know the denominator and are unsure of the numerator, it\u2019s hard for women to pinpoint the potential benefits. ", "answer": 1}, {"article": "AsthmaNet is a nationwide clinical research network created by the NHLBI in 2009.\n\"Results from this randomized controlled study showed that in young children with mild asthma, acetaminophen used as needed was not associated with increased asthma flares or more asthma symptoms.\n\"Previous observational studies had suggested that acetaminophen use was associated with asthma symptoms,\" says Kristie Ross, MD, MS, Clinical Director, Division of Pediatric Pulmonology, Allergy/Immunology and Sleep Medicine at University Hospitals Rainbow Babies & Children's Hospital (UH Rainbow) and co-author on the study.\nThe study, funded by the National Heart, Lung, and Blood Institute's (NHLBI) asthma network (AsthmaNet), appears in the August 18, 2016, issue of the New England Journal of Medicine.\nThe Division of Pediatric Pulmonology and Allergy/Immunology at UH Rainbow is currently recruiting for a number of asthma-related clinical trials.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "One of the questions the study attempted to answer was whether ibuprofen is a safer drug than acetaminophen in children with mild persistent asthma. Although the Boston Children\u2019s Hospital news release details the numbers, this news release does not include any quantitative data. It only states that researchers \u201cdid not find any significant differences in safety between the two drugs.\u201d The quantitative data are helpful because they show just how closely the two groups were matched and because they back up the claim to equivalent safety. As seen in many other news releases, the use of the word \u201csignificant\u201d here is ambiguous, since it is meant as being \u201cstatistically significant,\u201d instead of the colloquial use of the term.\nAs a result, we give the news release a Not Satisfactory rating here.", "answer": 0}, {"article": "\"For research, there's a lot of value,\" Knopman says.\nAnd it does leave one wondering if a lot more worry will be generated by the notion of \"preclinical Alzheimer's,\" when science and medicine can't offer anything to ease those fears.\nThe goal in all this, according to the Alzheimer's Association, is to increase opportunities for earlier diagnosis and treatment.\nBecause there are no treatments to prevent or stop Alzheimer's, many people may not consider this diagnosis a blessing.\nThe new definitions, which were just published online by the journal Alzheimer's & Dementia, acknowledge this dimly understood early phase of Alzheimer's.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nAs mentioned in the section on harms, this story tells readers that it is too soon to use lab tests or brain scans to diagnose Alzheimer\u2019s disease in routine clinical practice, so it is reasonable to defer consideration of potential benefits. This story is appropriately cautious about what benefits early diagnosis might offer, pointing out that receiving a diagnosis when there is no known treatment can cause worry and concern without offering an effective response..", "answer": 1}, {"article": "More than 2.2 million men in the U.S. are living with prostate cancer.\n\u201cThe walking had to be brisk for men to experience a benefit.\u201d\n\nThe researchers said the effect of brisk walking persisted independent of age, diagnosis, type of treatment and characteristics of disease.\nAnother potential source of the associated reduction was reduced inflammation due to a lower circulation of interleukin-6, high levels of which \u201cpredicted a 73% increased risk of dying from prostate cancer among normal-weight men,\u201d the researchers wrote.\nRichman and colleagues noted that the brisk walks may reduce insulin resistance, which decreases bioavailable insulin-like growth factor-1 (IGF1) and increases adiponectin levels, which are all associated with decreased risk of advanced or fatal prostate cancer in vitro and in vivo.\nThe authors theorize that the same may be true of acetaminophen; while not an NSAID, it does have anti-inflammatory properties.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We think a story like this should present raw numbers.\nSo, instead of:\n Why not explain 38% of what baseline?\u00a0 And 51% of what baseline?\nProjected benefits may be exaggerated by presenting them in the manner of this story.", "answer": 0}, {"article": "The first placebo-controlled study of two vaccines against the Ebola virus found they both successfully created a powerful antibody response for a year, suggesting they both could be tools to save lives in a future epidemic of the deadly disease.\n\nThe research, by doctors from the U.S. and Liberian governments and elsewhere, was published Wednesday in the New England Journal of Medicine. The study looked at 1,500 patients in Liberia, and took place amid and after the outbreak of Ebola in Liberia from 2014 into 2015.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story is very clear in giving data on the increased antibody levels among study participants getting either of the two vaccines, or the placebo. However, readers of stories about potential vaccines basically want to know if the vaccines will actually prevent the disease, and this trial was only able to show that the vaccines increased a person\u2019s antibody response. The story does, to its credit, include a statement from one expert stating that it isn\u2019t known what level of antibody response is needed to protect against the disease.", "answer": 1}, {"article": "Studies have shown that people with cancer are more prone to blood clots and that people with blood clots are at increased risk of cancer.\nHowever, they need to be confirmed, and the optimal dose, timing, and duration of use needs to be worked out, he says.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\nHarvard Medical School's Anthony Zietman, MD, president of ASTRO, tells WebMD that the findings are intriguing.\nThe findings were released at a news briefing held in advance of the annual meeting of the American Society for Radiation Oncology (ASTRO) in San Diego.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n\nThis story would have met this criterion if not for the headline and lead claiming that this study suggested aspirin may cut the risk of cancer death. Other than muddling the distinction between an association and a cause-and-effect relationship, the story does a generally good job of giving readers details about the study and its results. Although the lead highlights the difference in relative risk, the body of the story includes the absolute risk figures (10-year prostate cancer death rates of 10 percent vs. 4 percent). That said, the story should not have implied that the study proved the anticlotting drugs could clearly claim credit for the observed differences.", "answer": 0}, {"article": "The research involved in the current review had been conducted for an average period of four to eight years.\nAnd while cautioning that more research is necessary to build on this \"proof of principle,\" the authors suggested that people who embark on a long-term, low-dose aspirin regimen in their late 40s and 50s are probably the ones who stand to benefit the most.\nThe potential impact of aspirin on pancreatic, stomach and brain cancer death rates was more problematic to gauge, the authors noted, due to the relative paucity of deaths from those specific diseases.\nBut the study's lead author, Prof. Peter Rothwell from John Radcliffe Hospital and the University of Oxford, stressed that \"these results do not mean that all adults should immediately start taking aspirin.\"\nTwenty years after first beginning a low-dose aspirin program, death risk dropped by 10 percent among prostate cancer patients; 30 percent among lung cancer patients (although only those with adenocarcinomas, the type typically seen in nonsmokers); 40 percent among colorectal cancer patients; and 60 percent among esophageal cancer patients.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The use of relative risks throughout this story\u00a0inflates the\u00a0likely benefits of aspirin. For example, the story states that overall cancer death risk \u201cplummeted by 21 percent\u201d\u00a0among those taking low-dose aspirin while the studies were still underway. But in absolute terms, the rate of cancer death was\u00a02.3%\u00a0(327 deaths out of\u00a014035 people) in the aspirin group and\u00a03%\u00a0 (347 out of 11,535) in the\u00a0placebo group, for a reduction of 0.7%. This is statistically significant difference and may have important implications for the overall public health, but the benefit that this\u00a0represents for an individual is certainly much more limited than what the\u00a021% figure suggests \u2014\u00a0especially when one factors in the uncertain risk of\u00a0adverse effects.\u00a0To be fair, we had to search\u00a0the original study\u00a0pretty thoroughly and make our own calculations to determine this absolute risk. Nevertheless,\u00a0we expect\u00a0stories\u00a0to go the\u00a0extra mile to\u00a0make statistics meaningful for the decision-making of individual readers.", "answer": 0}, {"article": "Dr. Allyson Shrikhande is a physiatrist -- a doctor who specializes in physical medicine and rehabilitation -- at Lenox Hill Hospital in New York City.\nOne year after treatment, acupuncture patients had an average 20 percent drop in their pain score, compared with a little more than 6 percent among those who had simulated therapy, the researchers found.\n\"Although it was allowed for the participants to continue with the pharmacological [drug] treatment they were taking beforehand, when the study was finished, the patients who received individualized acupuncture were taking less medication than the group on sham acupuncture,\" Vas said.\nAccording to the study authors, nine out of 10 patients try some form of alternative therapy, such as massage or acupuncture, in addition to their regular pain medication.\nStill, Shrikhande said, \"the findings in this study help demonstrate that acupuncture is a safe and effective treatment for chronic pain patients.\"\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reports an improvement in perceived pain relief by the participants\u00a0receiving actual acupuncture (41 percent) versus those in the control group getting sham treatments (27 percent). It also reports that the reduction in pain persists for up to a year, although not to the same degree.\nIt\u2019s helpful that the story lists the relative reduction in pain seen in both groups for comparison purposes. However, the story would have been stronger had it indicated how the pain score used in the study works (e.g. What\u2019s the range of the scale?) and what the absolute reduction in pain scores was in both groups (e.g. If pain scores were already low to begin with, a 41 percent reduction might not be very meaningful). We would need that type of information to be able to judge the story Satisfactory on this criterion.", "answer": 0}, {"article": "The study comes a month after Gov.\nDr. William Zoghbi, director of Methodist Hospital's Cardiovascular Imaging Institute, said the cancer risk numbers reported in the study are actually fairly low compared to other tests that take X-rays of the chest area, such as a regular CAT scan or coronary angiography.\nThe study offers the most definitive estimate yet of the cancer risk from the radiation exposure that comes with increasingly popular CT scans, which provide pictures of the heart's arteries and quantify the risk of heart attack in people without symptoms.\nThey say the test's value is limited because it doesn't identify which plaque are stable and which could rupture and cause a heart attack.\nCritics note that no study has linked the use of CT scans with better patient outcomes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\n \nAs mentioned above, the story notes that while some experts recommend CT screening for coronary artery calcium deposits in order to increase the number of people receiving treatment to reduce the likelihood of a heart, others are skeptical about the real value of this type of screening for apparently health people. The reporter points out that many heart attacks strike people who do not have very high cholesterol levels or other indicators of elevated risk, but also that \u201cno study has linked the use of CT scans with better patient outcomes.\u201d\n\u00a0", "answer": 1}, {"article": "Shoulder movement and strength increased, while pain decreased.\nBut there are concerns about how well the results of RTSA will hold up over time in this group of patients.\nWhen complications occurred, long-term shoulder functioning was not as good but even with the high complication rate, 72 percent of patients rated their satisfaction level as excellent or good.\nStable Long-Term Results of RTSA in Patients Younger than 60\n\nThe researchers analyzed the long-term outcomes of RTSA in 20 patients, average age 57 years.\nThe average Constant score--a standard assessment accounting for shoulder motion, strength, daily activities, and pain--at the time of final-follow-up improved from 24 to 59 (out of a possible 100).\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does provide some numerical data on the benefits participants gained from the procedure:\u00a0 \u201cPatients\u2019 ratings of \u2018subjective shoulder value\u2019 improved from 20 percent to 71 percent (compared to 100 percent for a normal shoulder).\u201d\u00a0 It also provided the following: \u201cThe average Constant score\u2013a standard assessment accounting for shoulder motion, strength, daily activities, and pain\u2013at the time of final-follow-up improved from 24 to 59 (out of a possible 100).\u201d\u00a0 But what readers don\u2019t know \u2014 beyond the subjective views of participants \u2014 is how their shoulder movement improved in a practical sense.\u00a0 Could they reach items on high shelves?\u00a0 Could they play tennis, bowl\u00a0or other athletic activities?\u00a0 We have no way of knowing from the release if their quality of life improved, besides of course, the elimination of pain, which is itself an improvement.\nThe bigger picture is that with such a small group of patients, a 39 percent complication rate was very high. Twenty-five percent of the volunteers rated results as only fair. Further, range of motion deteriorated over time in all participants. The study results warrant further analysis with a prospective study to more accurately understand if this is a safe and effective procedure for the under-60 population.", "answer": 0}, {"article": "Doctor Challenges Cause Of MS And Treatment\n\nOne day 7 years ago, after a long walk with his dog along the Hudson River in Manhattan, Marc Stecker noticed he was limping.\nZamboni himself says that even if it turns out he's wrong, coming to a greater understanding of the disease would be the big reward \u2014 both for him and thousands of MS patients.\nRobert Zivadinov of the Buffalo Neuroimaging Analysis Center in New York says that not only is the procedure unsafe and costly to many patients, it is impeding necessary research.\nIt's so seductive, in fact, that Canadians and Americans with MS have been flocking overseas to get the \"liberation procedure.\"\nMany desperate patients have spent their life savings flying overseas to have the procedure, only to have it fail a few months later.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We should start here by\u00a0recognizing this story\u2019s\u00a0unusual choice of patient to profile in the opening paragraphs. The convention with a \u201cmiracle\u201d treatment like this is to lead with\u00a0a patient who experienced a dramatic benefit which is often unrepresentative of typical results. In this case, though, the story primes us to expect something miraculous\u00a0and then delivers the mundane truth: \u201cit didn\u2019t work.\u201d We wish more stories\u00a0focused on patients who represent the complicated reality of\u00a0health care instead of pumping up best case scenarios.\nWith that being said, we feel the story should have done more to describe the\u00a0range of outcomes that have been reported with this procedure as well as the need for better studies. For example, it didn\u2019t take our reviewers long to identify preliminary case series\u00a0data\u00a0\u00a0that could have been cited.\u00a0Though uncontrolled studies like this\u00a0one are prone to bias that can lead to inflated estimates of benefits, we think these published results \u2014 if carefully and responsibly explained \u2014 could have helped readers better understand the excitement surrounding the treatment. Alternately, the story could have sought out the perspective of doctors who have performed the procedure to get their take. As it stands, the coverage is dominated by\u00a0the perspectives of a single unsuccessfully treated patient and a skeptical researcher, so it\u2019s difficult for readers to grasp\u00a0why there has been such a heated public debate\u00a0about the surgery.", "answer": 0}, {"article": "\"The Suboxone got me far enough away to look and say 'wow, look at your life.\nPatients in the trial are given counseling as well as a new kind of anti-addiction drug called Suboxone.\nUnlike methadone, Suboxone can be prescribed by any doctor, even a family physician, so treatment for addicts can now be convenient and discreet.\nThe hope is one day that Suboxone can do for painkiller addiction that drugs like Prozac did for depression: convince the public that addiction is a brain disease, not a character flaw.\nIf the receptor is satisfied with drugs, the withdrawal symptoms stop and the person gets high.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The segment fails to report how effective Suboxone is at treating addiction. No data.\u00a0 Thus, also no data comparing with alternatives (methadone and/or psychotherapy or abstinence-based treatments). \u00a0 \nThe drug labeling states that the drug was shown in two trials to be about 17 and 28 percent effective (compared to 6 percent and 9 percent for placebo). ", "answer": 0}, {"article": "Researchers at Italy's Institute of Neuroscience injected rats and mice with botulinum neurotoxin A in doses comparable to those used in people.\nSomething else that can be seen in a different light is the hospitalizations and deaths that have been reported following Botox injections.\nYes, there was some evidence the toxin slipped into the bloodstream or the lymph system, but Botox in the bloodstream cannot enter the brain, says its manufacturer.\nA big reason Botox and its cousins, such as Myobloc, were OK'd was that preclinical testing showed that after being injected, they did not travel along the body's highways\u2014nerve cells\u2014to the brain and spinal cord.\nThose unapproved uses are another concern of the agency.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story focused on the cosmetic uses of this product, which is approved for use to treat a variety of conditions (neurological, urological, ocular). \u00a0While the story did mention this product is also used for lots of so-called \u2018off-label\u2019 applications, it did not shed much light on its benefits. The findings are interesting and should lead to additional research in this area.\u00a0 While the toxicity of these drugs may be related in some fashion to this spread, there are no data to support any definable toxicity in humans.\u00a0 Without placing this information in context (ie the benefit of these drugs), the reader is left with a imbalanced view on the topic. ", "answer": 0}, {"article": "But that\u2019s not enough.\nWhat is less clear is whether there is another group of individuals whose digestive systems have some \u201cgluten sensitivity\u201d and who would, therefore, benefit from avoiding gluten.\nThe study population was made up of people who complained of gastrointestinal symptoms consistent with NCGS.\nTwo authors reported on a woman in her early 40s who was experiencing significant \u201cgastrointestinal distress\u201d (bloating, gas, diarrhea, constipation, etc.)\nThe previous version also misstated the probability that gluten is responsible for gastrointestinal distress for those who experience gastrointestinal distress after consuming gluten and who don\u2019t have celiac disease or a wheat allergy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does a good job of addressing the symptoms associated with NCGS, which would presumably be eliminated by adopting a gluten-free diet. It also\u00a0provides useful numbers on the size and duration of the studies mentioned and how big the effects observed were. Example: \u201cThe authors found that 40 percent of patients on the entirely gluten-free diet reported a continuation of symptoms, compared with 68 percent of those who had consumed gluten.\u201d", "answer": 1}, {"article": "Dermatology professor Andrew G. Franks Jr., MD, of the NYU Langone Medical Center, says thalidomide is very effective for treating people with lupus skin conditions who do not respond to standard treatments such as steroids and antimalarial drugs.\nThe researchers note that the study dose was \u201cgenerally well-tolerated.\u201d No new nerve symptoms were reported.\nSimilar to treatment with thalidomide, most of the patients had a relapse of their skin problems within weeks of stopping the drug.\nThe lenalidomide study included 15 women with lupus skin conditions; six had lupus in other areas of the body, too.\nAll the other patients showed improvement, and the rash cleared up in 86%.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story was vague on the increased benefits seen with lenalidomide\u00a0stating \u201cAll the other patients showed improvement, and the rash cleared up in 86%.\u201d What does \u201cshowed improvement\u201d mean? The story could have been more explicit that this was an uncontrolled, very small trial and it is possible that those selected may have been more likely to respond or tolerate the medicine than other patients with this condition.", "answer": 0}, {"article": "Ancient Greek and Chinese medical practitioners used a patient\u2019s scent to make diagnoses.\nBut not every physician\u2019s nose is a precision instrument, and dogs, while adept at sniffing out cancer, get distracted.\nSo researchers have been trying for decades to figure out how to build an inexpensive odor sensor for quick, reliable and noninvasive diagnoses.\nThese molecules offer a whiff of who we are, revealing age, genetics, lifestyle, hometown \u2014 even metabolic processes that underlie our health.\nEach of us has a unique \u201codorprint\u201d made up of thousands of organic compounds.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "There is no real discussion of the actual benefits of any of these diagnostic technologies except to say that they are being studied in clinical trials. The closest we get to a discussion of actual benefits is when the article cites a\u00a0paper in ACS Nano\u00a0\u201cshowing that this artificially intelligent nanoarray could distinguish among 17 different diseases with up to 86 percent accuracy.\u201d \u00a0Even with over 1,400 participants in that trial we are told \u201cthe sample sizes for each disease were quite small. And the machine was better at distinguishing among some diseases than others,\u201d so it is unclear what one is to make of this.\nWe understand that this story is previewing technology before it\u2019s getting rigorously tested, but there\u2019s a lot of assumption being made that it will work\u2013after all, the headline is \u201cOne Day, a Machine Will Smell Whether You\u2019re Sick.\u201d The story says researchers are on \u201cthe cusp of succeeding.\u201d This could be said about almost any medical technology that\u2019s being tested clinically, and we didn\u2019t see any evidence that it was warranted in this case.", "answer": 0}, {"article": "A variation of a drug commonly given to cancer patients with bone damage appears to be an effective tool for preventing repeat hip fractures in elderly patients, according to a study in the New England Journal of Medicine.\n\nThe study results, which were to be presented yesterday in Hawaii, have potentially big implications because hip fractures are a common and debilitating injury for older people. Most of the 300,000 hip fractures each year in the U.S. are related to osteoporosis in older people, as well as falls, according...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported on the composite endpoint of any fracture where those treated were seen to have a statistically significant fewer number that those in the placebo group.\u00a0 The story did not, however, point out that while the number of hip fractures in the treated group was less than in the placebo group, this difference was not statistically significant.\nThe story did a good job of providing real numbers for the difference in the number of deaths observed in the two groups.\u00a0 ", "answer": 1}, {"article": "Other ways women can protect their bones as they age include weight-bearing exercise, and osteoporosis drugs for women at high risk for fractures.\nThe message here, Senay says, is that calcium supplements are useful for bone health \u2014 but you should only take them if you do so regularly, as directed by a doctor.\nIt's important to note that calcium intakes on food labels are based on adult requirements of 1,000 milligrams per day.\nThe drugs help them maintain strong bones\n\n.\nSupplements are an additional tool to be used when needed.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t quantify benefits in any way. ", "answer": 0}, {"article": "CHICAGO -- The diabetes drug Actos was able to slow the progression of plaque buildup in artery walls, while an older diabetes drug failed to stop the progression in patients with diabetes and coronary-artery disease, according to a study released Monday.\n\nUntil now, no diabetes-therapy regimen has been shown to reduce the progression of coronary atherosclerosis within the arterial walls among patients with Type 2 diabetes, a disease characterized by high blood-glucose levels that result from the body's inability to use insulin.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not quantify the benefits of treatment. Nor does the story mention that the clinical implications of plaque regression are unknown.", "answer": 0}, {"article": "Dr. Loren Wissner Greene is clinical associate professor of endocrinology at NYU Langone Medical Center in New York City.\nHowever, the incidence of episodes of hypoglycemia was much lower among patients taking TAK-875 (2 percent) than among those taking glimepiride (19 percent) and the same as those taking the placebo (2 percent).\nThe incidence of treatment-related side effects was 49 percent among patients taking TAK-875, 48 percent among those in the placebo group, and 61 percent among those in the glimepiride group, according to the researchers.\nAfter 12 weeks, all the patients taking the different doses of TAK-875 had significant drops in their blood sugar levels, the researchers said.\nA similar reduction occurred in patients taking glimepiride.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only gives percentage differences when talking about the hypoglycemia risk. The actual benefit in lowering blood sugar levels is vague. It says, \u201cAfter 12 weeks, all the patients taking the different doses of TAK-875 had significant drops in their blood sugar levels, the researchers said. A similar reduction occurred in patients taking glimepiride. However, the incidence of episodes of hypoglycemia was much lower among patients taking TAK-875 (2 percent) than among those taking glimepiride (19 percent) and the same as those taking the placebo (2 percent).\u201d", "answer": 0}, {"article": "That is very powerful.\"\nTo test this, researchers examined health records of 37,000 Marshfield Clinic patients looking for those with AMD, those taking L-DOPA and those with both L-DOPA and AMD.\nResearchers have discovered that patients who take the drug L-DOPA are significantly less likely to develop AMD, and if they do get AMD it's at a significantly older age, according to the study published online Nov. 4 in the American Journal of Medicine.\nThese provocative results were then confirmed in a much larger data set of 87 million patients where similar results were observed and the study expanded to include prevention and delay of \"wet\" AMD, the most devastating form of the disease.\n\"This study suggests an intriguing link between patients taking L-DOPA and a lower incidence and delayed onset of AMD,\" said Paul A. Sieving, M.D., Ph.D., director of the National Eye Institute.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release states that, based on the evaluation of a 37,000 clinic records of patients who took L-DOPA and noting those from the group that also developed AMD, that there appears to be a correlation between patients\u2019 taking of L-DOPA and their later development of AMD. It states that those taking the drug tend to develop the disease eight years later than those who don\u2019t. The release also suggests that in addition to delaying onset of the disease, the drug may also prevent it, although it is less clear in that claim. However, these numbers only portray relative risk rather than absolute risk and the number needed to treat (NNT). The numbers of people who developed AMD was relatively small, making it likely that the NNT would be very large (very many need to be treated in order to prevent or delay one case of blindness). Because the statistics used do not give readers a complete sense of the benefits attributable to to L-DOPA, we\u2019ll rule this Not Satisfactory.", "answer": 0}, {"article": "Knee surgery for a torn meniscus is done about half a million times each year in the U.S.\nBut those who stuck with therapy had improved as much six months and one year later as those who had arthroscopic surgery right away, researchers found.\nThirty percent of patients assigned to physical therapy wound up having surgery before the six months was up, often because they felt therapy wasn't helping them.\nOne study participant \u2014 Bob O'Keefe, 68, of suburban Boston \u2014 was glad to avoid surgery for his meniscus injury three years ago.\nPhysical therapy can be just as good for a common injury and at far less cost and risk, the most rigorous study to compare these treatments concludes.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "This description of benefits observed in the study seems sufficient to us:\n\u201cAfter six months, both groups had similar rates of functional improvement. Pain scores also were similar.\nThirty percent of patients assigned to physical therapy wound up having surgery before the six months was up, often because they felt therapy wasn\u2019t helping them. Yet they ended up the same as those who got surgery right away, as well as the rest of the physical therapy group who stuck with it and averted an operation.\u201d\nIt would have been interesting to learn how much the patients improved\u00a0from these injuries, and whether they regained total function or had\u00a0lingering impairment.", "answer": 1}, {"article": "\u201cThey seem credible to me, and they might hint that there are other mechanisms, besides just inflammation, linking the GI tract to the brain,\u201d he says.\nThat\u2019s why Dr. Roger McIntyre, professor of psychiatry and pharmacology at the University of Toronto, thinks the fMRI findings are the most interesting and important aspect of the new study: they signal that the probiotics may really be working on the brain itself.\n\u201cIt provides more scientific believability that something in the brain, at a very biological level, seems to be affected by this probiotic.\u201d\n\nNo serious side effects related to the probiotic were reported, suggesting that such a supplement could be a safe way to treat both stomach- and mood-related symptoms.\nWhile their data did not show significant independent changes in anxiety, constipation, diarrhea or pain, people who took the probiotic did report improvements in overall symptoms of IBS and in quality of life.\nOne explanation for the improved mood in the group taking probiotics could be that because their physical symptoms feel better, their mood gets better too.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states that twice as many people in the probiotic\u00a0group experienced a decrease in depression scores when compared to the placebo group (64% vs. 32%). However, readers aren\u2019t\u00a0told the\u00a0magnitude of the decrease in depression scores (did their depression decrease a little bit or a whole lot?). This is important information to include\u00a0as it speaks to the efficacy of the probiotic supplement as a potential treatment for depression. We also wanted to know more about how symptoms were measured, and if researchers used a clinically validated tool to do so.\nFor use of probiotics as a potential treatment for IBS, the story does discuss that no significant differences were found in improvement of symptoms between the groups.", "answer": 0}, {"article": "Medicated eye drops taken daily or twice daily can lower internal eye pressure to help prevent damage to the optic nerve.\n\"In making effective treatments easier for patients, the hope is that we can reduce vision loss from glaucoma, and possibly other diseases,\" said study author James D. Brandt, M.D., director of the UC Davis Medical Center Glaucoma Service.\nOur EyeSmart\u00ae program is a preeminent source of eye health information for the public and empowers people to preserve their vision.\nIn addition, the non-invasive nature of the device and its relatively large surface area make this technology a potential candidate for delivering multiple ocular drugs at once, further reducing the burden of self-administration on patients.\nA global community of 32,000 ophthalmologists, we are passionate about protecting sight and fighting preventable blindness.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release states that the ring containing the drug bimatoprose reduced eye pressure in glaucoma patients by about 20 percent over six months, and eye pressure fell 3.2 to 6.4 mmHg, compared with 4.2 to 6.4 mmHG for the group taking standard eye drops. The news release could have given more context to these numbers to help readers understand what they mean in terms of patient outcomes.\nIt\u2019s worth mentioning that reducing intraocular pressure is an intermediate outcome. The real goal is to slow vision loss. While this trial is too short for that, it could have been mentioned when discussing future trials that the real goal is yet to be studied. We won\u2019t dock points for that omission here since we address it below under the \u201cEvidence\u201d criterion.", "answer": 1}, {"article": "The relationship between statins and cancer is unclear, but other research exploring the impact of statins at the molecular level suggests that these cholesterol-lowering drugs may help control the development of tumor, as well as tumor growth.\n\u201cOur findings suggest that randomized controlled trials designed to test the hypothesis that statins reduce the risk of colorectal cancer are warranted.\u201d\n\nThis study was presented at a medical conference.\nThe findings should be considered preliminary as they have not yet undergone the \"peer review\" process, in which outside experts scrutinize the data prior to publication in a medical journal.\n\u201cThis effect was largely consistent across study design with both case control and cohort studies showing a strong correlation,\u201d he says in a news release.\n\u201cObservational studies have suggested that long-term use of statins is associated with reduced risk of several cancers, including breast, prostate, lung, pancreas and liver,\u201d says Samadder in the news release.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\u00a0The story reported the more impressive-sounding relative risk reduction (i.e. \"The analysis shows there was a 12% reduction of colorectal cancer risk among statin users.\") rather than indicating absolute risk reduction.\u00a0 This is such an important issue \u2013 so often misunderstood \u2013 that we offer a little primer on the topic.\u00a0\nJust as bothersome, the story really whiffed on the opportunity to explain the limitations of observational studies, and in so doing, it may have confused many readers.\u00a0 The headline says \"may cut risk.\" But the first line says both \"significant association\" and \"reduced risk.\"\u00a0 Wait a minute!\u00a0 Which is it?\u00a0 An association?\u00a0 Or an established cause-and-effect piece of evidence?\u00a0 Readers should have been told that observational studies CAN\u2019T establish cause and effect.\u00a0 So the story is wrong to use language like \"may cut risk\" or \"reduced risk\" in the headline and in the first sentence. ", "answer": 0}, {"article": "\"Transfer between hospitals takes a lot of time,\" said Turner.\nThis is because the accuracy of the device simplifies the decision made by emergency personnel about where to take patients first, according to Raymond D. Turner, M.D., professor of neurosurgery and chief of the Neuroscience Integrated Center of Clinical Excellence at MUSC.\nCompared to the neurologists' diagnoses, the device displayed 92 percent specificity -- the ability to detect the difference between patients with severe stroke and those with other conditions such as mild stroke or healthy participants with no brain pathology.\nThis places the VIPS device above standard physical examination tools used by emergency personnel that display specificity scores between 40 and 89 percent.\nIn the study, the VIPS device was deployed with emergency medical personnel in regions served by five Comprehensive Stroke Centers equipped with the endovascular capabilities to treat large-vessel occlusions that underlie severe stroke.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "It is important when discussing medical diagnosis to relate the test\u00a0sensitivity (the ability of a test to correctly identify those with the disease or the true positive rate), and the test\u00a0specificity (the ability of the test to correctly identify those without the disease or the true negative rate). This news release only mentions the specificity of the test, even though the actual study it was summarizing reports that \u201cthe VIPS device was able to differentiate severe stroke from minor strokes with a sensitivity of 93% (95% CI 83 to 98), specificity of 92% (95% CI 75 to 99)\u2026 and differentiate severe stroke from all other subjects with a sensitivity of 93% (95% CI 83 to 98), specificity of 87% (95% CI 81 to 92), and an AUC of 0.95 (95% CI 0.89 to 0.96).\u201d\nHowever, we should remember that diagnostic tests need to demonstrate that they offer a benefit beyond the current standard of care and that using them would improve patient outcomes. The current study doesn\u2019t measure that and so it is hard to know if it will be helpful in treating patients.", "answer": 1}, {"article": "Why have the side-effects?\"\nIn some of the test groups, overall success rates were fairly low, Lerman noted, but the study was conducted during the Great Recession, a time when financial stress may have depressed the chances of succeeding for everyone, regardless of which approach was used.\nThe results of the comparison showed that slow metabolizers did just as well on a nicotine patch or the drug varenicline (marketed as Chantix), a drug that works on the nicotine receptors in the brain.\nThe researchers, led by Caryn Lerman, a professort of psychiatry, divided 1,246 subjects into slow metabolizers of nicotine and normal metabolizers of the addictive chemical, based on the length of time it took for them to rid their bodies of the drug.\nNormal metabolizers of nicotine, meanwhile, had more success with varenicline because they tend to rid their systems of nicotine faster, limiting the effectiveness of the patch.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Great to see a story addressing the effectiveness of pills vs. patches. Glad also to hear discussion of side effects. Loved this scientist\u2019s comment: \u201cThe slower metabolizers, they do very well with the patch. And they get no incremental benefit from varenicline, Why spend the money? Why have the side-effects?\u201d\nBut again, we were looking for actual numbers. What were the overall success rates, and how did the researchers define \u201csuccess\u201d? How much better did the normal metabolizers do on the pills compared with the slow metabolizers? How less frequent are side effects with the patch compared with pills? By providing numbers to demonstrate the advantages of each approach for different individuals, the story could have made clearer why this was such an important study.", "answer": 0}, {"article": "They form when the skin is rapidly stretched, such as during puberty, pregnancy, and rapid weight gain, says Joshua Zeichner, MD, director of cosmetic and clinical research at Mt.\nNew stretch marks were also softer and smoother in 54 women who used the cream for three months, says Zoe Draelos, MD, a consulting professor of dermatology at Duke University Medical Center in Durham, N.C. \"The stretch marks did not go away,\" she tells WebMD.\n\"But [after several weeks of treatment], the cream made them look and feel better,\" she says.\nThe study, funded by Merz Pharmaceuticals, which makes the cream, was presented at the annual meeting of the American Academy of Dermatology.\nDraelos estimates that up to 98% of women and 75% of men have stretch marks, which appear as wavy, linear red scars, typically on the hips, breasts, thighs, and stomach of women, and the buttocks and pectoralarea of men.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Women\u00a0reported\u00a0that the treated stretch mark \"looked better, was less red, and was softer and smoother,\" according to the story, but\u00a0no\u00a0statistics are provided. There is no way\u00a0for the reader\u00a0to judge the frequency or magnitude of the benefits reported. \u00a0", "answer": 0}, {"article": "Mental disorders lack what most other health diagnoses rely on: biological markers.\nThe problem is that mental health diagnosis has essentially remained unchanged for 100 years, relying on symptoms and clinical interviews.\nThe test, says Bahn, can accurately predict whether someone will \u201cdevelop schizophrenia over the next two years.\u201d\n\nBahn\u2019s finding is one of several recent advancements toward a comprehensive system of biological mental health diagnostic tools.\nThat\u2019s because, Dulchin says, if a patient comes in with schizophrenia symptoms that a doctor knows can be alleviated with drugs, the doctor is not likely to deny that patient treatment\u2014no matter what a biological test says.\nIf there was a blood test for depression, it could just become part of a standard panel\u2014and thus help achieve earlier diagnoses, and in turn earlier treatment, across the board.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "In a piece with multiple studies mentioned, there was no quantification of any of the benefits found in any of those studies. Readers won\u2019t find out if\u00a0these tests found five people with various disorders or 500.\nWe were also concerned about overstatement of the benefits of this study: \u201cThe test, says Bahn, can accurately predict whether someone will \u2018develop schizophrenia over the next two years.'\u201d What does the story mean by \u201caccurate\u201d here? We encourage journalists to always discuss and define the test\u2019s sensitivity (how well the test finds people who have the disease) and specificity (how well the test rules out people who don\u2019t have the disease). In this story, we\u2019re not given any data points to see how this conclusion was made. And there\u2019s a general sense given to the reader that biomarker-based assessments would clearly be superior to diagnostic interviews, something that\u2019s not supported by any evidence presented in the story.", "answer": 0}, {"article": "The Ache: In the digital age, many people spend hours daily bent over computers, phones and tablets\u2014our necks craned forward. Some scientists say this unnatural position can lead to pain, headaches and other symptoms, sometimes collectively called \u201ctext neck.\u201d\n\nThe Claim: Technology itself comes to the rescue. An Android app called the Text Neck Indicator measures the angle of your phone and lets you know when you\u2019re holding it in a favorable viewing position. And a new wearable device, Alex, monitors the angle of your neck...", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story states very clearly that there are no proven benefits associated with either product, noting that \u201cneither product has been tested in a human study.\u201d Bonus points for noting that some scientists \u201ccaution that neck pain and headaches have complex causes, and\u2014to the surprise of some researchers\u2014a recent study found that better posture doesn\u2019t necessarily prevent pain.\u201d", "answer": 1}, {"article": "Now we can get a diagnosis sooner.\"\nDuring an FDA advisory panel meeting, committee members were mostly positive about DaTscan, though one neurologist objected to the average $1,500 cost of a scan versus $150 for a month's supply of carbidopa or levodopa medications for a Parkinson's patient, according to Medscape Medical News.\nIn cases where a diagnosis isn't necessarily clear-cut, the DaTscan offers important advances in patient care and treatment, said Dr. Michael Rezak, director of the Movement Disorders Center at Central DuPage Hospital, where the scan is offered.\nAs part of the study, recently diagnosed Parkinson's patients and healthy subjects are tested with DaTscan, and clinical and behavioral assessments are done to identify biomarkers of Parkinson's disease progression.\nDaTscan was first used at the University of Chicago Medical Center in August on a 75-year-old male patient who exhibited essential tremors, parkinsonian syndrome and some rigidity and slowness, said Dr. Tao Xie, assistant professor of neurology at the Medical Center's Center for Parkinson's Disease and Movement Disorders.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "\n\n\nThe unsatisfactory rating on this criterion also is related to the fundamental misrepresentation of the purpose of the DaTscan. The story repeatedly refers to getting patients on drug treatment for Parkinson\u2019s earlier. The only patient example presented to readers is of a man who says the test was the key piece of evidence that finally revealed he has Parkinson\u2019s after he was repeatedly told by other doctors that he had some other condition. In fact, conventional examinations are more likely to lead to a Parkinson\u2019s diagnosis than is a DaTscan test. The intended use of the test is to identify people who have been misdiagnosed as having Parkinson\u2019s when actually their symptoms are caused by some other condition. Also, while the story refers to clinical studies, it doesn\u2019t give readers any specifics about the results of those trials.\n", "answer": 0}, {"article": "Researchers have long known that people who are very thin tend to have a shorter life expectancy, often because they're dealing with cancer or other serious illnesses.\nBut the BMI, which is a general measure of body fat, has proven useful for thinking about the health of large groups of people, as in this study.\nAnd all of the people in this study are white, so that's a limitation.\nBut when they looked at the mortality rates in nonsmokers who had never had cancer or heart disease, it also became associated with a higher BMI over time.\nBut this does raise the prospect of whether it may soon be time to tweak the official definition of normal, healthy weight.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While the benefits\u2013increased survival\u2013were discussed, they were\u00a0quantified in a confusing way. For example, the story says that the risk of death for obese people, defined as having a BMI of at least 30, declined \u201cto the point that it was on a par with some people of so-called \u2018normal\u2019 weight.\u00a0So being fatter, at least a bit, may be healthier.\u201d\nIt is hard to figure out what that means.\u00a0It would have been more helpful if the story had quantified the death rates of the various groups discussed\u2013that way readers would have a clearer sense of how likely it is that the extra weight will help you \u201ccheat death.\u201d", "answer": 0}, {"article": "Dr. Kenneth Liao used the da Vinci surgical robot Thursday to restore lost blood flow to the heart of 58-year-old John Carter Holmes.\nUnlike other surgeries, there are no minimally invasive alternatives for valve repairs, he said.\nThe da Vinci is criticized by health policy experts as the poster child for the medical arms race \u2014 the competitive fever among hospitals to buy new technology whether or not it improves care.\nThe robotic systems come with million-dollar price tags and are used for a limited number of surgeries \u2014 mostly the removal of cancerous prostates in men or uteruses in women.\nStudies have disagreed on whether the outcomes of these surgeries are better when using the robotic system versus other minimally invasive techniques.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The report does not summarize findings of benefits and harms. It also allows a surgeon to say it has the benefit of reducing hospital time by half without pressing for some detail or source. ", "answer": 0}, {"article": "Although no one can pinpoint a reason for the link with certainty, \"essentially we think that alcohol may be having an effect by reducing the immune response, which leads to joint inflammation, and also that it may have a mild pain-killing effect,\" said Maxwell.\n\"This actually isn't a new concept.\nThe association was seen in both men and women, though it was stronger in males.\nThis finding is slightly different than what is reported in the current study (that the severity of the disease decreased with more alcohol).\nBecause the researchers assessed drinking frequency, rather than the amount of alcohol consumed, it is not clear how much alcohol might be helpful, they said.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Too vague.\u00a0 Terms were used such as: ", "answer": 0}, {"article": "(That\u2019s a high dose; a 3 oz.\nWhat\u2019s more, the people who showed the highest blood levels of the omega-3 fats (people absorb it at different rates) showed the greatest reduction in scarring \u2014 13% \u2014 compared to those with the lowest levels.\nThe effects remained strong even after the researchers accounted for the fact that all of the people were taking standard heart disease treatment drugs, including cholesterol-lowering statins and blood pressure medications.\nKwong and his team found that people taking the high dose of omega-3 fats showed 6% less of this decline in heart function than those taking placebo.\nFor the study, published in the journal , they studied nearly 360 people who recently had a heart attack, who were randomly assigned to take 4g of omega-3 fatty acids or a placebo pill for six months.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story\u00a0includes\u00a0the most salient quantitative evidence\u00a0of the study:\nThis is sufficient for a Satisfactory rating. However, more context would have made the story stronger: That researchers don\u2019t know what \u201c6% less scarring\u201d means in terms of actually reducing a repeat heart attack, death or another cardiac event.\nAnd from the original study, we learn that compared to\u00a0standard post-heart attack medical therapies, the benefits of fish oil were not significant:\n\u201cafter adjusting for standard post-MI (heart attack) medical therapies, there was only a nonstatistically significant trend for the treatment effect of O-3FA (omega-3 fatty acids) on noninfarct myocardial fibrosis (abnormal scarring of the heart muscle).\u201d", "answer": 1}, {"article": "Traumatic injuries to the head, often from car accidents, tend to sever brain cell connections and leave many neurons intact.\nThe imaging technique, called functional M.R.I., reveals changes in activity in specific brain regions.\nWithout this context, Dr. Fins said, the imaging tests could create some confusion, because like any medical tests they may occasionally go wrong, misidentifying patients as exhibiting consciousness or lacking it.\nBy contrast, brains starved of oxygen \u2014 like that of Ms. Schiavo, whose heart stopped temporarily \u2014 often suffer a massive loss of neurons, leaving virtually nothing unharmed.\nAbout 50 percent of people with such injuries recover some awareness in the first year after the injury, studies find; very few do so afterward.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Until it has been more systematically evaluated, there is no way to quantify the benefits of the imaging technique.", "answer": 2}, {"article": "Both groups went to their V.A.\nAfter the first year, 20 of the 464 veterans in the control group developed a squamous cell carcinoma that required surgery, but only five of the 468 veterans who got 5-FU did, a statistically significant 75 percent reduction in the risk, according to the study.\nIn the second year, BCC cases requiring surgery rose in the 5-FU group, but in years three and four, and by the end of the study, there was no significant overall difference in risk of developing a BCC requiring surgical treatment.\nIn the study's first year, 36 BCCs were treated with Mohs surgery in 27 participants in the control group, but only 17 BCCs were treated with the procedure among 14 patients in the 5-FU group.\nFor BCCs, there was an 11 percent reduced risk after the first year among the group that received 5-FU, but that difference was not statistically significant.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release clearly states:\u00a0 \u201cAfter the first year, 20 of the 464 veterans in the control group developed a squamous cell carcinoma that required surgery, but only five of the 468 veterans who got 5-FU did, a statistically significant 75 percent reduction in the risk, according to the study. For the subsequent three years, there was no longer a significant difference between the two groups in the number of patients who required surgical treatment for an SCC.\nThere were six outcomes measured\u00a0and\u00a0only the difference in squamous cell carcinomas at one year was statistically significant while the other five were not. This suggests that the one statistically significant difference could have been caused by chance alone or that there truly is a difference but only in this one period of time.", "answer": 1}, {"article": ".\nBakkum-Gomez has also used the method in her practice and is conducting a study of the IUD, which was originally designed as a contraceptive device, for this purpose.\n\"Well selected,\" in this case, means those with early-stage disease who want to maintain their fertility, much like the group in this trial.\nNine of the women in the study successfully delivered babies.\nParticipants -- all of whom were between ages 20 and 40 -- had an IUD known as Mirena, which released levonorgestrel, inserted for a year.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quantifies the benefits of the progestin IUD in several ways.", "answer": 1}, {"article": "In the UK, at least 40,000 people a year die prematurely from air pollution, with a cross-party committee of MPs calling it a \u201cpublic health emergency\u201d.\nBilstein said the inhaler could be useful around the world, as particulate air pollution is not just a European problem: \u201cEspecially in Asia \u2013 China in particular \u2013 the demand for such a product is even higher.\nThe perfect situation is that the patient inhales in the morning and evening at home.\u201d\n\nThe inhaler has been tested in three small groups of patients particularly at risk from air pollution, due to asthma, COPD and bronchitis, with the positive results due to be published soon, Bilstein said.\nAntioxidants can also provide some protection but there has been controversy over the effectiveness of such food supplements, he said: \u201cPersonally, I think it is much better to eat lots of vegetables and fruit rather than taking any supplements.\u201d\n\nDr Richard Russell, a consultant respiratory physician in the NHS and medical advisor to the British Lung Foundation, who was not involved in the research, said the inhaler was both credible and promising: \u201cEctoine is a beautifully elegant molecule and it clearly works by helping water to stabilise, giving you a film of water in times of stress.\u201d\n\n\u201cThe work that has been published thus far, in credible, internationally recognised journals, show that this stuff has positive properties, protecting against triggered inflammation,\u201d he told the Guardian.\n\u201cIt supports the natural barrier.\u201d\n\nWhen inhaled, this helps prevent the damage caused by air pollution particles that can lead to asthma, chronic obstructive pulmonary disease (COPD) and lung cancer, Bilstein said: \u201cDamage cannot occur as strongly and there is less inflammatory response, and so disease progression is reduced.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The reader is provided with no information on the presumed benefit of ectoine other than glowing comments and two references available via URL. The two studies noted include one in rats and one in human cell culture.\u00a0No information is provided about studies in humans, although one source says\u00a0the \u201cinhaler has been tested in three small groups of patients particularly at risk from air pollution, due to asthma, COPD and bronchitis, with the positive results due to be published soon.\u201d\nThis begs the question of the need for this story now rather than after the publication of the results.", "answer": 0}, {"article": "\"The band has a spotty history,\" Deveney said.\nThe procedure \"appears to result in relatively poor long-term outcomes,\" the researchers concluded.\nThe results: 12 years or more later, more than 60 percent of the banding patients said they were \"satisfied\" with their experience.\nHimpens said that patients should limit their expectations with respect to banding, noting that \"all weight-loss operations have a high failure rate\".\nDr. Mitchell S. Roslin, chief of bariatric surgery at Northern Westchester Hospital in Mount Kisco, N.Y., said he was not surprised by the findings.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story reported the average long term loss of excess weight that was observed in the study along with an insight from a clinician indicating that there is some variability observed among practices.", "answer": 1}, {"article": "\"So we thought, 'What if we change that by injecting the therapy drug into the metastatic lesions and change the microenvironment of the cancer?'\n\"For all patients with advanced cancer, immunotherapy using PD-1 inhibitors has really changed the face of cancer treatment.\nThe research was an early-stage study, conducted to test the side effects and best dosage of a potential new combined therapy, and the findings were published today in the journal Cancer Discovery.\nSeven of those nine had a positive response to the drug combination, including two for whom the tumors disappeared completely.\nThe study highlights the need for more research into combination therapies like this one, because many people with cancer do not respond to immunotherapy or experience a reoccurrence of their tumors after treatment.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release describes the responses the patients in the study had to the treatment. But the benefits of this response are overstated in the following paragraph, which describes the results as \u201csuggest[ing] that the combination of pembrolizumab and SD-101 could provide an alternative treatment for people with melanoma whose tumors have not responded or would be unlikely to respond to other therapies.\u201d\nThe study was not designed to look at this and did not show this. It was a trial to test for safety and safest dosages. What were the safety results? Readers don\u2019t find out.", "answer": 0}, {"article": ".\nAfter six months of treatment, more than 93 percent of 901 respondents reported their pain dropped from a median of eight to four on a 10-point scale.\nAfter six months, more than 18 percent of patients surveyed had stopped using opioid analgesics or had reduced their dosage.\nClose to 60 percent of patients who originally reported \"bad\" or \"very bad\" quality of life upgraded to \"good\" or \"very good\" after six months.\nMore than 70 percent of patients surveyed reported moderate to significant improvement in their condition.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The study abstract provides numerical data: \u201cAfter six months of treatment, 93.7% of the respondents\u00a0reported improvement in their condition and the reported pain level was reduced from a median of 8 on a scale\u00a0of 0\u201310 to a median of 4.\u201d However, the release got it wrong, saying that, \u201cmore than 93 percent of 901 respondents reported their pain dropped from a median of eight to four on a 10-point scale.\u201d That isn\u2019t the case. The release mixed it up.\nIn addition, the news release provides positive outcomes in pain control and quality of life using relative percentages, not absolute numbers. Further, the results are based on self-reporting in questionnaires, which are highly subjective and notoriously unreliable. Only about 900 (33%) of the original 2,736 subjects actually completed the study, and their follow-up was quite short at six months.", "answer": 0}, {"article": "Visit sirweb.org.\nOne month later, researchers followed the progress of eight patients and found that GAE significantly decreased pain (-58 mm on the Visual Analog Scale), reduced stiffness and increased physical function (-36.3 on the Western Ontario and McMaster University Osteoarthritis Index).\nAbstract 210: Geniculate Artery Embolization (GAE) for Osteoarthritis (OA)-related Knee Pain: Interim Results from a Multicenter US Trial.\n\"A majority of our patients with osteoarthritis of the knee saw significant pain reduction, not only just a few days after the procedure, but a month after as well, making this an accessible treatment for patients looking to improve their quality of life without surgery,\" said Sandeep Bagla, M.D., director of interventional radiology at the Vascular Institute of Virginia and lead author of the study.\nIn the first U.S. clinical trial on geniculate artery embolization (GAE), a minimally invasive, image-guided treatment that blocks key arteries in the knee to reduce inflammation and pain, resulted in a majority of study participants achieving significant pain reduction and improvements in range of motion, avoiding more invasive measures.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "Although the release reports improvement in physical function and decreasing pain based on standard measurements, it\u2019s impossible to use this preliminary report to make any clinical recommendations. Successfully demonstrating the value of this procedure as an effective approach to resolve pain and improve function in an individual with painful OA of the knee will require a longer period of followup and a comparison with control groups including a sham needle insertion group and a group receiving a corticosteroid injection in the knee.", "answer": 0}, {"article": "Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model \u2013 Growth Pharma.\nAn 18-week clinical study of CoolSculpting in submental fat treatment found that 77 percent of patients showed improved appearance of lax tissue and 75 percent of patients reported their chin looked more toned following treatment.3\n\n\"In my own patients, I have noticed the improved appearance of lax tissue when using the CoolMini\u00ae applicator for the CoolSculpting\u00ae system to treat the submental area,\" said Jeffrey S. Dover, MD, FRCPC, Co-Director of SkinCare Physicians of Chestnut Hill, Mass.\n\"A 2017 American Society for Dermatologic Surgery (ASDS) survey revealed that 73 percent of patients are bothered by excess fat under the chin.2 We are pleased this patient concern can successfully be addressed by CoolSculpting through a non-invasive approach, and furthermore improve the appearance of lax tissue in the treated area.\"\nYou should not have the CoolSculpting procedure if you suffer from cryoglobulinemia, cold agglutinin disease, or paroxysmal cold hemoglobinuria.\nThese factors include, among others, the difficulty of predicting the timing or outcome of FDA approvals or actions, if any; the impact of competitive products and pricing; market acceptance of and continued demand for Allergan's products; the impact of uncertainty around timing of generic entry related to key products, including RESTASIS\u00ae, on our financial results; uncertainty associated with financial projections, projected cost reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Allergan's periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan's Annual Report on Form 10-K for the year ended December 31, 2016 and Allergan's Quarterly Report on Form 10-Q for the period ended September 30, 2017.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release presents all evidence in relative terms. For example, the double chin treatment \u201creduced fat up to 20 percent in the treated area after one treatment.\u201d Furthermore, \u201c77 percent of patients showed improved appearance of lax tissue and 75 percent of patients reported their chin looked more toned following treatment.\u201d\nWhen data are given like this, it\u2019s important to ask \u201cx percent of what?\u201d There\u2019s a big difference between having 4 people in a study versus 10,000. And how big was the treated area and how exactly was improvement measured?\u00a0 How much improvement is there with a 20 percent reduction in fat collection? \u00a0How much was the improvement in lax tissue?\nWe recommend presenting benefits data in absolute terms when possible. One journal article reported that in 60 study volunteers, 20 percent chin fat reduction correlated to a 2.0 mm reduction on average. Clinical photographs and ultrasound imaging were used to assess treatment efficacy. Pre-treatment and post-treatment photographs were shown to three physicians, who had to determine which image was the pre\u2010treatment one. Participants were also given a written questionnaire after 12 weeks to evaluate their satisfaction.\nSince benefits data are given in relative terms and we are not told how many patients were involved with the studies (it was 60 in the study cited above and just 14 in another), we rate this one Not Satisfactory.", "answer": 0}, {"article": "After her mother unexpectedly died from a tear in the wall of her heart at age 63, Patricia Walters talked to her doctor, Leslie Cho, about how to better monitor her own heart health.\n\nPregnant at the time with her own daughter, Ms. Walters, now 46, says she was \"a nervous wreck\" worrying that she, too, might face serious cardiac risk.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story quotes the inventor of the test and an advocate for its use using the results of the Jupiter Study as a reference.\u00a0 The reader is provided with virtually no information about the study or its results other than the comments of the senior researcher.\u00a0 In reality, the Jupiter study did not have a control group (those with low hs-CRP levels).\u00a0 A more recent and larger study demonstrated that treatment with a statin reduced events even in people with low baseline CRP levels. (see\u00a0Heart Protection Study Collaborative G. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet. 2011;377:469\u2013476.)", "answer": 0}, {"article": "As a result, we set out to conduct a systematic search of all the scientific literature.\"\n\"Whilst we know a low-dose of aspirin has been shown to reduce the incidence of cancer, its role in the treatment of cancer remains uncertain.\nProfessor Elwood added: \"While there is a desperate need for more detailed research to verify our review and to obtain evidence on less common cancers, we'd urge patients diagnosed with cancer to speak to their doctor about our findings so they can make an informed decision as to whether or not they should take a low-dose aspirin as part of their cancer treatment.\"\nThat's why we specifically looked at the available evidence of bleeding and we wrote to all authors asking for further data.\n\"The results from six studies of other cancers also suggest a reduction, but the numbers of patients were too few to enable confident interpretation.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We\u2019re told that, during a given span of 5 years, a low-dose aspirin regimen in a patient with colorectal, prostate, or breast cancer is associated with a 15-20% reduction in death and spread of cancer. We generally want to see absolute (actual number of patients or volunteers) as well as relative risk reduction numbers. However, the study only provides relative risk data. Nevertheless, we think it\u2019s incumbent upon news release writers to present benefits data in terms that are meaningful for readers. And if those results aren\u2019t included in the study being described, news release writers should press their sources for more detailed and complete information.", "answer": 0}, {"article": "There had been no research on whether that was beneficial.\nThirteen of the women taking the drug for an additional five years developed breast cancer in the opposite breast during the study, compared with 31 taking the placebo; 55 and 68, respectively, developed a recurrence of cancer in the original breast.\nPut another way, the risk of cancer returning in the original or the opposite breast was 34 percent lower in women on 10 years of letrozole compared with those who stopped after five.\nAfter following the women for a median of just over six years, found Dr. Paul Goss of Massachusetts General Hospital and his colleagues, 95 percent of those taking letrozole for the additional five years remained free of breast cancer (meaning the disease had not returned in the original breast or developed in the opposite one).\nWomen receiving five more years of letrozole also had greater loss of bone in their hip, worse osteoporosis, and more fractures.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The benefit of continuing\u00a0aromatase inhibitors for five additional years is presented clearly. The study shows that among hormone-receptor positive breast cancer survivors, the risk of recurrence is lower for women continuing aromatase compared to those who did not, particularly in the opposite breast. The story breaks down\u00a0the figures by whether recurrence occurred in the original breast or in the opposite breast:\nIn a randomized controlled trial, 959 women were given the drug and 959 a placebo. Thirteen of the women taking the drug for an additional five years developed breast cancer in the opposite breast during the study, compared with 31 taking the placebo; 55 and 68, respectively, developed a recurrence of cancer in the original breast.\nLater in the story, the overall recurrence rate is given.\n95 percent of those taking letrozole for the additional five years remained free of breast cancer (meaning the disease had not returned in the original breast or developed in the opposite one). Of those taking an inert pill, or placebo, 91 percent did.\nThe story could have gone a step further by explaining more clearly what the recurrence rate for breast cancer is normally. The description of \u201c200 to 1 odds per year\u201d is not easy to understand and it\u2019s unclear if the recurrence rate in the study was lower than expected in the general population.", "answer": 1}, {"article": "\"We have the side view and the back view,\" said Kaufman.\nThis next step in virtual colonoscopy, called \"immersive colonoscopy,\" projects 3D images of the colon large enough to fill the walls of a room.\nFor the patient, a virtual colonoscopy is low risk but does involve additional exposure to radiation.\nSuch highly specific screening may allow doctors to detect more abnormal growths, called polyps, when they are as small as .10 mm, so they can be removed before they become full-blown cancer tumors.\nDr. Arie Kaufman of SUNY Stony Brook demonstrated the virtual colonoscopy for CBS New York's Dr. Max Gomez.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The piece states that virtual colonoscopy helps doctors view the organ in \u201cremarkable detail.\u201d Dr. Arie Kaufman, the only source quoted in the story, talks about how physicians can \u201cview 100 percent of the surface including legions.\u201d\nBut what is missing is how more detailed imaging translates to better health outcomes. Are there any studies proving the link between virtual colonoscopy and more lives saved? Can virtual colonoscopy detect more abnormal growths than a regular colonoscopy? And what exactly are the benefits for patients if they opt for a virtual colonoscopy instead of the traditional option? In this 2005 study in the journal Radiology, researchers reported that CT colonoscopy helped detect a \u201csubstantial number\u2026 [of] clinically important extracolonic findings,\u201d but this did not translate to improved health outcomes.\nVirtual colonoscopies still require patients to prepare for the exam, which may include drinking plenty of clear liquids, taking laxatives and swallowing foul-tasting oral solutions. The procedure also entails the insertion of a rectal tube and the pumping of air into the rectum.\nFurthermore, virtual colonoscopies are often not able to detect polyps smaller than 10 mm, although regular colonoscopies can detect polyps of all sizes. And virtual colonoscopies do not allow doctors to remove tissue samples or polyps from the colon, whereas traditional colonoscopies can.\nSince the benefits of the procedure aren\u2019t made clear, we give the story a Not Satisfactory rating here.", "answer": 0}, {"article": "\"Each person needs to think about how they metabolize caffeine or coffee.\"\nWhile these results are encouraging, it doesn't mean we should just go out and start drinking lots of coffee, says Mia Hashibe, lead researcher and an assistant professor in the department of family and preventive medicine at the University of Utah.\nBut coffee contains over 1,000 different chemical compounds, including cancer-fighting antioxidants, and it\u2019s those antioxidants that may provide a \u201cplausible explanation\u201d for reducing the cancer risk, says Hensrud.\nBut he is concerned that the side effects of coffee are not addressed in this study.\nIn the past, there\u2019s been a perception that coffee may be bad for you, according to Dr. Donald Hensrud, chair of preventive medicine at the Mayo Clinic.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The online and on-air stories still used inappropriate causal\u00a0 language \u2013 as the WebMD story did \u2013 in describing the results of a study that can\u2019t establish cause-and-effect. \nThe online story said \"may cut risk\" and \"may lower the risk.\"\u00a0 Adding the qualifying \"may\" doesn\u2019t detract from the inappropriate causal verb that follows. \nThe on-air story used the term \"benefit\" when benefit can not be established in this kind of study. \nInappropriate.\u00a0 Inaccurate.\u00a0 ", "answer": 0}, {"article": "Lumbar disk herniation is a common, often debilitating, condition that affects the disks that act as cushions between the vertebrae of the lower spine.\n\"The effect of pulsed radiofrequency is fast and without adverse events.\"\nPatients who received pRF saw greater overall improvement in pain and disability scores during the first year.\nThe results of the study are superior to those typically reported for usual care strategies and injections and may help a substantial number of patients with sciatic disk compression to avoid surgery, Dr. Napoli added.\n\"Pulsed radiofrequency creates a nerve modulation, significantly reducing inflammation and its associated symptoms,\" said study senior author Alessandro Napoli, M.D., Ph.D., professor of interventional radiology at Sapienza University of Rome in Italy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release reports these 1-year outcomes:\nThe terminology here is very vague. It would have been helpful to clarify what the rate and probability of \u201cperceived recovery\u201d mean, and how they\u2019re measured.", "answer": 0}, {"article": "\u201cThere was no joy to life,\u201d she said.\nDr. Solomon and other experts cautioned that bigger studies with other masters and approaches were necessary.\nBut not all of these reports have been conclusive, and tai chi is hard to study because there are many styles and approaches.\nDr. Chenchen Wang, a Tufts rheumatologist who led the study, said she attributed the results to the fact that \u201cfibromyalgia is a very complex problem\u201d and \u201ctai chi has multiple components \u2014 physical, psychological, social and spiritual.\u201d\n\nThe therapy impressed Mary Petersen, 59, a retired phone company employee from Lynn, Mass., who said that before participating in the 2008 study, \u201cI couldn\u2019t walk half a mile,\u201d and it \u201churt me so much just to put my hands over my head.\u201d Sleeping was difficult, and she was overweight.\n\u201cIt\u2019s hard for some patients\u2019 families and their doctors to get their head around what it is and whether it\u2019s real.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story presents the evidence in relative terms. It would have been nice to see the absolute numbers. Still, it\u2019s easy to calculate roughly what one third of 33 would be and one sixth would be. Essentially about 11 people stopped taking drugs after tai chi, and 5 or 6 stopped using other therapies. That\u2019s not a huge difference, but, because there was any improvement, the researchers and the journal were understandably curious and hoping the study might spark more research.", "answer": 1}, {"article": "Earlier studies have found that women taking bisphosphonates have a lower risk of breast cancer.\n\u201cThe lower risk of colorectal cancer risk seen among bisphosphonate users in this study is intriguing,\u201d Eric Jacobs of the American Cancer Society, who wasn\u2019t involved in the study, told Reuters Health by e-mail.\nAlso, not all patients asked to participate in the study agreed, which could limit the results further.\nThe researchers then found a comparison group of women without the disease, who matched the first group in age, ethnicity and clinics where they received treatment.\nColon cancer, on the other hand, has not been linked to estrogen, said Dr. Gad Rennert of the Carmel Medical Center in Haifa, whose findings are published in the Journal of Clinical Oncology.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story only presented the benefits in relative percentage terms, saying, \u201cEven after considering other factors tied to the disease \u2014 like aspirin or statin use and eating lots of vegetables \u2014 their risk was 59 percent lower than that of women who hadn\u2019t taken the drugs.\u201d Again, readers deserve to know the raw numbers here. The story should have said that 138 women in the non-cancer group took biophosphonates and 97 in the cancer group took them, meaning that 41 women appear to have benefited from taking the drugs. If the study had found that 97 women had taken these drugs in both groups, the study would not have made headlines. Also, it might have been helpful to show that there were actually larger differences in some of the other factors that were studied. For example, 120 women in the group of cancer patients had a history of colorectal cancer in the family compared to 75 women in the control group.", "answer": 0}, {"article": "Professor Peter Sadler, a medicinal chemist at the University of Warwick commented:\n\n\"Platinum compounds are the most widely used drugs for cancer chemotherapy, but we urgently need to respond to the challenges of circumventing resistance and side-effects.\nThe researchers have been focusing on the potential to use this compound on ovarian and prostate cancers.\nSince this new research functions in a totally new and unique way, it may overcome this acquired resistance and widen the spectrum of anticancer activity.\nUniquely, this chemo-catalyst treatment can be recycled and reused within a cancer cell to attack it repeatedly.\nImportantly, the development opens up a possibility for a more selective cancer treatment as JPC11 was observed to specifically target the biochemistry of cancer cells, leaving healthy cells largely untouched - another improvement compared to existing platinum-based drugs, which can also attack non-cancerous cells.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t adequately explain the limitations of the in vitro model and that it remains unclear how the compound would perform in human studies.\nThe release does not tell readers how effective JPC11 was at attacking cancer cells during in vitro testing. How effective was it at killing cancer cells, or preventing cancer cells from multiplying? For that matter, the release does not tell readers what types of cancer cells were used in the testing. While the release does mention that \u201cresearchers have been focusing on the potential to use this compound on ovarian and prostate cancers,\u201d it\u2019s not clear whether those cancers were the subject of this particular paper. More on this under the section on Quality of Evidence.", "answer": 0}, {"article": "Ohio\u2019s roads stink. Here are 5 options to fix them\n\nNobody likes paying more. But it turns out, if we want our roads to improve, we might have to.", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story opens by stating that taking hormones \"doubles the risk of breast cancer.\" The source of this statement is not provided, nor is even a mention of where to find the source. In any event, if the statement is correct it is unnecessarily provocative.\nThe reporter recovers in the last paragraph, stating that \"most women will not get breast cancer by taking the pills in the short term,\" adding that a couple of years of hormone use translates into \"a few extra cases of cancer a year\" per 1,000 women. But again, it\u2019s not clear what data that assessment is based on.\u00a0 \nIn any case, the information at the bottom should have appeared much higher up.\u00a0 ", "answer": 0}, {"article": "\u2022 Gaziano TA, Fonarow GC, et al.\nEAST HANOVER, N.J., June 22, 2016 /PRNewswire/ -- A new analysis published today in JAMA Cardiology has found that timely and broad adoption of Entresto\u00ae (sacubitril/valsartan) by all eligible heart failure patients with reduced ejection fraction (HFrEF) could prevent or postpone more than 28,000 deaths each year in the US alone.1 This analysis, based on an application of the results of PARADIGM-HF to published heart failure statistics, is the first to quantify the possible impact of Entresto's potential benefit in reducing death.1\n\nHeart failure is a chronic condition that contributes to more than 300,000 deaths in the US every year.4 About half of people with heart failure have HFrEF.5 This new analysis estimates that as many as 28,484 deaths in HFrEF patients annually could be prevented or postponed with optimal use of Entresto (with sensitivity analyses demonstrating a range of 18,230 to 41,017).1\n\nFurther, the study suggests that delaying routine use of Entresto in clinical practice could have a substantial negative effect on patients, given the expected risk-benefit profile, as it could result in failure to prevent tens of thousands of deaths.1 These findings demonstrate the significant survival benefits Entresto could offer to those living with HFrEF, if patients in the group defined by the authors were given access to treatment.1 The study authors stated that nearly 84% of HFrEF patients \u2013 2.2 million people \u2013 may be candidates for treatment with Entresto.1\n\nHeart failure is a life-threatening condition and despite available medicines, about half of patients diagnosed with heart failure die within 5 years.4,6,7 According to the study authors, these findings may substantially impact the national health of the HFrEF population, offering significant clinical benefit in preventing or postponing death when applied in clinical practice.1\n\n\"This expert analysis adds to the already compelling case for the treatment of heart failure patients with reduced ejection fraction with Entresto,\" said Fabrice Chouraqui, president of Novartis Pharmaceuticals Corporation.\n\"In addition to survival benefits, the study also recognizes other treatment effects of Entresto, particularly in reducing HF hospitalizations.1 Coupled with the recent Class I recommendation, the strongest endorsement, in the focused update to the US HF Guideline,2 these findings underscore the potential of Entresto as a standard therapy for chronic HFrEF patients.\"\nThe target treatment dose of Entresto is 97/103 mg twice daily.11\n\nNovartis is committed to providing patients with affordable access and resources through Entresto Central.\nIn particular, management's expectations regarding Entresto could be affected by, among other things, the uncertainties inherent in research and development, including unexpected clinical trial results and additional analysis of existing clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain proprietary intellectual property protection; general economic and industry conditions; global trends toward health care cost containment, including ongoing pricing pressures; unexpected safety, quality or manufacturing issues, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release makes several statements about benefits to an entire population, not necessarily the benefits to an individual patient. The release provides a useful number-needed-to-treat explanation.\n\u201cFor every 1,000 patients treated with Entresto vs. enalapril, potentially 59.7 HF hospital admissions could be averted per each year alive in the model.3 In addition, Entresto increased life expectancy at an incremental cost-effectiveness ratio consistent with other high-value widely accepted cardiovascular interventions such as implantable cardioverter defibrillators (ICDs) and cholesterol-lowering statins before they became generic.3\u2033\nOne weakness in describing the benefits was the omission in the release (but not in the published study) of actual figures or percentages to back up the cost-effectiveness claim.", "answer": 1}, {"article": "The U.S. Preventive Services Task Force on Sunday issued new guidance for the use of cholesterol-busting statin drugs.\nIn an opinion piece Sunday, Redberg and Mitchell Katz, deputy editor of JAMA Internal Medicine, advised everyone to take \u201ca step back\u201d and ask \u201cwhy this debate is so contentious.\u201d They suggest that the estimates of the benefits of statins may be inflated, that the drugs as an intervention are \u201cweak,\u201d and that the reports of adverse events are incomplete.\nThe task force and AHA groups carry tremendous influence in medical practice and in what insurance companies will cover.\nIndividual doctors are free to take the advice or leave it, and in recent months there has been a lot of debate about what the scientific evidence really shows regarding the therapy.\nThe report greatly expands the universe of people who should be screened to see if they need the medication to everyone over age 40 regardless of whether they have a history of cardiovascular disease.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "We don\u2019t know to what extent people in this category of risk (more than 10% or more than 7.5%) would benefit from statins, which would seem an essential and basic element of the story. Any recommendation that has the potential to alter the drug-taking habits of a huge swath of the population must be explained in numerical terms and so this was an unfilled gap.", "answer": 0}, {"article": "Enlarged prostate is characterized by a host of unpleasant symptoms, including weak or slow urine flow, an urgent need to urinate frequently, incomplete bladder emptying and having to get up repeatedly at night to urinate.\nIn this study, PAE helped most of the 67 patients who underwent the procedure, according to the researchers, who noted that 66 men who had not responded to medications experienced improvements in symptoms as well as a reduction in prostate volume.\nDr. Franklin Lowe, associate director of urology at St. Luke's-Roosevelt Hospital in New York City, said PAE was \"unlikely\" to be used much to treat enlarged prostate.\n\"PAE is potentially fraught with complications,\" Lowe said, adding that the study follow-up of less than one year was short for a disease that lasts decades.\nSince the study is being presented at a medical meeting and has not yet been published in a peer-reviewed journal, the findings should be considered preliminary.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "While reporting that 66 out 67 patients in the study experienced \u2018improvement\u2019 in symptoms, it was not clear to readers what exactly was improved, the extent to which it was improved, and what the satisfaction level with the improvement was. \u00a0There was not an adequate presentation about the benefits from this procedure.", "answer": 0}, {"article": "Biopsies may be performed via open surgery on the breast or with a less invasive core-needle biopsy in which a small sample of breast tissue from the affected area is removed through a special needle inserted through the skin.\nA new review of more than 80 studies on the two breast cancer screening methods shows breast needle biopsy was able to distinguish between cancerous and noncancerous breast lesions with about the same accuracy as surgical biopsy and less than half the risk of complications.\nIn addition, the study showed women initially diagnosed with breast cancer with needle biopsy were more likely to be treated with a single breast cancer surgery than those initially diagnosed by open surgical biopsy.\nThe results showed that core needle biopsies were about as accurate as open surgery at detecting cancerous vs. noncancerous breast lesions.\nThey say additional studies are needed to find out what factors affect the accuracy of core-needle breast biopsy.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story does not compare the specificity of core needle biopsy v. surgical biopsy for accurately diagnosing breast cancer.\u00a0 The story does not mention that evidence from the recent analysis was for women with average risk of developing breast cancer.\u00a0 For women at higher risk, the accuracy may be different. ", "answer": 0}, {"article": "The disease can cause cirrhosis, which is a scarring of the liver, as well as liver cancer.\nBut in Vertex\u2019s trial, about 70 percent of those who achieved an effective cure were able to do so in 24 weeks, or about six months.\nThat shorter time line, plus a higher chance of success, could entice more people to be treated, experts say.\nBut experts hope that eventually several of the pills now in development could be used together, much as AIDS is treated, doing away with the need for interferon.\nIt is not quite clear how those drugs work.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story talks\u00a0a lot about the benefits but doesn\u2019t really quantify them. Given that 1,095 patients were in the trial, let\u2019s assume that half were in the drug group and half in the placebo group. Of the drug group, let\u2019s assume half were in the 24 week group and half were in the eight week group. By our math, that means that about 154 people had better outcomes than those in the control group. Also, the story\u00a0does a pretty good job of walking people through the results, but the story is framed as a \"new era\" versus an old, torturous treatment. Only when you get to the end of the story do you realize that the new drug only works in combination with the old, torturous treatment. So the torture is not going away, it\u2019s just taking on a new layer of medication, and new costs.\nRelapses after completing therapy are common with standard therapy of IFN and ribavirin.\u00a0 In a recently published study in the NEJM\u00a0involving patients who had previously failed IFN and ribavirin, there was a 76% \"cure\" at the end of the treatment period, but only a 51% \"cure\" 24 weeks after the end of treatment. So in the data reported in this article, is the 75% \"cure\" 24 weeks after the end of treatment or is it at the end of the treatment period? Finally, the information presented doesn\u2019t translate into how many patients need to be treated to have one meaningful cure.", "answer": 0}, {"article": "Finally, in 2000, a group of researchers including Dr. Segal in Toronto, J.\nYet so far, the evidence that mindfulness meditation helps relieve psychiatric symptoms is thin, and in some cases, it may make people worse, some studies suggest.\nThe mindfulness treatment \u201cmay be contraindicated for this group of patients,\u201d S. Helen Ma and Dr. Teasdale of the Medical Research Council concluded in a 2004 study of the therapy.\nOthers, like Dr. Linehan, insist that patients in severe mental distress are the best candidates for mindfulness.\nA recent review by Canadian researchers, focusing specifically on mindfulness meditation, concluded that it did \u201cnot have a reliable effect on depression and anxiety.\u201d\n\nTherapists who incorporate mindfulness practices do not agree when the meditation is most useful, either.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story notes the evidence of potential benefit for some patients, and a lack of evidence for use\u00a0 of mindfulness mediation with certain populations.\u00a0 However, benefit from psychotherapy is difficult to quantify as endpoints are not always standardized. ", "answer": 1}, {"article": ".\nTheir findings indicate that targeting SecA is an attractive antimicrobial strategy against MRSA and may be several times more effective than the antibiotics now available for treating the infection.\nThis study also confirmed that SecA inhibitors have the potential for being broad-spectrum antimicrobials, can directly block virulence factor production and can null the effect of efflux pumps.\nThe best inhibitor in this group, SCA-50, showed strong activity against MRSA Mu50 strain and an inhibitory effect on MRSA Mu50 that was two-to-60 times more potent than all commonly used antibiotics, including vancomycin, the last resort option for treating MRSA-related infections.\nIn a study recently published online in the journal ChemMedChem, the researchers synthesized and evaluated another new class of triazole-pyrimidine analogs as SecA inhibitors.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The news release accurately reports the benefits of the SecA inhibitors over antibiotics. The study considered three traits to be desirable in an antimicrobial.\u00a0Numerical evidence that SecA inhibitors are preferable over existing antibiotics is reported\u00a0for two of the traits: potency and inhibiting virulence factor production. However, the news release fails to quantify the advantages of the proposed SecA inhibitors in overcoming the negative effect of efflux pumps on potency.", "answer": 1}, {"article": "Other texts might include something like, \"Hi, Elizabeth.\nNot only does this research provide evidence that a text-based program can improve heart disease risk factors, but it also shows that a bunch of bells and whistles aren't required for successful health outcomes.\nIt can't tell us whether text messaging could eventually lead to fewer subsequent heart attacks among the patients receiving those messages or whether the positive health outcomes would continue past the six-month study window.\nIt can be hard to view those everyday decisions in light of more distant consequences, like having another heart attack or not living as long a life as desired.\nYet patients in Chow's study resoundingly said that the text messaging helped them make the necessary changes \u2013 more than 90 percent of the participants found the program useful.\n", "question": "Does the story adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The story addresses the range of benefits reported in the study, such as reduced cholesterol and blood pressure, but doesn\u2019t quantify that information or offer readers any context. For example, while the story says \u201cpatients who had received the text messages had reduced their cholesterol,\u201d the JAMA paper reports that patients who received the text messages had a \u201cmean difference [of] \u22125 mg/dL\u201d in \u201cLDL-C.\u201d In other words, the information in the paper, while quantified, probably isn\u2019t very useful to many readers outside the health industry. Is \u201ca mean difference of\u00a0\u22125 mg/dL in LDL-C\u201d good? Bad? Irrelevant?\nThis is where reporters have an opportunity to shine. If a news story can take those numbers and translate them into language that is accessible to non-experts, it provides a very real service. It would have been great to see that here.", "answer": 0}, {"article": ".\nThis preliminary study showed that three months after stroke, 182 out of every 1,000 patients treated before arriving at hospital were less disabled, including 58 patients who had zero disability, compared to people who received treatment after reaching the hospital.\nAbout half of the participants received the clot-busting drug at the hospital, and half received it while still in the ambulance.\nResearchers analyzed information about patients' disabilities to determine how many needed to be treated in the mobile stroke unit to yield a greater benefit in disability outcomes when compared to patients who received tPA at the hospital.\nResearchers analyzed results from 658 stroke patients who were treated with tPA - a drug that dissolves blood clots.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does describe the benefits using numbers, but it does so in such a way that readers could be misled. The entire study only included 658 stroke patients. Half received a clot-busting drug at the hospital and half received it in the ambulance. And yet when presenting the benefits, the release presents them as a rate, saying that \u201cthree months after stroke, 182 out of every 1,000 patients treated before arriving at hospital were less disabled, including 58 patients who had zero disability, compared to people who received treatment after reaching the hospital.\u201d\nHow a rate like this based on just 329 patients (half of the total cohort) was derived is never explained, and the description makes it sound like there were thousands of patients in the study.", "answer": 0}, {"article": "In nonblood-based tumors, such as melanoma, only about one-half of patients have T cells in their tumors that can be harvested, and only about one-half of those harvested cells can be grown.\n\"What we learned in this small trial is that large numbers of activated MILs can selectively target and kill myeloma cells,\" says Johns Hopkins immunologist Ivan Borrello, M.D., who led the clinical trial.\nOne year after receiving the MILs therapy, 13 of the 22 patients had at least a partial response to the therapy, meaning that their cancers had shrunk by at least 50 percent.\nResults of the trial involving a particular type of tumor-targeting T cell, known as marrow-infiltrating lymphocytes (MILs), are described in the May 20 issue of Science Translational Medicine.\nFor the clinical trial, the Johns Hopkins team enrolled 25 patients with newly diagnosed or relapsed multiple myeloma, although three of the patients relapsed before they could receive the MILs therapy.\n", "question": "Does the news release adequately quantify the benefits of the treatment/test/product/procedure?", "explanation": "The release does a good job of spelling out the results of this phase\u00a01 trial by providing data showing that MILs can target and kill cancer cells. It shows that in more than half of the study\u2019s patients, their cancers had shrunk by at least half. In 15 of the 22 patients, their cancers did not progress for nearly a year after the MILs therapy. This wasn\u2019t a controlled study, so it\u2019s unclear how these patients would have fared without the MILs treatment, and the release could have attempted to provide some insight on that point. But we\u2019re pleased that the release focuses appropriately on the apparent safety of the approach, rather than trying to make claims about survival benefits that aren\u2019t supportable by this kind of small, uncontrolled study. The release also explains that the research provides information suggesting which patients might benefit best from this approach, and that other research at this cancer center is centered on testing this approach on different forms of cancer.", "answer": 1}]